WO2003072578A1 - Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity - Google Patents

Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity Download PDF

Info

Publication number
WO2003072578A1
WO2003072578A1 PCT/US2003/002688 US0302688W WO03072578A1 WO 2003072578 A1 WO2003072578 A1 WO 2003072578A1 US 0302688 W US0302688 W US 0302688W WO 03072578 A1 WO03072578 A1 WO 03072578A1
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
carboxamide
hept
chloro
oct
Prior art date
Application number
PCT/US2003/002688
Other languages
French (fr)
Inventor
Eric Jon Jacobsen
Jason K. Myers
Daniel P. Walker
Donn G. Wishka
Steven C. Reitz
David W. Piotrowski
Brad A. Acker
Jr. Vincent E. Groppi
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Priority to EP20030710784 priority Critical patent/EP1478646A1/en
Priority to MXPA04007083A priority patent/MXPA04007083A/en
Priority to BR0307874-4A priority patent/BR0307874A/en
Priority to AU2003214936A priority patent/AU2003214936A1/en
Priority to JP2003571284A priority patent/JP2005525357A/en
Priority to CA002475773A priority patent/CA2475773A1/en
Publication of WO2003072578A1 publication Critical patent/WO2003072578A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Nicotinic acetylcholine receptors play a large role in central nervous 5 system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable 0 properties of nicotine is its addictive nature and the low ratio between efficacy and safety.
  • the present invention relates to molecules that have a greater effect upon the ⁇ 7 nAChRs as compared to other closely related members of this large ligand-gated receptor family.
  • the invention provides compounds that are active drug molecules with fewer side effects.
  • the invention also concerns the synthesis of and isolation of intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or salts thereof.
  • nAChRs comprise a large family of ligand-gated ion channels that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co- assemble to form multiple subtypes of receptors that have a distinctive pharmacology. 5 Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non- selectively activates all nAChRs.
  • the ⁇ 7 nAChR is one receptor system that has proved to be a difficult target for testing.
  • Native 7 nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, J. Neurochem., 1997, 68(5):2140-51).
  • Another feature that makes functional assays of ⁇ 7 nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly limits the functional assays that can be used to measure channel activity.
  • US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the ⁇ 7 receptor subtype with little or no activation of the ⁇ 4 ⁇ 2 or other receptor subtypes.
  • US Patent 5,919,793 discloses heterocyclic derivatives useful in lowering cholesterol levels in blood plasma.
  • US Patent 5,741,819 discloses arylsulfonylbenzene derivatives and their use as factor Xa inhibitors as being useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases.
  • US Patent 5,723,103 discloses substituted benzamides and radioligand analogs and methods of using the compounds for the identification of 5-HT receptors and the detection and treatment of abnormal conditions associated therewith.
  • US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration.
  • US Patent 5,273,972 discloses novel 2-subs-ituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals.
  • US Patent 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity.
  • US Patent 5,236,931 discloses novel 3-quinuclidinyl benzamides and benzoates which have utility as therapeutical agents which exhibit anxiolytic, antipsychotic, cognition improvement, antiemetic and gastric prokinetic effects in warm blooded animals.
  • US Patent 5,206,246 discloses anxiolytic-R-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5- chloro-2-methoxybenzamide.
  • US Patent 5,084,460 discloses methods of therapeutic treatment with N-(3- quinuclidinyl)-2-hydroxybenzamides and thiobenzamides.
  • the therapeutic agents are disclosed as exhibiting anxiolytic antipsychotic and cognitive improving effects in warm blooded animals.
  • US Patent 5,070,095 discloses novel l-(azabicyclo[2.2.2]oct-3- or -4- yl)benzamides substituted on the benzene ring with the basic substituted aminomethyleneamino group which has been found to be useful in treating emesis, including emesis due to chemical and radiation anticancer therapy, anxiety, and impaired gastric emptying.
  • US Patent 5,057,519 discloses 5-HT 3 antagonists as being useful in reducing opiate tolerance.
  • US Patent 5,039,680 disclose 5-HT antagonists in preventing or reducing dependency on dependency-inducing agents.
  • US Patent 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(l-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is S(-)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2- methoxybenzamide .
  • US Patent 5,017,580 discloses memory enhancing-R-N-(l- azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino- N-(l-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • US Patent 4,908,370 discloses anxiolytic-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides as having anxiolytic activity, in particular, activity against anxiety induced by the withdrawal from ingested substances such as narcotics.
  • US Patent 4,877,794 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia.
  • US Patent 4,877,780 discloses antiemetic N-substituted benzamides having pharmaceutical properties rendering them useful as antiemetic agents with reduced undesirable side effects.
  • US Patent 4,870,181 discloses a process for the preparation of 2-alkoxy-N-(l- azabicyclo[2.2.2])octan-3-yl)aminobenzamide.
  • US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.
  • US Patent 4,820,715 discloses anti-emetic quinuclidinyl benzamides. The compounds are particularly useful in the treatment of chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility.
  • US Patent 4,803, 199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
  • US Patent 4,798,829 discloses l-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and or anti-emetic activity and/or 5-HT receptor antagonist activity.
  • US Patent 4,721 ,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.
  • US Patent 4,717,563 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non- platinum anticancer drugs.
  • US Patent 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators.
  • US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.
  • US Patent 4,593,034 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3- yl)benzamides and thiobenzamides having gastrokinetic and anti-emetic activity.
  • US Patent 4,093,734 discloses amino-benzoic acid amides useful as anxiolytics, anticonvulsives, antiemetics and antiulcerogenics.
  • US Patent 3,702,324 discloses 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines which exert a specific effect on the central nervous system and a somewhat lesser effect on muscle function, and thus have utility as tranquilizers.
  • WO 01/76576 A2 discloses a pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines.
  • WO 01/60821 Al discloses novel biarylcarboxamides and their use in therapy, especially in the treatement of prophylaxis of psychotic and intellectual impairment conditions.
  • WO 01/36417 Al discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.
  • WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the ⁇ 7 nAChR and the 5-HT 3 R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the ⁇ 7 nAChR.
  • WO 92/15579 discloses multicyclic tertiary amine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds.
  • WO 92/11259 discloses azabicyclic amides or esters of halogenated benzoic acids having 5-HT 3 receptor antagonist activity.
  • FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents.
  • the 5-HT 3 antagonist tropisetron (ICS 205-930) is discussed as a potent and selective ⁇ 7 nicotinic receptor partial agonist.
  • the brain ⁇ 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.
  • the present invention discloses compounds of the Formula I:
  • W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six- six-fused-ring system, and further having 1 -2 substitutents independently selected from R 3 , provided that when Azabicyclo is VII the 10-membered system has 1-2 nitrogen atoms, and further provided that when there are two R 3 , each R 3 is other than X is O or S;
  • Ro is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl
  • Ri is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
  • R 2 is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k is 1 or 2, provided that when k is 2, each R 2 is other than H;
  • Each R 3 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, -ORio, -SR ⁇ 0 , -SORio, -SO 2 R ⁇ 0 , -NR 10 C(O)R 7 , -NR I0 C(O)R 8 , -NR, 0 C(O)R 9 , -NR 10 R,o, -NO 2 , -C(O)R 10 , -CN,
  • Each R 5 is independently H, alkyl, or substituted alkyl
  • R 6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH 2 , -NH(alkyl), or -N(alkyl) 2 ;
  • each A is independently CR] 8 or N, provided that only up to one A is N, E 1 and E 2 are independently selected from CR ⁇ 8 , O, S, or NR )4 , and G is CR )8 , provided that Ris or R ⁇ of E 1 , E 2 , and G can be a bond when — forms a double bond and further provided that only one R ⁇ 8 or R ) can be a bond for bonding R to a moiety to which it is attached;
  • Each R 8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R ⁇ 5 ;
  • R 9 is 6-membered heteroaromatic mono-cyclic moi
  • Each R t o is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R ]3 , cycloalkyl substituted with 1 substituent selected from R ⁇ 3 , heterocycloalkyl substituted with 1 substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each Rn is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R( 2 is -OR ⁇ , -SR ⁇ , alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NR n R ⁇ , -C(O)R ⁇ , -NO 2 , -C(O)NRnR n , -CN, -NR u C(O)R ⁇ , -S(O) 2 NR ⁇ R ⁇ , or -NR ⁇ S ⁇ .R, ,;
  • R 13 is -OR ⁇ , -SR, ,, -NR n R ⁇ , -C(O)R réelle, -SOR n , -SO 2 R, hope -C(O)NR n R ⁇ , -CN, -CF 3 , -NR n C(O)Rn, -S(O) 2 NR n Rn, -NR n S(O) 2 R ⁇ , or -NO 2 ;
  • Each R ⁇ is independently bond, H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • Ris is alkyl, substituted alkyl, halogenated alky, -OR ⁇ , -CN, -NO 2 , -NRioRio;
  • Each Ri 8 is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR n , -SRi i, -NRi iR] ⁇ , -C(O)Rn, -NO 2 , -C(O)NR perfumeR M , -CN, -NR n C(O)R ⁇ , -S ⁇ NR, ⁇ , , or -NR ⁇ S(O) 2 R[ i, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core
  • the compounds of Formula I are used to treat, or are used to prepare a medicament to treat, any one of or combination of cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated
  • Embodiments of the invention may include one or more or combination of the following.
  • a further embodiment of the present invention includes the compounds of the present invention, pharmaceutical compositions containing the active compounds as the free base or as a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, and methods to treat the identified diseases.
  • the invention includes treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs (also called anti-psychotic agents).
  • antipsychotic drugs also called anti-psychotic agents.
  • the compounds of the present invention and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously, the compounds of the present invention and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of the present invention and at least one other containing antipsychotic drugs, can be administered simultaneously.
  • a further embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition contains said compound to the mammal.
  • the present invention also includes pharmaceutical composition(s) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, and optionally antipsychotic agent(s), e.g., at least one, in the same pharmaceutical composition or in a separate pharmaceutical composition(s).
  • Each pharmaceutical composition is independently administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.
  • the pharmaceutical composition composing the compound of Formula I is administered to deliver the compound in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
  • the pharmaceutical composition is also administered to deliver the compound of the present invention in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
  • the present invention also includes a method to treat using a compound according to Formula I or pharmaceutically acceptable salt thereof, or use of a compound according to Formula I or pharmaceutically acceptable salt thereof to prepare a medicament for treating, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of ⁇ 7 nicotinic acetylcholine receptor agonist.
  • the present invention also includes a method to treat using a compound according to Formula I or pharmaceutically acceptable salt thereof, or use of a compound according to Formula I or pharmaceutically acceptable salt thereof to prepare a medicament for treating, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of ⁇ 7 nicotinic acetylcholine receptor agonist, wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntingdon'
  • the compounds of Formula I have asymmetric center(s) on the Azabicyclo moiety.
  • exo and endo are stereochemical prefixes that describe the relative configuration of a substituent on a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented toward the larger of the other bridges, it is endo. If a substituent is oriented toward the smaller bridge it is exo. Depending on the substitution on the carbon atoms, the endo and exo orientations can give rise to different stereoisomers.
  • Azabicyclo VII when carbons 1 and 4 are substituted with hydrogen and carbon 2 is bonded to a nitrogen-containing species, the endo orientation gives rise to the possibility of a pair of enantiomers: either the IS, 2S, 4R isomer or its enantiomer, the IR, 2R, 4S isomer.
  • the exo orientation gives rise to the possibility of another pair of stereoisomers which are diastereomeric and C-2 epimeric with respect to the endo isomers: either thelR, 2S, 4S isomer or its enantiomer, the IS, 2R, 4R isomer.
  • the compounds of this invention where Azabicyclo is VII exist in the exo orientation.
  • the compounds of Formula I (Azabicyclo is I) have asymmetric center(s) on the quinuclidine ring.
  • the compounds of the present invention include quinuclidines with the 3R configuration, 2S configuration and also includes racemic mixtures, the separate stereoisomers, and compositions of varying degrees of stereochemical purity.
  • compounds of Formula I include compounds with stereospecificity including:
  • the compounds of Formula I (Azabicyclo is II) have asymmetric center(s) on the [2.2.1] azabicyclic ring at C3 and C4.
  • the scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being endo-4S, endo-4R, exo-4S, exo-4R:
  • the endo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of Formula I (Azabicyclo is III) have asymmetric center(s) on the [3.2.1] azabicyclic ring at C3 and C5.
  • the scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being endo-3S, 5R, endo-3R, 5S, ex ⁇ -3R, 5R, exo-3S, 5S:
  • the compounds of Formula I (Azabicyclo is IN) have asymmetric centers on the [3.2.2] azabicyclic ring with one center being at C3 when R 2 is H.
  • the scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being 3(S) and 3(R):
  • the compounds of Formula I (Azabicyclo N) have asymmetric center(s) on the [2.2.1] azabicyclic ring at Cl, C4 and C5.
  • the scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being (1R,4R,5S), (1R,4R,5R), (1S,4S,5R), (1S,4S,5S):
  • the endo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of Formula I (Azabicyclo NI) have asymmetric center(s) on the [2.2.1] azabicyclic ring at Cl, C4 and C6.
  • the scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being exo-( ⁇ S,4R,6S), exo-( ⁇ R,4S,6R), endo-( ⁇ S,4R,6R), and endo- (1R,4S,6S):
  • the endo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1 ] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of Formula I where Azabicyclo is Nil have asymmetric centers on the 7-azabicyclo[2.2. ljheptane ring which can exhibit a number of stereochemical configurations.
  • the compounds of the present invention have the exo orientation at the C-2 carbon and S configuration at the C-l carbon and the R configuration at the C-2 and the C-4 carbons of the 7-azabicyclo[2.2.1]heptane ring.
  • inventive compounds exhibit much higher activity relative to compounds lacking the exo, IS, 2R, and 4R stereochemistry.
  • the ratio of activities for compounds having the exo, IS, 2R, and 4R configuration to other stereochemical configurations may be greater than about 100:1. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required.
  • compositions can include one or more compounds, each having an exo, IS, 2R, and 4R configuration, or mixtures of compounds having exo, IS, 2R, and 4R and other configurations.
  • those species possessing stereochemical configurations other than exo, IS, 2R, and 4R act as diluents and tend to lower the activity of the pharmaceutical composition.
  • the compounds of the present invention having the specified stereochemistry have different levels of activity and that for a given set of values for the variable substitutuents one isomer may be preferred over the other isomers.
  • This invention involves racemic mixtures and compositions of varying degrees of stereochemical purities when the Azabicyclo is substituted with only the amide/thioamide or is substituted with substituents in addition to the amide/thioamide, e.g., R 2 is alkyl.
  • racemic mixtures and compositions are referenced, it is meant racemic mixtures and compositions of varying degrees of stereochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially enantiomerically pure materials. Suitable stereoselective synthetic procedures for producing enantiomerically pure materials are well known in the art, as are procedures for purifying racemic mixtures into enantiomerically pure fractions.
  • Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially enantiomerically pure materials.
  • Suitable stereoselective synthetic procedures for producing enantiomerically pure materials are well known in the art, as are procedures for purifying racemic mixtures into enantiomerically pure fractions.
  • the compound has the R absolute stereochemistry at C-3 as discussed herein and stereochemistry is unspecified at C-6,
  • the compound has the R absolute stereochemistry at C-3 as discussed herein and S absolute stereochemistry at C-2 as discussed herein, or
  • the compound has the S absolute stereochemistry at C-3 as discussed herein and stereochemistry is unspecified at C-6.
  • R is H
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • R is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • the 2.2.1 moiety has the exo-4(S) absolute stereochemistry and R 2 has any definition as discussed herein.
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
  • R is H
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
  • Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
  • R is H
  • R 2 has any definition as discussed herein and where the Azabicyclo has the absolute stereochemistry of 3R, 5R;
  • k 5 is 2, where R . a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, and where R 2 . b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k 5 is 1, where R is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (v) k is 1, where R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
  • R 2 is H
  • k 6 is 2, where each R . a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where each R 2 - b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; (iii) k 6 is 1 , where R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or (iv) k ⁇ is 1, where R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
  • Another group of compounds of Formula I includes compounds where Azabicyclo is:
  • R 2 each R 5 and R 6 are each H;
  • R 2 is H and each R 5 is independently H, alkyl, or substituted alkyl;
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; and each R 5 is independently H, alkyl, or substituted alkyl; or (iv) R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; each R 5 is independently H, alkyl, or substituted alkyl; and R 6 is alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH 2 , -NH(alkyl), or -N(alkyl) 2 , respectively.
  • W is the six-membered heterocyclic ring system.
  • said ring system include, but are not limited to, all positional isomers of pyridine, pyrimidine, pryazine, and pyridazine, any of which is optionally substituted as Formula I allows; for example, but not limitation, W is optionally substituted with up to 2 substituents independently selected from F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CN, -NO 2 , -OR 10 , -SRio, -N(R 10 ) 2 , -C(O)N(R, 0 ) 2 , or -C(O)R, 0 , wherein each Rio is independently H, lower alkyl, or lower halogenated alkyl.
  • W is the 10- membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms provided that when Azabicyclo is Nil, W has at least one nitrogen atom, where W includes, but is not limited to, all positional isomers of naphthalene, quinoline, isoquinoline, quinazoline, quinoxaline, phthalazine, and 1 ,2-diazanaphthalene, any of which is optionally substituted as Formula I allows; for example, but not limitation, W is optionally substituted with up to 2 substituents independently selected from F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -C ⁇ , -NO 2 , -OR 10 , -SR1 0 , -N(R ⁇ o) 2 , -C(O)N(R ⁇ 0 ) 2 , or -C(O)R ⁇ 0
  • Another group of compounds of Formula I includes compounds where W is the six-membered heterocyclic ring system and is substituted with 1-2 substituents independently selected from R . The substitution can occur wherever valency allows.
  • W is the 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms and is substituted with 1-2 substituents independently selected from R 3 .
  • the substitution can occur wherever valency allows: substitution can independently be on one ring or on both rings.
  • quinolinyl as an example of the 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms, substitution can occur in the following ways:
  • Another group of compounds of Formula I includes compounds where Ro is H.
  • Ro is lower alkyl, lower substituted alkyl, or lower halogenated alkyl.
  • Another group of compounds of Formula I includes compounds where Ri is H.
  • Another group of compounds of Formula I includes compounds where Ri includes any one of alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl.
  • Another group of compounds of Formula I includes compounds where R 2 is H.
  • Another group of compounds of Formula I includes compounds where R 2 includes any one of alkyl including methyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl. Another group of compounds of Formula I includes compounds where R 2 includes any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl. Another group of compounds of Formula I includes compounds where R 3 is H.
  • R 3 independently includes any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, substituted phenyl, -OR ⁇ 0 , -SR ]0 , -SORio, -SO 2 R, 0 , -NR ⁇ 0 R ⁇ o, -NO 2 , -C(O)R, 0 , -CN, -C(O) 2 R 10 , -C(O)NR,oR,o, -SCN, -NR, 0 C(O)R ⁇ 0 , -S(O)NR, 0 R ⁇ o, -S(O) 2
  • R 3 includes any one of F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CN, -NO 2 , -ORio, -SRio, -N(R, 0 ) 2 , -C(O)N(R ⁇ 0 ) 2 , or -C(O)R 10 , wherein each Rio is independently H, lower alkyl, or lower halogenated alkyl.
  • Another group of compounds of Formula I includes compounds where each Rio is independently any one or more or combination of the following: H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R ⁇ 3 , cycloalkyl substituted with 1 substituent selected from R ⁇ 3 , heterocycloalkyl substituted with 1 substituent selected from R ⁇ 3 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl.
  • Another group of compounds of Formula I includes compounds where each R 5 is H. Another group of compounds of Formula I includes compounds where one R 5 is H and the other R 5 includes any one of alkyl, or substituted alkyl. Another group of compounds of Formula I includes compounds where each R 5 includes any one of alkyl, or substituted alkyl.
  • Another group of compounds of Formula I includes compounds where R 6 is H.
  • Another group of compounds of Formula I includes compounds where R 6 includes any one of alkyl, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH 2 , -NH(alkyl), or -N(alkyl) 2 .
  • alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, or substituted alkynyl is allowed, the following, respectively, are also allowed: lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkenyl, lower halogenated alkenyl, lower substituted alkenyl, lower alkynyl, lower halogenated alkynyl, or lower substituted alkynyl.
  • the present invention also includes the intermediates, the processes to make them and the active compounds of Formula I, pharmaceutical compositions including the active compounds, and methods to treat the identified diseases.
  • the core molecule is the Azabicyclo-carboxamide/thioamide-W:
  • a bond directly or indirectly attached to the core molecule would be the bond attached between the substituent and W of the core molecule, e.,g., between the oxygen of -O-R and W.
  • Another aspect of the present invention includes, by representation but not limitation, any compound named or exemplified as a single compound or any combination thereof and pharmaceutically acceptable salt thereof, discussed herein.
  • the present invention includes, but is not limited to the following compounds or pharmaceutically acceptable salt thereof:
  • the invention also concerns the synthesis of and isolation of stereospecific intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine, or salts thereof. Although there are known procedures for making l-azabicyclo[3.2.1]octan-3- amine, separation of the different stereoismers as described herein occurs without using a chiral HPLC separation procedure. The procedure within this invention results in an efficient selective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine.
  • Another aspect of the present invention includes a method for making (3R,5R)- l-azabicyclo[3.2.1]octan-3-amine or salt thereof.
  • One process for producing (3R,5R)- l-azabicyclo[3.2.1]octan-3-amine or a salt thereof, from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate comprises: the process of producing (5R)-3-oxo-l- [(lS)-l-phenylethyl]-l-azoniabicyclo[3.2.1]octane chloride from (3R)-methyl 1-[(S)- 1 -phenylethyl]pyrrolidine-3 -acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof from (5R)-3-oxo-l -[( 1 S)- 1 -phenylethyl]- 1 -azon
  • Another process comprises: the process of producing (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate from (3R)-l-[(S)-l-phenethyl]-3- (cyanomethyl)pyrrolidine; the process of producing (5R)-3-oxo-l-[(lS)-l-phenylethy ⁇ ]-l- azoniabicyclo[ 3.2.1] octane chloride from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof from (5R)-3-oxo- 1 -[(1 S)- 1 -phenylethyl]- 1 -azoniabicyclo[3.2.1 ]octane chloride; and the process of producing (3R,5R)-l-azabicyclo[3.2.1]oct
  • Another process comprises: the process of producing (3S)-1-[(S)-1 -phenethyl] - 5-oxo-3-pyrrolidine-carboxylic acid from (S)-(-)- ⁇ -methyl benzylamine; the process of isolating (3S)-1 -[(S)- 1 -phenethyl] -5 -oxo-3-pyrrolidine- carboxylic acid from a racemic mixture using a precipitating solvent without causing the precipitation of other isomers, where the solvent can include a primary alcohol, including but not limited to methanol; the process of producing (3S)-l-[(S)-l-phenethyl]-3- (hydroxymethyl)pyrrolidine from (3S)-l-[(S)-l-phenethyl]-5-oxo-3-pyrrolidine- carboxylic acid; the process of producing (3S)-l-[(S)-l-phenethyl]-3-(chloromethyl)pyrrolidine from (3S)
  • W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a
  • 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six- six-fused-ring system, and further having 1-2 substitutents independently selected from R 3 , provided that when Azabicyclo is VII the 10-membered system has 1-2 nitrogen atoms, and further provided that when there are two R 3 , each R 3 is other than H;
  • X is O or S
  • Ro is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl
  • Ri is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl
  • R 2 is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; k is 1 or 2, provided that when k is 2, each R 2 is other than H;
  • Each R 3 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, -ORio, -SRio, -SORio, -SO 2 R ⁇ 0 , -NR
  • Each R 5 is independently H, alkyl, or substituted alkyl;
  • R 6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH 2 , -NH(alkyl), or -N(alkyl) 2 ;
  • Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from Rj 2 and 0-3 substituents independently selected from F, Cl, Br, or I;
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R ⁇ 2 and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;
  • Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms
  • Lower alkyl is both straight- and branched-chain moieties having from 1-4 carbon atoms;
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having
  • Lower halogenated alkyl is an alkyl moiety having from 1-4 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , -ORio, -SRio, -NR ⁇ 0 R ⁇ o, -C(O)R 10 , -C(O)NR, 0 R ⁇ o, -CN, -NR ⁇ oC(O)R ⁇ o, -S(O) 2 NR, 0 R ⁇ o, -NR ⁇ 0 S(O) 2 R 10 , -NO 2 , phenyl, or phenyl having 1 substituent selected from R ⁇ 5 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • Lower substituted alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from -ORio, -SR,o, -N(R ⁇ o) 2 , -C(O)R ⁇ o, -C(O)N(R, 0 ) 2 , -CN, -NR, 0 C(O)R, 0 , -S(O) 2 N(R, 0 ) 2 , -NRi 0 S(O) 2 Rio, -NO 2 , or phenyl, wherein each Rio is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl, wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl, and is further optionally substituted with one other substituent independently selected from -OR ⁇ , -SR
  • Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond; Lower alkenyl is straight- and branched-chain moieties having from 2-4 carbon atoms and having at least one carbon-carbon double bond;
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Lower halogenated alkenyl is an unsaturated alkenyl moiety having from 2-4 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R , R 9 , -ORio, -SRio, -NR ]0 R ⁇ o, -C(O)R ⁇ o, -C(O)NR, 0 Rio, -NR 10 C(O)R, 0 , -S(O) 2 NR, 0 R ⁇ o, -NR 10 S(O) 2 R, 0 , -CN, phenyl, or phenyl having 1 substituent selected from R ⁇ , and further having 0-3 substituents independently selected from F, Cl, Br, or I; Lower substituted alkenyl is lower alkenyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -OR 10 , -SRio, -N(R,o) 2 , -
  • Lower alkynyl is straight- and branched-chained moieties having from 2-4 carbon atoms and having at least one carbon-carbon triple bond;
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Lower halogenated alkynyl is an unsaturated alkynyl moiety having from 3-4 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 7 , R 9 , -ORio, -SRio, -NR ⁇ 0 R ⁇ o, -C(O)R ⁇ 0 , -C(O)NR ⁇ oR ⁇ o, -NRi 0 C(O)Rio, -S(O) 2 NR 10 R,o, -NR ⁇ 0 S(O) 2 R, 0 , -CN, phenyl, or phenyl having 1 substituent selected from R ⁇ 5 , and further
  • Lower substituted alkynyl is lower alkynyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -OR 10 , -SRio, -N(R,o) 2 , -C(O)R,o, -C(O)N(R ⁇ o) 2 , -CN, -NR 10 C(O)R 10 , -S(O) 2 N(R 10 ) 2 , -NR, 0 S(O) 2 R ⁇ o, -NO 2 , or phenyl, wherein each Rio is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl, wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl, and is further optionally substituted with one other substituent independently selected from -ORn, -SRêt, -N(
  • Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl; Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -ORio, -SRio, -NRioRio, -C(O)R ⁇ 0 , -CN, -C(O)NR ⁇ 0 R ⁇ o, -NR 10 C(O)R,o, -S(O) 2 NR ⁇ oR ⁇ o, -NR ⁇ 0 S(O) 2 R ⁇ 0 , -NO 2 , phenyl, or phenyl having 1 substituent selected from R ⁇ 5 , and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R ⁇ 9 )-, or -O-;
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R] 9 )-, or -O-, and having 1-4 substituents independently selected from F, or Cl;
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R ⁇ )-, or -O- and having 0-3 substituents independently selected from -F, or -Cl, and further having 1 substituent selected from R 7 , R 9 , -ORio, -SRio, -NR 10 R, 0 , -C(O)R 10 , -C(O)NR, 0 R ⁇ o, -CN, -NR ⁇ 0 C(O)R ⁇ 0 , -NO 2 , -S(O) 2 NR ⁇ oR ⁇ o, -NRi 0 S(O) Rio, phenyl, or phenyl having 1 substituent selected from Ris and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • each A is independently CR ⁇ 8 or N, provided that only up to one A is N, E 1 and E 2 are independently selected from CR ⁇ 8 , O, S, or NR t , and G is CR ⁇ 8 , provided
  • R[ 8 or R ⁇ 4 of E , E , and G can be a bond when — forms a double bond and further provided that only one R ⁇ 8 or R ]4 can be a bond for bonding R 7 to a moiety to which it is attached;
  • Each R 8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R ⁇ 5 ;
  • Each Rio is independently -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R ⁇ 3 , cycloalkyl substituted with 1 substituent selected from R ) , heterocycloalkyl substituted with 1 substituent selected from R ⁇ 3 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each Ri i is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R ⁇ 2 is -ORi i, -SRi i, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnR ⁇ , -C(O)Rn, -NO 2 , -C(0)NRnRn, -CN, -NR ⁇ C ⁇ OjR,,, -S(O) 2 NR, ,Rn, or -NR,,S(O) 2 Rn;
  • R 13 is -ORn, -SR, ,, -NRnRii, -C(O)R u , -SORlois, -SO 2 Rn, -C(O)NRnR u , -CN, -CF 3 , -NR requirementC(O)Rn, -S(O) 2 NR,,R,,, -NR ⁇ S(O) 2 R n , or -NO 2 ;
  • Each R ⁇ 4 is independently bond, H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • Ris is alkyl, substituted alkyl, halogenated alky, -ORn, -CN, -NO 2 , -NR JO R IO ;
  • Each R ⁇ is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRi i, -NR] iRn, -C(O)R ⁇ , -NO 2 , -C(O)NR ⁇ R ⁇ , -CN, -NR ⁇ C(O)R ⁇ , -S(O) 2 NR ⁇ R ⁇ , or -NR ⁇ S(O) 2 R ⁇ , F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule
  • R ⁇ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and Rj 5 ; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
  • the compound of Formula I are used to treat, or are used to prepare medicament(s) to treat, a disease or condition, wherein the diseases, disorders, and or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age
  • AChR refers to acetylcholine receptor.
  • nAChR refers to nicotinic acetylcholine receptor.
  • Pre-senile dementia is also known as mild cognitive impairment.
  • 5HT 3 R refers to the serotonin-type 3 receptor.
  • ⁇ -btx refers to ⁇ -bungarotoxin.
  • FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecular Screening, 1(2), p 75-80, 1996).
  • TLC refers to thin-layer chromatography
  • HPLC refers to high pressure liquid chromatography.
  • MeOH refers to methanol.
  • EtOH refers to ethanol
  • IP A refers to isopropyl alcohol.
  • THF refers to tetrahydrofuran.
  • DMSO refers to dimethylsulfoxide.
  • DMF refers to N,N-dimethylformamide.
  • EtOAc refers to ethyl acetate.
  • TMS refers to tetramethylsilane.
  • TEA refers to triethylamine.
  • DIEA refers to N.N-diisopropylethylamine.
  • MLA refers to methyllycaconitine
  • Ether refers to diethyl ether.
  • HATU refers to O-(7-azabenzotriazol-l-yl)- ⁇ , ⁇ , ⁇ ', N'-tetramethyluronium hexafluorophosphate .
  • DBU refers to l,8-diazobicyclo[5.4.0]undec-7-one.
  • CDI refers to carbonyl diimidazole.
  • NMO refers to N-methylmorpholine-N-oxide.
  • TPAP refers to tetrapropylammonium perruthenate.
  • Halogen is F, Cl, Br, or I.
  • Na SO 4 refers to sodium sulfate.
  • K 2 CO 3 refers to potassium carbonate.
  • MgSO 4 refers to magnesium sulfate.
  • Non-inclusive examples of heteroaryl compounds that fall within the definition of R 7 and R 9 include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pydridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl
  • heterocycloalkyl include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine, azetidino, azetidinono, oxindolo, dihydroimidazolo, and pyrrolidinono
  • Mammal denotes human and other mammals.
  • Brine refers to an aqueous saturated sodium chloride solution.
  • Equ means molar equivalents.
  • IR refers to infrared spectroscopy.
  • Lv refers to leaving groups within a molecule, including Cl, OH, or mixed anhydride.
  • NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm ( ⁇ ) downfield from TMS.
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit.
  • HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit.
  • [M+H] + refers to an ion composed of the parent plus a proton.
  • [M-H] " refers to an ion composed of the parent minus a proton.
  • [M+Na] + refers to an ion composed of the parent plus a sodium ion.
  • [M+K] + refers to an ion composed of the parent plus a potassium ion.
  • El refers to electron impact.
  • ESI refers to electrospray ionization.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), tert butoxy carbonyl (BOC) and the like. Examples of other suitable amino protecting groups are known to person skilled in the art and can be found in "Protective Groups in Organic synthesis,” 3rd Edition, authored by Theodora Greene and Peter Wuts.
  • compositions of the present invention maybe in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino- ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like.
  • cyclic amines such as arginine, betaine, caffeine, choline, N, N
  • Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C ⁇ - 6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
  • an effective amount of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.
  • the amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely.
  • the compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I.
  • the pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult.
  • the daily dose can be administered in one to four doses per day.
  • the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients.
  • carrier material or excipient herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration.
  • Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition.
  • Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl- methyl cellulose, or other methods known to those skilled in the art.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.
  • the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly.
  • saline solution, dextrose solution, or water may be used as a suitable carrier.
  • Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the serotonin type 3 receptor is a member of a superfamily of ligand- gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the ⁇ -aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT 3 R exhibits a large degree of sequence homology with ⁇ 7 nAChR but functionally the two ligand-gated ion channels are very different. For example, ⁇ 7 nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine.
  • 5HT 3 R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin.
  • OJ nAChR is a ligand-gated Ca ++ channel formed by a homopentamer of ⁇ 7 subunits.
  • ⁇ -bungarotoxin ⁇ -btx
  • ⁇ 7 nAChR has a high affinity binding site for both ⁇ -btx and methyllycaconitine (MLA).
  • MVA methyllycaconitine
  • ⁇ 7 nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas.
  • ⁇ 7 nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
  • Schizophrenia is a complex multifactorial illness caused by genetic and non- genetic risk factors that produce a constellation of positive and negative symptoms.
  • the positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing.
  • No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors.
  • Clozapine an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine' s utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., Am J Psychiatry, 153:321- 30, 1996).
  • One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating.
  • P50 auditory event-related potential
  • EEG electroencepholographic
  • Normal individuals respond to the first click with greater degree than to the second click.
  • schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, CM.
  • schizophrenics express the same ⁇ 7 nAChR as non-schizophrenics.
  • Selective ⁇ 7 nAChR agonists may be found using a functional assay on FLIPR
  • FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes.
  • This assay may be used to accurately measure the functional pharmacology of ⁇ 7 nAChR and 5HT 3 R.
  • To conduct such an assay one uses cell lines that expressed functional forms of the OJ nAChR using the ⁇ 7/5-HT 3 channel as the drug target and cell lines that expressed functional 5HT 3 R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.
  • the compounds of the present invention are ⁇ 7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.
  • Schizophrenia is a disease having multiple aspects.
  • drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions.
  • One drug, Clozapine is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients.
  • a drug to treat the cognitive and attention deficits associated with schizophrenia.
  • schizoaffective disorders or similar symptoms found in the relatives of schizophrenic patients.
  • Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him.
  • the term psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
  • the conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
  • Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects.
  • the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.
  • the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals.
  • the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition.
  • two separate compositions i.e., one containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously.
  • anti-psychotic drugs include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX, Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.
  • a pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I and a therapeutically effective amount of anti-psychotic drugs. These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and maybe formulated as sustained relief dosage forms and the like.
  • compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule.
  • One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval.
  • a therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b).
  • the methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.
  • the compounds of the present invention are al nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
  • diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
  • Alzheimer's disease has many aspects, including cognitive and attention deficits.
  • these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects.
  • Neurodegeneration is a common problem associated with diseases such as
  • Alzheimer's disease While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease.
  • Pre-senile dementia mimild cognitive impairment
  • Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient.
  • Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits. Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.
  • the compounds of the present invention are ⁇ 7 nAChR agonists. Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Attention deficit disorder is generally treated with
  • ADHD Attention deficit hyperactivity disorder
  • Treatment may include medications such as methylphenidate, dextroamphetamine, or pemoline, which act to decrease impulsivity and hyperactivity and to increase attention. No "cure" for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.
  • HCA heterocyclic antidepressants
  • MAOI's monoamine oxidase inhibitors
  • Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.
  • Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of umet medical needs in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IN (1994), pp 393-394, for various disease forms of anxiety.
  • GAD General anxiety disorder
  • Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed.
  • PTSD post-traumatic stress disorder
  • the disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp.
  • the affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly lost a loved one.
  • Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression.
  • Various forms of exposure therapy (such as systemic desensitization and imaginal flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.
  • HCA's heterocyclic antidepressant
  • MAOI's monoamine oxidase inhibitors
  • Benign side effects from the use of lithium include, but are not limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor. Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful.
  • Borderline personality disorder although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.
  • AIDS Acquired immune deficiency syndrome
  • HIN human immunodeficiency virus
  • This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems.
  • HIN infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS.
  • Amyotrophic lateral sclerosis also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement.
  • motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement.
  • Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.
  • Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms of behavioral and cognitive problems.
  • Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium.
  • Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.
  • Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address the symptoms of tardive dyskinesia.
  • Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances.
  • Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances.
  • antipsychotic medications may alleviate symptoms in FTD patients who are experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.
  • Dysregulation of food intake associated with eating disease involve neurophysiological pathways.
  • Anorexia nervosa is hard to treat due to patients not entering or remaining in after entering programs.
  • Cognitive behavioral therapy has helped patients suffering from bulemia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.
  • Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.
  • Smoke cessation programs may involve oral dosing of the drug of choice.
  • the drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during the day.
  • the preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed.
  • Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help control nicotine craving or thoughts about cigarette use in people trying to quit.
  • Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking.
  • These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous injection, especially if sustained release formulations are used.
  • Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.
  • Drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug.
  • Drugs that produce strong physical dependence such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some pleasurable manner.
  • narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal symptoms, and then gradually taper off the substitute medication.
  • the medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives. Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.
  • Gilles de la Tourette's Syndrome is an inherited neurological disorder.
  • the disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements.
  • the symptoms generally manifest in an individual before the person is 18 years of age.
  • the movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones.
  • Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances.
  • Coprolalia involuntary scatologic utterances
  • Tics tend to be more complex than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.
  • Clonidine may be used for simple and complex tics. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases, antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.
  • Age-related macular degeneration is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision required for "straight ahead" activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD.
  • Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision.
  • Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease intraocular pressure.
  • current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.
  • Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitablity.
  • Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma. Persons afflicted with pain often have what is referred to as the "terrible triad" of suffering from the pain, resulting in sleeplessness and sadness, all of which are hard on the afflicted individual and that individual's family.
  • typical and atypical anti-psychotic drugs also called an anti-psychotic agent
  • Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs.
  • Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol.
  • Some atypical antipsychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine.
  • Compounds of Formula I can be prepared as shown in Scheme 1.
  • Suitable activating reagents are well known in the art, for examples see Kiso, Y., Yajima, H. "Peptides” pp. 39-91, San Diego, CA, Academic Press, (1995), and include, but are not limited to, agents such as carbodiimides, phosphonium and uronium salts (such as HATU).
  • the acid is activated using HATU or is converted to the acyl azide by using DPPA or is converted into a mixed anhydride by treatment with bis (2-oxo-3- oxazolidinyl) phosphinic chloride in the presence of TEA with CH C1 2 or CHC1 3 as the solvent.
  • R 6 is tert-butyloxycarbonyl (where Azabicyclo is VII)
  • deprotection of the 7-aza group can be conveniently accomplished under acidic conditions in a suitable solvent such as methanol.
  • the acid is converted into a mixed anhydride by treatment with bis (2-oxo-3 -oxazolidinyl) phosphinic chloride in the presence of TEA with CH 2 C1 2 or CHC1 3 as the solvent.
  • the resulting anhydride solution is directly reacted with the appropriate Azabicyclo moiety added neat or using DMF or aqueous DMF as solvent.
  • the ester (Lv being OMe or OEt) may be reacted directly with the amine in refluxing methanol or ethanol to give the compounds of Formula I.
  • the appropriate amine is reacted with TEA if the amine is in the form of an acid salt and added to a solution of the appropriate anhydride or azide to give the desired final compounds.
  • the ester (Lv being OMe or OEt) may be reacted directly with the amine in refluxing methanol or ethanol to give the compounds of Formula I.
  • Substituted ?-naphthoic acids are prepared by several known methods, making noncritical changes (Schemes 2-4).
  • the acids required in Examples 2, 3 and 4 are synthesized from the requisite naphthols according to the method of Kehr et. al. (Kehr, C; Neidlein, R.; Engh, R.A.; Brandstetter, H.; Kucznierz, R.; Leinert, H.; Marzenal, K.; Strein, K.; von der Saal, W. Helv. Chim. Acta 1997, 80, 892.
  • Kehr, C Neidlein, R.; Engh, R.A.; Brandstetter, H.; Kucznierz, R.; Leinert, H.; Marzenal, K.; Strein, K.; von der Saal, W. Helv. Chim. Acta 1997, 80, 892.
  • the naphthol is converted to the trilate with an aryl sulfonimide in the presence of a base. Cyanation of the triflate is accomplished by the action of a palladium catalyst in the presence of zinc cyanide. Hydrolysis of the resulting nitrile with potassium hydroxide yields the naphthoic acid.
  • the acids required for Examples 5 and 6 are constructed from methoxynaphthonitrile as shown in Scheme 3.
  • the methyl ether is removed with boron tribromide in dichloromethane.
  • Conditions for demethylation of a methyl ether are well know in the art (for examples see Greene, T.W.; and Wuts, P.G.M. Protective Groups in Organic Synthesis, Wiley Interscience: New York, 1991; ppl46-149 and references therein).
  • the resulting alcohol is reacted with a base such as sodium hydride followed by benzyl bromide to give the benzyl ether.
  • Example 6 the required hydroxy acid is synthesized by removal of the corresponding benzyl ether by catalytic transfer hydrogenation using palladium on carbon as the catalyst and 1,4-cyclohexadiene.
  • Example 7 the triflate intermediate described above is converted directly to the desired carboxylic amide by a palladium catalyzed carbonylation in the presence of 3-aminoquinulcidine. (Hammarberg, et. al. J. Med. Chem, 2000, 43, 2827-2850, Scheme 4).
  • Substituted isoquinoline carboxylic acids in Examples 13 and 14 are synthesized from the corresponding phthalic acids as shown in Scheme 5.
  • the phthalic acid is converted to the diester under Fisher esterification conditions, reduced to the diol with LAH then oxidized to the dialdehyde under Swern conditions (Faroq, O. Synthesis, 1994, 1035-1036).
  • the dialdehyde is treated with a phosphonoglycinate reagent to form the isoquinoline ring. (Hiebl, J.; et.al. Jet. Lett., 1999, 40, 7935- 7938. Zoller, U.; Ben-Ishai, D. Tetrahedron, 1975, 31, 863-866. Schmidt, U.; Lieberknecht, A.; Wild, j. Synthesis, 1984, 53-60.). Hydrolysis of the ester with potassium hydroxide is well known in the art and gives the isoquinoline carboxylic acid.
  • the amine precursor for Azabicyclo I where R 2 is other than H can be obtained.
  • the scheme depicted below is for compounds where R 2 is at the C-6 position of the quinuclidine, one of ordinary skill in the art would be able to obtain the quinuclidine with substitution at C-2 also.
  • the substituted-[2.2.2]-3-amine can be prepared by reduction of an oxime or an imine of the corresponding substituted-3-quinuclidinone by methods known to one of ordinary skill in the art (see J. Labelled Compds. Radiopharm. 1995, 53; J. Med. Chem. 1998, 988; Synth. Commun. 1992, 1895; Synth. Commun. 1996, 2009).
  • the substituted-[2.2.2]-3-amine can be prepared from a substituted- 3- hydroxyquinuclidine by Mitsunobu reaction followed by deprotection as described in Synth. Commun. 1995, 1895.
  • the substituted-[2.2.2]-3-amine can be prepared by conversion of a substituted-3-hydroxyquinuclidine into the corresponding mesylate or tosylate, followed by displacement with sodium azide and reduction as described inJ. Med. Chem. 1975, 587.
  • the 2-substituted-3-quinuclidinones where R 2 is substituted alkyl or cycloalkyl, can be prepared by known procedures (see Jett. Eett. 1972, 1015; J. Am. Chem. Soc. 1994, 1278; J. Am. Chem. Soc. 1989, 4548; Tetrahedron, 2000, 1139).
  • the 2-substituted-3-quinuclidinones, where R 2 is aryl can be prepared by palladium catalyzed arylation as described inJ. Am. Chem. Soc. 1999, 1473 andJ. Am. Chem. Soc. 2000, 1360.
  • the 6-substituted-3-quinuclidinones can be prepared by known procedures (see J. Gen. Chem. Russia 1963, 3791, J. Chem. Soc. Perkin Trans. 71991, 409, J. Org. Chem. 2000, 3982).
  • compounds can also be prepared by modification of intermediates described in the synthesis of ex ⁇ -3- amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein.
  • Int 6 can be oxidized to the aldehyde and treated with an organometallic reagent to provide Int 20 using procedures described in Tetrahedron (1999), 55, p 13899.
  • Int 20 can be converted into the amine using methods described for the synthesis of exo-3-amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt. Once the amine is obtained, the desired salt can be made using standard procedures.
  • the respective amine precursors for Azabicyclo V and Azabicyclo NI can be prepared by reduction of an oxime or an imine of the corresponding N-2- azabicyclo[2.2. l]-heptanone by methods known to one skilled in the art (see J. Labelled Compds. Radiopharm., 53-60 (1995), J. Med. Chem. 988-995, (1998), Synth. Commun. 1895-1911 (1992), Synth. Commun. 2009-2015 (1996)).
  • the oximes can be prepared by treatment of the N-2-azabicyclo[2.2.1]heptanones with hydroxylamine hydrochloride in the presence of a base.
  • the imines can be prepared by treatment of the N-2-azabicyclo[2.2.1]-heptanones with a primary amine under dehydrating conditions.
  • the N-2-azabicyclo[2.2.1 ]heptanones can be prepared by known procedures (see Jet. Eett. 1419-1422 (1999), J. Med. Chem. 2184-2191 (1992), J. Med. Chem. 706-720 (2000), J. Org. Chem., 4602-4616 (1995)).
  • Step A Preparation of 2-(benzoyloxy)- 1 -nitroethane (Int 1 ).
  • Step B Preparation of ethyl E-4-(benzylarnino)-2-butenoate (Int 2).
  • Ethyl E-4-bromo-2-butenoate (10 mL, 56 mmol, tech grade) is added to a stirred solution of benzylamine (16 mL, 146 mmol) in CH C1 2 (200 mL) at rt.
  • the reaction mixture stirs for 15 min, and is diluted with ether (1 L).
  • the mixture is washed with saturated aqueous NaHCO 3 solution (3x) and water, dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • the residue is purified by flash chromatography on silica gel.
  • Step C Preparation of tr-.n-?-4-nitro-l-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 3).
  • Step D Preparation of tr ⁇ ns-4-amino- 1 -(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 4).
  • Step E Preparation of tr-.n->-4-(l,l-dimethylethoxycarbonylamido)-l-
  • Step F Preparation of trans (tert-butoxycarbonylamino)-4-(2-hydroxyethyl)- 1 - (N-phenylmethyl) pyrrolidine (Int 6).
  • LiAlH 4 powder (627 mg, 16.5 mmol) is added in small portions to a stirred solution of Int 5 (3.0 g, 8.3 mmol) in anhydrous THF (125 mL) in a -5°C bath. The mixture is stirred for 20 min in a -5°C bath, then quenched by the sequential addition of water (0.6 mL), 15% (w/v) aqueous NaOH (0.6 mL) and water (1.8 mL). Excess anhydrous K 2 CO is added, and the mixture is stirred for 1 h, then filtered. The filtrate is concentrated in vacuo. The residue is purified by flash chromatography on silica gel.
  • Int 6 is a racemic mixture that can be resolved via chromatography using a Diacel chiral pack AD column. From the two enantiomers thus obtained, the (+)-enantiomer, [ ] 25 o +35 (c 1.0, MeOH), gives rise to the corresponding enantiomerically pure ex ⁇ -4-S final compounds, whereas the (-)-enantiomer, [o] 25 D - 34 (c 0.98, MeOH), gives rise to enantiomerically pure exo-4-R final compounds.
  • the methods described herein use the (+)-enantiomer of Int 6 to obtain the enantiomerically pure exo-4-S final compounds. However, the methods used are equally applicable to the (-)-enantiomer of Int 6, making non-critical changes to the methods provided herein to obtain the enantiomerically pure exo-4-R final compounds.
  • Step G Preparation of exo 3-(tert-butoxycarbonylamino)-l- azabicyclo[2.2.1]heptane (Int 7).
  • TEA 8.0 g, 78.9 mml
  • CH 3 SO 2 Cl 5.5 g, 47.8 mmol
  • the resulting yellow mixture is diluted with saturated aqueous NaHCO 3 solution, extracted with CH 2 C1 several times until no product remains in the aqueous layer by TLC.
  • Step H Preparation of exo-3-amino-l-azabicyclo[2.2.1]heptane bis(hydro- > r -toluenesulfonate).
  • P ⁇ r -toluenesulfonic acid monohydrate (1.46 g, 7.68 mmol) is added to a stirred solution of Int 7 (770 mg, 3.63 mmol) in EtOH (50 mL).
  • the reaction mixture is heated to reflux for 10 h, followed by cooling to rt.
  • Step I Preparation of ethyl 5-hydroxy-6-oxo- 1 ,2,3,6-tetrahydropyridine-4- carboxylate (Int 10).
  • Absolute EtOH (92.0 mL, 1.58 mol) is added to a mechanically stirred suspension of potassium ethoxide (33.2 g, 395 mmol) in dry toluene (0.470 L).
  • 2-pyrrolidinone (33.6 g, 395 mmol) is added, and then a solution of diethyl oxalate (53.1 mL, 390 mmol) in toluene (98 mL) is added via an addition funnel.
  • toluene (118 mL) and EtOH (78 mL) are added sequentially.
  • the mixture is heated to reflux for 18 h.
  • Int 11 (3J g, 19.9 mmol) as a solid is added in small portions to a stirred solution of LiAlH 4 in THF (80 mL of a 1.0 M solution) in an ice-water bath. The mixture is warmed to rt, and then the reaction is heated to reflux for 48 h. The mixture is cooled in an ice-water bath before water (3.0 mL, 170 mmol) is added dropwise, followed by the sequential addition of NaOH (3.0 mL of a 15% (w/v) solution) and water (9.0 mL, 500 mmol). Excess K 2 CO 3 is added, and the mixture is stirred vigorously for 15 min.
  • Step L Preparation of benzyl c/-.-3-hydroxy-4-(hydroxymethyl)piperidine- 1 - carboxylate (Int 13).
  • N-(benzyloxy carbonyloxy)succinimide (3.04 g, 12.2 mmol) is added to a stirred solution of Int 12 (1.6 g, 12.2 mmol) in saturated aqueous ⁇ aHCO (15 mL) at rt. The mixture is stirred at rt for 18 h. The organic and aqueous layers are separated. The aqueous layer is extracted with ether (3X).
  • Step M Preparation of benzyl c «-3-hydroxy-4-[(4-methylphenyl)sulfonyl oxymethyl]piperidine-l -carboxylate (Int 14).
  • E ⁇ ra-toluenesulfonyl chloride (1.0 g, 5.3 mmol) is added to a stirred solution of Int 13 (3.6 g, 5.3 mmol) in pyridine (10 mL) in a -15°C bath. The mixture is stirred for 4 h, followed by addition of HCl (4.5 mL of a 6.0 M solution). CH 2 C1 2 (5 mL) is added. The organic and aqueous layers are separated. The aqueous layer is extracted with CH C1 .
  • Step N Preparation of exo- 1 -azabicyclo[2.2.1 ]heptan-3-ol (Int 15).
  • a mixture of Int 14 (3.6 g, 8.6 mmol) and 10% Pd/C catalyst (500 mg) in EtOH (50 mL) is placed under an atmosphere of hydrogen. The mixture is shaken for 16 h. The mixture is filtered through Celite. Solid NaHCO 3 (1.1 g, 13 mmol) is added to the filtrate, and the mixture is heated in an oil bath at 50°C for 5 h. The solvent is removed in vacuo. The residue is dissolved in saturated aqueous K CO 3 solution.
  • the pH of the aqueous layer is adjusted to 9 with 50% aqueous NaOH solution.
  • the aqueous layer is extracted with CH 2 C1 2 (3X), and the combined organic layers are washed with brine, dried over Na SO , filtered and concentrated in vacuo.
  • the crude product is purified by flash chromatography on silica gel. Elution with CHCl 3 -MeOH-NH 4 OH (92:7:1) affords Int 16 as a colorless oil (41% yield): 1H NMR (300 MHz, CDC1 3 ) ⁇ 4.1 , 3.2, 2.8, 2.7-2.5, 2.2, 1.9, 1.5.
  • Step P Preparation of en-io-3-amino-l-azabicyclo[2.2.1]heptane bis(hydro- ? ra-toluenesulfonate).
  • Methyl propiolate (52 ml, 0.583 mole) is combined with recrystallized N- bromo-succinimide (120 g, 0.674 mole) in 1,700 ml acetone under nitrogen.
  • the solution is treated with silver nitrate (9.9 g, 0.0583 mole) neat in a single lot and the reaction is stirred 6 h at RT.
  • the acetone is removed under reduced pressure (25°C, bath temperature) to provide a gray slurry.
  • the slurry is washed with 2 x 200 ml hexane, the gray solid is removed by filtration, and the filtrate is concentrated in vacuo to provide 95 g of a pale yellow oily residue.
  • Methyl-3-bromo-propiolate (83J g, 0.513 mole) is added to N-t-butyloxy- pyrrole (430 ml, 2.57 mole) under nitrogen.
  • the dark mixture is warmed in a 90 °C bath for 30 h, is cooled, and the bulk of the excess N-t-butyloxy-pyrrole is removed in vacuo using a dry ice/acetone condenser.
  • the dark oily residue is chromatographed over 1 kg silica gel (230-400 mesh) eluting with 0-15% EtOAc/hexane.
  • (+/-)E «-fo-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1 ]heptane-2,7-dicarboxylate (72.8 g, 0.285 mole) is dissolved in 1000 ml dry MeOH in a dried flask under nitrogen.
  • the solution is treated with solid NaOMe (38.5 g, 0.713 mole) neat, in a single lot and the reaction is warmed to reflux for 4h.
  • the mixture is cooled to 0°C, is treated with 400 ml water, and the reaction is stirred lh as it warms to RT.
  • the mixture is concentrated in vacuo to about 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12N HCl.
  • (+/-)Exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (32.5 g, 0.135 mole) is combined with TEA (24.4 ml, 0.175 mole) in 560 ml dry toluene in a dry flask under nitrogen.
  • the solution is treated drop-wise with diphenylphosphoryl azide (37.7 ml, 0.175 mole), and is allowed to stir for 20 min at RT.
  • the mixture is treated with benzyl alcohol (18.1 ml, 0.175 mole), and the reaction is stirred overnight at 50°C.
  • the mixture is cooled, is extracted successively with 2 x 250 ml 5% citric acid, 2 x 200 ml water, 2 x 200 ml saturated sodium bicarbonate, and 2 x 100 ml saturated NaCl.
  • the organic layer is dried over anhydrous MgSO and concentrated in vacuo to an amber oil.
  • the crude material was chromatographed over 800 g silica gel (230-400 mesh), eluting with 15-50% EtOAc/hexane.
  • the 2R enantiomer is triturated with 12 ml ether followed by 12 ml hexane (to remove lingering diastereo and enantiomeric impurities) and is dried to afford 9.5 g (43%) of purified exo-tert-butyl (IS, 2R, 4R)-(+)-2 ⁇ [(benzyloxy)carbonyl]amino ⁇ -7- azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess.
  • Exo-tert-butyl (IS, 2R, 4R)-(+)-2 ⁇ [(benzyloxy)carbonyl]amino ⁇ -7- azabicyclo[2.2.1]heptane-7-carboxylate (9.5 g, 27.4 mmol) is combined with 950 mg 10%) Pd/C in 75 ml absolute ⁇ tOH in a 500 ml Parr bottle.
  • the reaction mixture is hydrogenated at 50 PSI for 3h, the catalyst is removed by filtration, and the filter cake was washed with MeOH. The filtrate is concentrated in vacuo to give 6.4 g of a residue.
  • Acetyl chloride (270 mL, 3.8 mol) was carefully added to a flask containing chilled (0°C) methanol (1100 mL). After the addition was complete, the acidic solution stirred for 45 min (0 °C) and then (3R)-l-[(S)-l-phenethyl]-3- (cyanomethyl)pyrrolidine (40.50 g, 189.0 mmol) in methanol (200 mL) was added. The ice bath was removed and the mixture stirred for 100 h at rt. The resulting suspension was concentrated. Water (-600 mL) was added, the mixture stirred for 45 min and then the pH was adjusted (made basic) through the addition of -700 mL sat.
  • Sodium hydride (60% oil dispersion, 2.01 g, 50.2 mmol) is washed with pentane (3X) and suspended in dry THF (40 mL). The solution is cooled to 0°C before diethyl (2-oxopropyl)phosphonate (9.75 g, 50.2 mmol) is added dropwise. After complete addition, the solution is warmed to rt and stirred for 30 min.
  • tert- Butyl 4-oxo-l-piperidinecarboxylate (5.0g, 25.1 mmol) is added in portions over 10 min, followed by stirring at rt for 2 h. A saturated aqueous solution of ammonium chloride is added, followed by dilution with ether.
  • the amine can be coupled to form the appropriate amides as a racemic mixture.
  • the racemic mixture can then be resolved by chromatography using chiral columns or chiral HPLC, techniques widely known in the art, to provide the requisite resolved enantiomers 3(R) and 3(5) of said amides.
  • 2- ⁇ aphthoic acid (0.19g, 1.1 mmol) and TEA (LOmL, 7.2mmol) are dissolved in lOmL THF.
  • Diphenylphosphinic chloride (0.26g, 1.lmmol) is added dropwise.
  • (2S,3R)-2-methyl-l-azabicyclo[2.2.2]octan-3-amine dihydrochloride (0.21g, l.Ommol) is added, and the reaction is allowed to stir at RT.
  • IN NaOH is added, and the mixture is extracted with CHC1 3 .
  • the combined organic layers are dried (MgSO 4 ), filtered and concentrated.
  • N-Phenyl-bis(trifluoromethanesulfonamide) (6.14g, 17.2mmol) is added to a solution of 2-hydroxy-7-methoxy naphthalene (3.0g, 17.2mmol) and TEA (2.4mL,
  • HATU (532mg, 1.4mmol) is added to a solution of DIEA (730 ⁇ L, 4.2mmol), (R)-3-aminoquinuclidine dihydrochloride (28 lmg, 1.4mmol) and 7-methoxy-2- naphthoic acid (285 mg, 4mmol) in DMF (8mL). The resulting solution is stirred at rt for 24 hours. Methanol (lOmL) is added and the resulting mixture is loaded onto a column of AG50Wx2 resin(H + form). The column is washed with methanol then the product is eluted with 5% TEA in methanol. The solvents are removed by evaporation to give Example 2 as a white solid (423mg, 97%).
  • HRMS (FAB) calculated for C ⁇ 9 H 22 N 2 O 2 +H + : 311.1759, found 311.1755.
  • Bromocatecholborane (4.1 lg, 20Jmmol) is added to a solution of 1,6- dimethoxynaphthalene (3.89g, 20Jmmol) in dichloroethane (60mL). The resulting solution is heated to reflux for 72 hours, allowed to cool, and then poured into IN HCl. The resulting mixture is extracted three times with CH 2 C1 2 . The combined organic layers are dried (Na 2 SO 4 ), filtered and concentrated to dryness. The product is purified by three columns (step gradient of 50-60-65%CH 2 Cl in hexanes) to give 5- methoxy-2-hydroxy naphthalene as an oil that solidifies on sitting (955mg, 27%>). 1H NMR (300 MHz, CDC1 3 ) ⁇ 8.17, 7.2-7.4, 7.0-7.1, 6.66, 5.08, 3.97.
  • HATU (380mg, l.Ommol) is added to a solution of DIEA (521 ⁇ L, 3.0mmol), (R)-3-aminoquinuclidine dihydrochloride (199mg, l .Ommol) and 5-methoxy-2- naphthoic acid (204, l.Ommol) in DMF (5mL) containing a few drops of water.
  • DIEA 521 ⁇ L, 3.0mmol
  • (R)-3-aminoquinuclidine dihydrochloride 199mg, l .Ommol
  • 5-methoxy-2- naphthoic acid 204, l.Ommol
  • Methanol (lOmL) is added and the resulting mixture is loaded onto a column of AG50Wx2 resin (H + form). The column is washed with methanol then the product is eluted with 5%> TEA in methanol.
  • Bromocatecholborane (4.18g, 21 mmol) is added to a solution of 1,7- dimethoxynaphthalene (1.97g, 10.5mmol) in dichloroethane (20mL). The resulting solution is heated to reflux for 72 hours, allowed to cool and then poured into IN HCl. The resulting mixture is extracted three times with CH 2 C1 . The combined organic layers are dried (Na 2 SO ), filtered and concentrated to dryness. The product is purified by three columns (step gradient of 50-60-70% CH C1 in hexanes) to give 8- methoxy-2 -hydroxy naphthalene as a gummy solid (92% pure, 633mg, 35%). ⁇ NMR (300 MHz, CDC1 3 ) ⁇ 7.72, 7.55, 7.36, 7.20, 7.11, 6.79, 5.02, 3.97.
  • N-Phenyl-bis(trifluoromethanesulfonimide) (1.3g, 3.6mmol) is added to a solution of 2-hydroxy-8-methoxy naphthalene (630mg, 3.6mmol) and TEA (504 ⁇ L, 3.6mmol) in CH 2 C1 2 (8mL). The reaction is allowed to stir for 18 hours then poured into water. The resulting solution is extracted three times with CH 2 C1 2 . The combined organic extracts are dried ( ⁇ a SO 4 ), filtered and concentrated.
  • Example 5 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide fumarate:
  • Example 6 is obtained following the coupling procedures of Example 5 making non-critical changes and recrystallizing from MeOH/CH 3 C ⁇ to give Example 6 as an off-white solid (127mg, 67%).
  • (R)-3-aminoquinuclidine dihydrochloride is free-based by dissolving the salt in minimal water and MeOH and passing it through a plug of Amberjet resin (OH " form). This material is repeatedly concentrated from MeCN until a white solid is obtained. This white solid (1.00 g, 7.94 mmol) is combined with 5-[(tert- butoxycarbonyl)amino]-2-naphthyl trifluoromethanesulfonate (0.932 g, 2.38 mmol), palladium (II) acetate (0.178 g, 0J9 mmol), and l,3-bis(diphenylphosphino)ferrocene (0.484 g, 0.87 mmol).
  • DMSO (10 mL) is added and the reaction is stirred vigorously.
  • the flask is evacuated and flushed six times with CO, and the reaction is stirred under a CO balloon at 70°C for 18 hours.
  • the reaction is cooled to rt and 50 mL of water is added.
  • the water layer is washed with 5 x 50 mL of methyl-tert-butyl ether, and then 5 x 200 mL of EtOAc.
  • the methyl-tert-butyl ether layers are discarded, and the EtOAc layers are dried (MgSO 4 ), filtered, and concentrated.
  • the crude product is dissolved in MeOH and loaded onto a column of AGW-X2 resin (H + form).
  • Example 9 is obtained using the procedure of Example 8, making non-critical changes.
  • Example 9 is obtained as a white solid (0.34 g, 19.4%) by triturating the crude product in hot MeOH, cooling to rt, and rinsing with MeOH.
  • HRMS (FAB) calculated for C ⁇ 7 H ⁇ 9 ⁇ 3 O + H + : 282.1606, found 282.1604.
  • Example 10 is obtained using the procedure of Example 8, making non-critical changes.
  • the crude salt is dissolved in MeOH and passed through a plug of Amberjet resin (OH " form).
  • the solution is loaded onto a column of AG50Wx2 ion exchange resin (H + form).
  • the resin is washed with MeOH and the product is eluted with a solution of 5% TEA in MeOH.
  • the solution is evaporated to dryness then concentrated from MeCN.
  • the resulting material is concentrated from MeOH/water then dried in vacuo to yield Example 10 as a brown solid (0.58 g, 42%).
  • HRMS (FAB) calculated for C ⁇ 7 H !9 N 3 O + H + : 282.1606, found 282.1606.
  • Example 11 is obtained in 82%> yield as a brown solid using the procedure of Example 8, making non-critical changes.
  • the monosodium salt of 4-chlorophthalic acid (10.00 g, 45 mmol) is added to MeOH (100 mL). Concentrated H 2 SO 4 (5 mL) is added, and the solution is heated at reflux for 48 hours under ⁇ . The reaction is cooled to rt and concentrated to a yellow solid. 100 mL of H O is added and the aqueous layer is extracted with 3 x 100 mL of EtOAc. The organic layers are combined and washed with 2 x 100 mL of brine solution followed by 2 x 100 mL of water, and then dried (MgSO 4 ), filtered, and concentrated.
  • LAH (1.81 g, 47.8 mmol) is added to an oven-dried flask under N 2 followed by dry THF (75 mL). The solution is cooled to -78°C. Dimethyl-4-chlorophthalate (5.45 g, 23.9 mmol) is added as a solution in THF (25 mL) via an addition funnel over one hour. The reaction is warmed slowly to rt, and then heated at reflux for 18 hours. The reaction is cooled to 0°C and quenched with 200 mL of ice-cold 15% NaOH solution followed by 200 mL of water. The aqueous layer is extracted with 150 mL of THF, which is washed with 3 x 150 mL of brine solution.
  • Oxalyl chloride (3.3 mL, 38.0 mmol) is added to 70 mL of CH 2 C1 2 under N 2 and the resulting solution is cooled to -78°C.
  • DMSO (5.9 mL, 83.6 mmol) is added drop-wise as a solution in CH C1 2 (5.9 mL) followed by ((4-chloro-2- hydroxymethyl)phenyl)methanol (3.29 g, 19.1 mmol) as a solution in CH 2 C1 2 (20 mL) and DMSO (3 mL).
  • TEA 47.9 mL, 342 mmol
  • Methyl 6-chloro-isoquinoline3-carboxylate (0.80 g, 3.6 mmol) is suspended in 95% EtOH (35 mL).
  • KOH (0.61 g, 10.9 mmol) is added, and the reaction is heated to 80°C. When a white precipitate begins to form, 10 mL of H 2 O is added and all solid is redissolved. After heating for 1 hour, the reaction is cooled to rt and a white precipitate forms. The precipitate (identified as the K + salt) is collected by vacuum filtration. The filtrate is acidified with concentrated HCl until the pH is between 4 and 5. The filtrate is loaded directly onto a column of AGW-X2 resin (H + form) and the column is rinsed with MeOH.
  • the resin is washed with MeOH and the product is eluted with a solution of 5%> TEA in MeOH.
  • the resultant brown solid is concentrated twice from MeCN and dried in vacuo at 60°C.
  • the free base is dissolved in MeOH, 10 mL of 1 N HCl/MeOH is added, and the solution is concentrated to dryness.
  • the HCl salt is crystallized from MeOH//-PrOH, and the solid is filtered.
  • the HCl salt is too hygroscopic to isolate, so the salt is dissolved in MeOH and passed through a plug of Amberjet resin (OH " form).
  • Example 13 is evaporated from MeCN three times, and then dried at 60°C in vacuo for 24 hours to yield Example 13 as a brown solid (0.062 g, 32%).
  • HRMS (FAB) calculated for C 17 H, 8 C1 N 3 O + H + : 316.1216, found 316.1206.
  • LAH (2.88 g, 76.0 mmol) is added to an oven-dried flask under N 2 .
  • Dry THF 120 mL is added, and the reaction is cooled to -78°C.
  • the reaction is warmed slowly to rt and then heated at reflux for 18 hours.
  • the reaction is cooled to 0°C and quenched with 300 mL of ice-cold 15% NaOH solution, followed by 300 mL of water.
  • 200 mL of THF is added and the two layers are separated.
  • the THF layer is washed with 2 x 250 mL of brine solution.
  • Oxalyl chloride (5.6 mL, 64 mmol) is added to CH C1 2 (115 mL) under N 2 and the reaction is cooled to -78°C.
  • DMSO 10.0 mL, 141 mmol
  • CH 2 C1 2 (10.0 mL) is added drop-wise and the resulting solution is stirred for 5 minutes.
  • ((4-Methyl-2- hydroxymethyl)phenyl)methanol (4.82 g, 32 mmol) dissolved in a minimal volume of CH 2 C1 2 is added drop-wise to the reaction, which is stirred for 30 minutes.
  • this precipitate (the K + salt) is filtered and dried at 60°C in vacuo.
  • the precipitate is dissolved in water and the pH is adjusted to 4-5.
  • the water solution is then loaded onto a column of AGW-X2 resin (H + form).
  • the resin is rinsed with MeOH, and the desired product is eluted with a solution of 5% TEA in MeOH.
  • the product is concentrated three times from MeOH/ MeCN and dried in vacuo. The solid is then dried overnight at 60°C to yield 6-methyl-isoquinoline-3-carboxylic acid (0.41 g, 71%).
  • HRMS (FAB) calculated for Cn H 8 N O 2 K: 188.0711, found 188.0714.
  • Example 15 is obtained using the coupling procedures of Example 3, making non-critical changes to give Example 15 as a solid.
  • the present invention also includes, by representation but not limitation, any one compound as a racemic mixture or pure enantiomer as discussed herein or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes: N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-pyridine-2-carboxamide;
  • the present invention also includes, by representation but not limitation, any one compound as a racemic mixture or pure enantiomer as discussed herein or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes:
  • the chimeric ⁇ 7-5HT 3 ion channel was inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and hygromycin B, respectively. Both plasmids were simultaneously transfected into SH- EP1 cells and cell lines were selected that were resistant to both G-418 and hyrgromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent ⁇ -bungarotoxin on their cell surface. The cells with the highest amount of fluorescent ⁇ -bungarotoxin binding were isolated using a Fluorescent Activated Cell Sorter (FACS).
  • FACS Fluorescent Activated Cell Sorter
  • Cell lines that stably expressed the chimeric ⁇ 7-5HT 3 were identified by measuring fluorescent ⁇ -bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 ⁇ g/ml hygromycin B, and 400 ⁇ g/ml G-418 at 37° C with 6% CO 2 in a standard mammalian cell incubator for at least 4 weeks in continuous culture.
  • the ion conditions of the MMEBSS was adjusted to maximize the flux of calcium ion through the chimeric ⁇ 7-5HT 3 ion channel as described in WO 00/73431.
  • the activity of compounds on the chimeric ⁇ 7-5HT 3 ion channel was analyzed on FLIPR.
  • the instrument was set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio.
  • Agonist activity of each compound was measured by directly adding the compound to cells expressing the chimeric ⁇ 7-5HT 3 ion channel and measuring the resulting increase in intracellular calcium that is caused by the agonist-induced activation of the chimeric ion channel.
  • the assay is quantitative such that concentration-dependent increase in intracelluar calcium is measured as concentration-dependent change in Calcium Green fluorescence.
  • the effective concentration needed for a compound to cause a 50% maximal increase in intracellular calcium is termed the EC 50 .
  • Example 8 is inactive; the rest of the examples have EC 50 values from about 30 nM to about 49,500 nM.
  • Another way for measuring ⁇ 7 nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay.
  • ⁇ 7 nAChR agonists there is good correlation between functional EC 50 values using the chimeric ⁇ 7-5HT 3 ion channel as a drug target and binding affinity of compounds to the endogenous ⁇ 7 nAChR.
  • 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 ?C.
  • Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 mis MLA for a final concentration of 1 ?M, added before the radioligand.
  • drugs are added in increasing concentrations to the test tubes before addition of 0.05 mis [3H]-MLA for a final concentration 3.0 to 4.0 nM.
  • the incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester.
  • Filters are pre-soaked in 50 mM Tris HCl pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry. Data Analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compounds of Formula I: (1) wherein Azabicyclo is (2) W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of ten bicyclic-six-six-fused-ring system, and further having 1-2 substituents independently selected from R3. These compounds may be in the form of pharamaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharamaceuticals to treat diseases or conditions in which α7 is known t be involved.

Description

AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY
FIELD OF INVENTION
Nicotinic acetylcholine receptors (nAChRs) play a large role in central nervous 5 system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable 0 properties of nicotine is its addictive nature and the low ratio between efficacy and safety. The present invention relates to molecules that have a greater effect upon the α7 nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects. 5 The invention also concerns the synthesis of and isolation of intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or salts thereof.
BACKGROUND OF THE INVENTION 0 Cell surface receptors are, in general, excellent and validated drug targets. nAChRs comprise a large family of ligand-gated ion channels that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co- assemble to form multiple subtypes of receptors that have a distinctive pharmacology. 5 Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non- selectively activates all nAChRs.
The α7 nAChR is one receptor system that has proved to be a difficult target for testing. Native 7 nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, J. Neurochem., 1997, 68(5):2140-51). 0 Another feature that makes functional assays of α7 nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly limits the functional assays that can be used to measure channel activity. Recently, Eisele et al. has indicated that a chimeric receptor formed between the N-terminal ligand binding domain of the αJ nAChR (Eisele et al., Nature, 366(6454), p 479-83, 1993), and the pore forming C-terminal domain of the 5-HT3 receptor expressed well in Xenopus oocytes while retaining nicotinic agonist sensitivity. Eisele et al. used the N-terminus of the avian (chick) form of the α7 nAChR receptor and the C-terminus of the mouse form of the 5-HT3 gene. However, under physiological conditions the α7 nAChR is a calcium channel while the 5-HT3R is a sodium and potassium channel. Indeed, Eisele et al. teaches that the chicken α7 nAChR mouse 5-HT3R behaves quite differently than the native 7 nAChR with the pore element not conducting calcium but actually being blocked by calcium ions. WO 00/73431 A2 reports on assay conditions under which the 5-HT3R can be made to conduct calcium. This assay may be used to screen for agonist activity at this receptor.
US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the α7 receptor subtype with little or no activation of the α4β2 or other receptor subtypes.
US Patent 5,919,793 discloses heterocyclic derivatives useful in lowering cholesterol levels in blood plasma.
US Patent 5,741,819 discloses arylsulfonylbenzene derivatives and their use as factor Xa inhibitors as being useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases.
US Patent 5,723,103 discloses substituted benzamides and radioligand analogs and methods of using the compounds for the identification of 5-HT receptors and the detection and treatment of abnormal conditions associated therewith.
US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration. US Patent 5,273,972 discloses novel 2-subs-ituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals. US Patent 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity.
US Patent 5,236,931 discloses novel 3-quinuclidinyl benzamides and benzoates which have utility as therapeutical agents which exhibit anxiolytic, antipsychotic, cognition improvement, antiemetic and gastric prokinetic effects in warm blooded animals.
US Patent 5,206,246 discloses anxiolytic-R-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5- chloro-2-methoxybenzamide.
US Patent 5,106, 843 discloses heterocyclic compounds useful as 5-HT3 antagonists.
US Patent 5,084,460 discloses methods of therapeutic treatment with N-(3- quinuclidinyl)-2-hydroxybenzamides and thiobenzamides. The therapeutic agents are disclosed as exhibiting anxiolytic antipsychotic and cognitive improving effects in warm blooded animals.
US Patent 5,070,095 discloses novel l-(azabicyclo[2.2.2]oct-3- or -4- yl)benzamides substituted on the benzene ring with the basic substituted aminomethyleneamino group which has been found to be useful in treating emesis, including emesis due to chemical and radiation anticancer therapy, anxiety, and impaired gastric emptying.
US Patent 5,057,519 discloses 5-HT3 antagonists as being useful in reducing opiate tolerance. US Patent 5,039,680 disclose 5-HT antagonists in preventing or reducing dependency on dependency-inducing agents.
US Patent 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(l-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is S(-)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2- methoxybenzamide .
US Patent 5,017,580 discloses memory enhancing-R-N-(l- azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino- N-(l-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
US Patent 4,908,370 discloses anxiolytic-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides as having anxiolytic activity, in particular, activity against anxiety induced by the withdrawal from ingested substances such as narcotics.
US Patent 4,877,794 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia.
US Patent 4,877,780 discloses antiemetic N-substituted benzamides having pharmaceutical properties rendering them useful as antiemetic agents with reduced undesirable side effects.
US Patent 4,870,181 discloses a process for the preparation of 2-alkoxy-N-(l- azabicyclo[2.2.2])octan-3-yl)aminobenzamide.
US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.
US Patent 4,820,715 discloses anti-emetic quinuclidinyl benzamides. The compounds are particularly useful in the treatment of chemotherapy-induced emesis in cancer patients. Some of the compounds are also useful in disorders relating to impaired gastric motility. US Patent 4,803, 199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
US Patent 4,798,829 discloses l-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and or anti-emetic activity and/or 5-HT receptor antagonist activity. US Patent 4,721 ,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome. US Patent 4,717,563 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non- platinum anticancer drugs.
US Patent 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators.
US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof. US Patent 4,593,034 discloses 2-alkoxy-N-(l-azabicyclo[2.2.2]oct-3- yl)benzamides and thiobenzamides having gastrokinetic and anti-emetic activity.
US Patent 4,093,734 discloses amino-benzoic acid amides useful as anxiolytics, anticonvulsives, antiemetics and antiulcerogenics.
US Patent 3,702,324 discloses 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines which exert a specific effect on the central nervous system and a somewhat lesser effect on muscle function, and thus have utility as tranquilizers.
WO 01/76576 A2 discloses a pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines. WO 01/60821 Al discloses novel biarylcarboxamides and their use in therapy, especially in the treatement of prophylaxis of psychotic and intellectual impairment conditions.
WO 01/36417 Al discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.
WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the α7 nAChR and the 5-HT3R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the α7 nAChR. WO 92/15579 discloses multicyclic tertiary amine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds. WO 92/11259 discloses azabicyclic amides or esters of halogenated benzoic acids having 5-HT3 receptor antagonist activity.
FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents. In Bioorg. & Med. Chem. Lett. 11 (2001 ) 319-321 , the 5-HT3 antagonist tropisetron (ICS 205-930) is discussed as a potent and selective α7 nicotinic receptor partial agonist.
In Behavioral Brain Res. , 113 (2000) 169- 181 , it is discussed that the brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.
SUMMARY OF THE INVENTION
The present invention discloses compounds of the Formula I:
Azabicyclo
Figure imgf000007_0001
Formula I wherein Azabicyclo is
Figure imgf000007_0002
W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six- six-fused-ring system, and further having 1 -2 substitutents independently selected from R3, provided that when Azabicyclo is VII the 10-membered system has 1-2 nitrogen atoms, and further provided that when there are two R3, each R3 is other than X is O or S;
Ro is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl;
Ri is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl; R2 is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; k is 1 or 2, provided that when k is 2, each R2 is other than H;
Each R3 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, -ORio, -SRι0, -SORio, -SO2Rι0, -NR10C(O)R7, -NRI0C(O)R8, -NR,0C(O)R9, -NR10R,o, -NO2, -C(O)R10, -CN, -C(O)2R10, -C(O)NR10Rio, -SCN, -NR,0C(O)R10, -S(O)NR,0Rιo, -S(O)2NR10Rιo, -NR10S(O)2Ri0, R7, or R9;
Each R5 is independently H, alkyl, or substituted alkyl;
R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH(alkyl), or -N(alkyl)2;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from -O-, =N-, -N(Rj4)-, and -S-, and having 0-1 substituent selected from-Rι5 and 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
Figure imgf000008_0001
wherein each A is independently CR]8 or N, provided that only up to one A is N, E1 and E2 are independently selected from CRι8, O, S, or NR)4, and G is CR)8, provided that Ris or Rι of E1, E2, and G can be a bond when — forms a double bond and further provided that only one Rι8 or R) can be a bond for bonding R to a moiety to which it is attached; Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or Rι5; R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from Rι2 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or
R is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R)2 and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond for bonding R to a moiety to which it is attached where valency allows;
Each Rto is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R]3, cycloalkyl substituted with 1 substituent selected from Rι3, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
Each Rn is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; R(2 is -ORπ, -SRπ, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRιι, -C(O)Rπ, -NO2, -C(O)NRnRn, -CN, -NRuC(O)Rπ, -S(O)2NRπRπ, or -NRπS^.R, ,;
R13 is -ORπ, -SR, ,, -NRnRπ, -C(O)R„, -SORn, -SO2R, „ -C(O)NRnRπ, -CN, -CF3, -NRnC(O)Rn, -S(O)2NRnRn, -NRnS(O)2Rπ, or -NO2;
Each Rι is independently bond, H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
Ris is alkyl, substituted alkyl, halogenated alky, -ORπ, -CN, -NO2, -NRioRio; Each Ri8 is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRi i, -NRi iR] ι, -C(O)Rn, -NO2, -C(O)NR„RM, -CN, -NRnC(O)Rπ, -S^NR,^, ,, or -NRπS(O)2R[ i, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRnRn, -C(O)Rπ, -NO2, -C(O)NRnR,i, -CN, -NRnC(O)Ru, -S(O)2NRnRn, or -NR,,S(O)2R,ι, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I; Ri9 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and Rι5; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
The compounds of Formula I are used to treat, or are used to prepare a medicament to treat, any one of or combination of cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
Embodiments of the invention may include one or more or combination of the following.
The compound of Formula I, wherein X is O. The compound of Formula I, where X is S. A further embodiment of the present invention includes the compounds of the present invention, pharmaceutical compositions containing the active compounds as the free base or as a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, and methods to treat the identified diseases. In another aspect, the invention includes treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs (also called anti-psychotic agents). The compounds of the present invention and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously, the compounds of the present invention and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of the present invention and at least one other containing antipsychotic drugs, can be administered simultaneously.
A further embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition contains said compound to the mammal.
The present invention also includes pharmaceutical composition(s) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, and optionally antipsychotic agent(s), e.g., at least one, in the same pharmaceutical composition or in a separate pharmaceutical composition(s). Each pharmaceutical composition is independently administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval. The pharmaceutical composition composing the compound of Formula I is administered to deliver the compound in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day. The pharmaceutical composition is also administered to deliver the compound of the present invention in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day. One of ordinary skill in the art will know how to administer the antipsychotic drug(s). The present invention also includes a method to treat using a compound according to Formula I or pharmaceutically acceptable salt thereof, or use of a compound according to Formula I or pharmaceutically acceptable salt thereof to prepare a medicament for treating, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist.
The present invention also includes a method to treat using a compound according to Formula I or pharmaceutically acceptable salt thereof, or use of a compound according to Formula I or pharmaceutically acceptable salt thereof to prepare a medicament for treating, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist, wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntingdon's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
The compounds of Formula I have asymmetric center(s) on the Azabicyclo moiety. The terms exo and endo are stereochemical prefixes that describe the relative configuration of a substituent on a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented toward the larger of the other bridges, it is endo. If a substituent is oriented toward the smaller bridge it is exo. Depending on the substitution on the carbon atoms, the endo and exo orientations can give rise to different stereoisomers. For instance, with Azabicyclo VII, when carbons 1 and 4 are substituted with hydrogen and carbon 2 is bonded to a nitrogen-containing species, the endo orientation gives rise to the possibility of a pair of enantiomers: either the IS, 2S, 4R isomer or its enantiomer, the IR, 2R, 4S isomer. Likewise, the exo orientation gives rise to the possibility of another pair of stereoisomers which are diastereomeric and C-2 epimeric with respect to the endo isomers: either thelR, 2S, 4S isomer or its enantiomer, the IS, 2R, 4R isomer. The compounds of this invention where Azabicyclo is VII exist in the exo orientation. For example, when R2 = R4 = H, the absolute stereochemistry is exø-(lS, 2R, 4R). Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially enantiomerically pure materials. Suitable stereoselective synthetic procedures for producing enantiomerically pure materials are well known in the art, as are procedures for purifying racemic mixtures into enantiomerically pure fractions. The compound of Formula I, where Azabicyclo is any one of the following: I,
II, III, IV, V, VI, or VII.
The compounds of Formula I (Azabicyclo is I) have asymmetric center(s) on the quinuclidine ring. The compounds of the present invention include quinuclidines with the 3R configuration, 2S configuration and also includes racemic mixtures, the separate stereoisomers, and compositions of varying degrees of stereochemical purity. For example, and not by limitation, compounds of Formula I include compounds with stereospecificity including:
Figure imgf000013_0001
3R 3S 3R.2S
The compounds of Formula I (Azabicyclo is II) have asymmetric center(s) on the [2.2.1] azabicyclic ring at C3 and C4. The scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being endo-4S, endo-4R, exo-4S, exo-4R:
Figure imgf000013_0002
endo-4S endo-4R exø-4S e o-4R
The endo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exø-4(R), exo-4(S), endo-4(R), and endo- 4(S).
The compounds of Formula I (Azabicyclo is III) have asymmetric center(s) on the [3.2.1] azabicyclic ring at C3 and C5. The scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being endo-3S, 5R, endo-3R, 5S, exø-3R, 5R, exo-3S, 5S:
Figure imgf000014_0001
endo- S, 5R endo-3R, 5S exo-3R, 5R exo-3S, 5S
The compounds of Formula I (Azabicyclo is IN) have asymmetric centers on the [3.2.2] azabicyclic ring with one center being at C3 when R2 is H. The scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being 3(S) and 3(R):
Figure imgf000014_0002
3(S) 3(R)
The compounds of Formula I (Azabicyclo N) have asymmetric center(s) on the [2.2.1] azabicyclic ring at Cl, C4 and C5. The scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being (1R,4R,5S), (1R,4R,5R), (1S,4S,5R), (1S,4S,5S):
Figure imgf000014_0003
endo-\R,4R,5R endo-lS,4S,5S exo-\R,4R,5S exo-\S,4S,5R The endo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exo-(\R,4R,5S), exo-(\S,4S,5R), endo- (\S,4S,5S), endo-(\R,4R,5R). The compounds of Formula I (Azabicyclo NI) have asymmetric center(s) on the [2.2.1] azabicyclic ring at Cl, C4 and C6. The scope of this invention includes racemic mixtures of varying degrees of stereochemical purities, the separate stereoisomers, and compositions of varying degrees of stereochemical purities of Formula I being exo-(\S,4R,6S), exo-(\R,4S,6R), endo-(\S,4R,6R), and endo- (1R,4S,6S):
Figure imgf000015_0001
en-/ø-lR,4S,6S endo-\S,4R,6R exo-\R,4S,6R exo-lS,4R,6S
The endo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1 ] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exo-(\S,4R,6S), exo-(\R,4S,6R), endo- (1S,4R,6R), and endo-(\R,4S,6S).
The compounds of Formula I where Azabicyclo is Nil have asymmetric centers on the 7-azabicyclo[2.2. ljheptane ring which can exhibit a number of stereochemical configurations.
Figure imgf000015_0002
The compounds of the present invention have the exo orientation at the C-2 carbon and S configuration at the C-l carbon and the R configuration at the C-2 and the C-4 carbons of the 7-azabicyclo[2.2.1]heptane ring. Unexpectedly, the inventive compounds exhibit much higher activity relative to compounds lacking the exo, IS, 2R, and 4R stereochemistry. For example, the ratio of activities for compounds having the exo, IS, 2R, and 4R configuration to other stereochemical configurations may be greater than about 100:1. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. For example, pharmaceutical compositions can include one or more compounds, each having an exo, IS, 2R, and 4R configuration, or mixtures of compounds having exo, IS, 2R, and 4R and other configurations. In mixtures of compounds, those species possessing stereochemical configurations other than exo, IS, 2R, and 4R act as diluents and tend to lower the activity of the pharmaceutical composition. Typically, pharmaceutical compositions including mixtures of compounds possess a larger percentage of species having the exo, IS, 2R, and 4R configuration relative to other configurations. The compounds of the present invention having the specified stereochemistry have different levels of activity and that for a given set of values for the variable substitutuents one isomer may be preferred over the other isomers. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. This invention involves racemic mixtures and compositions of varying degrees of stereochemical purities when the Azabicyclo is substituted with only the amide/thioamide or is substituted with substituents in addition to the amide/thioamide, e.g., R2 is alkyl. When racemic mixtures and compositions are referenced, it is meant racemic mixtures and compositions of varying degrees of stereochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially enantiomerically pure materials. Suitable stereoselective synthetic procedures for producing enantiomerically pure materials are well known in the art, as are procedures for purifying racemic mixtures into enantiomerically pure fractions.
Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially enantiomerically pure materials. Suitable stereoselective synthetic procedures for producing enantiomerically pure materials are well known in the art, as are procedures for purifying racemic mixtures into enantiomerically pure fractions.
Another embodiment of the compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000016_0001
(i) (ϋ) (iii) (iv) where (i) the compound is a mixture of diastereomers,
(ii) the compound has the R absolute stereochemistry at C-3 as discussed herein and stereochemistry is unspecified at C-6,
(iii) the compound has the R absolute stereochemistry at C-3 as discussed herein and S absolute stereochemistry at C-2 as discussed herein, or
(iv) the compound has the S absolute stereochemistry at C-3 as discussed herein and stereochemistry is unspecified at C-6.
Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000017_0001
where (i) R is H;
(ii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; (iii) R is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or (iv) the 2.2.1 moiety has the exo-4(S) absolute stereochemistry and R2 has any definition as discussed herein.
Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000017_0002
(ii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
(iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000017_0003
where (i) R is H;
(ii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
(iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl. Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000018_0001
where (i) R is H;
(ii) R2 has any definition as discussed herein and where the Azabicyclo has the absolute stereochemistry of 3R, 5R;
(iii) k5 is 2, where R .a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, and where R2.b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
(iv) k5 is 1, where R is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
(v) k is 1, where R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for Azabicyclo:
Figure imgf000018_0002
where (i) R2 is H;
(ii) k6 is 2, where each R .a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where each R2-b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; (iii) k6 is 1 , where R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or (iv) kβ is 1, where R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl.
Another group of compounds of Formula I includes compounds where Azabicyclo is:
Figure imgf000019_0001
where (i) R2, each R5 and R6 are each H;
(ii) R2 is H and each R5 is independently H, alkyl, or substituted alkyl;
(iii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; and each R5 is independently H, alkyl, or substituted alkyl; or (iv) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; each R5 is independently H, alkyl, or substituted alkyl; and R6 is alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH(alkyl), or -N(alkyl)2, respectively.
Another group of compounds of Formula I includes compounds where W is the six-membered heterocyclic ring system. Examples of said ring system include, but are not limited to, all positional isomers of pyridine, pyrimidine, pryazine, and pyridazine, any of which is optionally substituted as Formula I allows; for example, but not limitation, W is optionally substituted with up to 2 substituents independently selected from F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CN, -NO2, -OR10, -SRio, -N(R10)2, -C(O)N(R,0)2, or -C(O)R,0, wherein each Rio is independently H, lower alkyl, or lower halogenated alkyl. Another group of compounds of Formula I includes compounds where W is the 10- membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms provided that when Azabicyclo is Nil, W has at least one nitrogen atom, where W includes, but is not limited to, all positional isomers of naphthalene, quinoline, isoquinoline, quinazoline, quinoxaline, phthalazine, and 1 ,2-diazanaphthalene, any of which is optionally substituted as Formula I allows; for example, but not limitation, W is optionally substituted with up to 2 substituents independently selected from F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CΝ, -NO2, -OR10, -SR10, -N(Rιo)2, -C(O)N(Rι0)2, or -C(O)Rι0, wherein each R10 is independently H, lower alkyl, or lower halogenated alkyl.
Another group of compounds of Formula I includes compounds where W is the six-membered heterocyclic ring system and is substituted with 1-2 substituents independently selected from R . The substitution can occur wherever valency allows.
Another group of compounds of Formula I includes compounds where W is the 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms and is substituted with 1-2 substituents independently selected from R3. The substitution can occur wherever valency allows: substitution can independently be on one ring or on both rings. Using quinolinyl as an example of the 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms, substitution can occur in the following ways:
Figure imgf000020_0001
Another group of compounds of Formula I includes compounds where Ro is H.
Other compounds within the scope of the present invention are where Ro is -CH3.
Other compounds within the scope of the present invention are where Ro is lower alkyl, lower substituted alkyl, or lower halogenated alkyl.
Another group of compounds of Formula I includes compounds where Ri is H. Another group of compounds of Formula I includes compounds where Ri includes any one of alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl.
Another group of compounds of Formula I includes compounds where R2 is H.
Another group of compounds of Formula I includes compounds where R2 includes any one of alkyl including methyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl. Another group of compounds of Formula I includes compounds where R2 includes any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl. Another group of compounds of Formula I includes compounds where R3 is H. Another group of compounds of Formula I includes compounds where each R3 independently includes any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, substituted phenyl, -ORι0, -SR]0, -SORio, -SO2R,0, -NRι0Rιo, -NO2, -C(O)R,0, -CN, -C(O)2R10, -C(O)NR,oR,o, -SCN, -NR,0C(O)Rι0, -S(O)NR,0Rιo, -S(O)2NR10Rιo,
Figure imgf000021_0001
Another group of compounds of Formula I includes compounds where R3 includes any one of F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CN, -NO2, -ORio, -SRio, -N(R,0)2, -C(O)N(Rι0)2, or -C(O)R10, wherein each Rio is independently H, lower alkyl, or lower halogenated alkyl.
Another group of compounds of Formula I includes compounds where each Rio is independently any one or more or combination of the following: H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rι3, cycloalkyl substituted with 1 substituent selected from Rι3, heterocycloalkyl substituted with 1 substituent selected from Rι3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl.
Another group of compounds of Formula I includes compounds where each R5 is H. Another group of compounds of Formula I includes compounds where one R5 is H and the other R5 includes any one of alkyl, or substituted alkyl. Another group of compounds of Formula I includes compounds where each R5 includes any one of alkyl, or substituted alkyl.
Another group of compounds of Formula I includes compounds where R6 is H. Another group of compounds of Formula I includes compounds where R6 includes any one of alkyl, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH(alkyl), or -N(alkyl)2.
One of ordinary skill in the art will recognize that where alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, or substituted alkynyl is allowed, the following, respectively, are also allowed: lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkenyl, lower halogenated alkenyl, lower substituted alkenyl, lower alkynyl, lower halogenated alkynyl, or lower substituted alkynyl. The present invention also includes the intermediates, the processes to make them and the active compounds of Formula I, pharmaceutical compositions including the active compounds, and methods to treat the identified diseases.
The core molecule is the Azabicyclo-carboxamide/thioamide-W:
"core molecule"
Figure imgf000022_0001
Therefore, a bond directly or indirectly attached to the core molecule would be the bond attached between the substituent and W of the core molecule, e.,g., between the oxygen of -O-R and W.
Another aspect of the present invention includes, by representation but not limitation, any compound named or exemplified as a single compound or any combination thereof and pharmaceutically acceptable salt thereof, discussed herein.
For example, but not limitation, the present invention includes, but is not limited to the following compounds or pharmaceutically acceptable salt thereof:
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-pyridine-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-4-(methylthio)pyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-pyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-benzyloxy-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-2-naphthamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-8-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-ethynyl-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloroisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloroisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ethynyl isoquinoline-3-carboxamide; any of which is optionally substituted at the C-2 position of quinuclidine in the S configuration with methyl, e.g., N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- ethynyl isoquinoline-3-carboxamide.
The invention also concerns the synthesis of and isolation of stereospecific intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine, or salts thereof. Although there are known procedures for making l-azabicyclo[3.2.1]octan-3- amine, separation of the different stereoismers as described herein occurs without using a chiral HPLC separation procedure. The procedure within this invention results in an efficient selective synthesis of (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine. Another aspect of the present invention includes a method for making (3R,5R)- l-azabicyclo[3.2.1]octan-3-amine or salt thereof. One process for producing (3R,5R)- l-azabicyclo[3.2.1]octan-3-amine or a salt thereof, from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate, comprises: the process of producing (5R)-3-oxo-l- [(lS)-l-phenylethyl]-l-azoniabicyclo[3.2.1]octane chloride from (3R)-methyl 1-[(S)- 1 -phenylethyl]pyrrolidine-3 -acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof from (5R)-3-oxo-l -[( 1 S)- 1 -phenylethyl]- 1 -azoniabicyclo[3.2.1 joctane chloride; and the process of producing (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or a salt thereof from (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof.
Another process comprises: the process of producing (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate from (3R)-l-[(S)-l-phenethyl]-3- (cyanomethyl)pyrrolidine; the process of producing (5R)-3-oxo-l-[(lS)-l-phenylethyι]-l- azoniabicyclo[ 3.2.1] octane chloride from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof from (5R)-3-oxo- 1 -[(1 S)- 1 -phenylethyl]- 1 -azoniabicyclo[3.2.1 ]octane chloride; and the process of producing (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or a salt thereof from (5R)-l-azabicyclo[3.2.1]octan-3-one or a salt thereof.
Another process comprises: the process of producing (3S)-1-[(S)-1 -phenethyl] - 5-oxo-3-pyrrolidine-carboxylic acid from (S)-(-)-α-methyl benzylamine; the process of isolating (3S)-1 -[(S)- 1 -phenethyl] -5 -oxo-3-pyrrolidine- carboxylic acid from a racemic mixture using a precipitating solvent without causing the precipitation of other isomers, where the solvent can include a primary alcohol, including but not limited to methanol; the process of producing (3S)-l-[(S)-l-phenethyl]-3- (hydroxymethyl)pyrrolidine from (3S)-l-[(S)-l-phenethyl]-5-oxo-3-pyrrolidine- carboxylic acid; the process of producing (3S)-l-[(S)-l-phenethyl]-3-(chloromethyl)pyrrolidine from (3S)-l-[(S)-l-phenethyl]-3-(hydroxymethyl)pyrrolidine; the process of producing (3R)-l-[(S)-l-phenethyl]-3-(cyanomethyl)pyrrolidine from (3S)-l-[(S)-l-ρhenethyl]-3-(chloromethyl)pyrrolidine; the process of producing (3R)-methyl l-[(S)-l-phenylethyl]pyrrolidine-3- acetate from (3R)-l-[(S)-l-phenethyl]-3-(cyanomethyl)pyrrolidine; the process of producing (5R)-3-oxo-l-[(lS)-l-phenylethyl]-l- azoniabicyclo[3.2.1]octane chloride from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or salt thereof from (5R)-3-oxo- 1 -[( 1 S)- 1 -phenylethyl]- 1 -azoniabicyclo[3.2.1 joctane chloride; and the process of producing (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or salt thereof from (5R)-l-azabicyclo[3.2.1]octan-3-one or salt thereof. Another process comprises: the process of producing (3S)-1-[(S)-1 -phenethyl] -
5-oxo-3-pyrrolidine-carboxylic acid from (S)-(-)-α-methyl benzylamine; the process of producing (3S)-l-[(S)-l-phenethyl]-3- (hydroxymethyl)pyrrolidine from (3S)-l-[(S)-l-phenethyl]-5-oxo-3-pyrτolidine- carboxylic acid; the process of producing (3S)-l-[(S)-l-phenethyl]-3-(chloromethyl)pyrrolidine from (3S)- 1 -[(S)- 1 -phenethyl]-3-(hydroxymethyl)pyrrolidine; the process of producing (3R)-l-[(S)-l-phenethyl]-3-(cyanomethyl)pyrrolidine from (3S)- 1 -[(S)- 1 -phenethyl]-3-(chloromethyl)pyrrolidine; the process of producing (3R)-methyl l-[(S)-l-phenylethyl]pyrrolidine-3- acetate from (3R)-l-[(S)-l-phenethyl]-3-(cyanomethyl)pyrrolidine; the process of producing (5R)-3-oxo-l-[(lS)-l-phenylethyl]-l- azoniabicyclo[3.2.1]octane chloride from (3R)-methyl 1-[(S)-1- phenylethyl]pyrrolidine-3-acetate; the process of producing (5R)-l-azabicyclo[3.2.1]octan-3-one or salt thereof from (5R)-3-oxo-l-[(lS)-l-phenylethyl]-l-azoniabicyclo[3.2.1]octane chloride; and the process of producing (3R,5R)-l-azabicyclo[3.2.1]octan-3-amine or salt thereof from (5R)- 1 -azabicyclo [3.2. l]octan-3 -one or salt thereof.
Further aspects and embodiments of the invention may become apparent to those skilled in the art from a review of the following detailed description, taken in conjunction with the examples and the appended claims. While the invention is susceptible of embodiments in various forms, described hereafter are specific embodiments of the invention with the understanding that the present disclosure is intended as illustrative, and is not intended to limit the invention to the specific embodiments described herein.
DETAILED DESCRIPTION OF THE INVENTION
Surprisingly, we have found that compounds of Formula I:
Azabicyclo
Figure imgf000027_0001
Formula I wherein Azabicyclo is
Figure imgf000027_0002
W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a
10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six- six-fused-ring system, and further having 1-2 substitutents independently selected from R3, provided that when Azabicyclo is VII the 10-membered system has 1-2 nitrogen atoms, and further provided that when there are two R3, each R3 is other than H;
X is O or S;
Ro is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl; Ri is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
R2 is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; k is 1 or 2, provided that when k is 2, each R2 is other than H; Each R3 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, -ORio, -SRio, -SORio, -SO2Rι0, -NRi0C(O)R7, -NRi0C(O)R8, -NRι0C(O)R9, -NR,0Rι0, -NO2, -C(O)R,0, -CN, -C(O)2R,0, -C(O)NRιoR,o, -SCN, -NRι0C(O)Rι0, -S(O)NR10Rιo, -S(O)2NR10Rιo, -NRi0S(O)2R,o, R7, or R9;
Each R5 is independently H, alkyl, or substituted alkyl; R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH(alkyl), or -N(alkyl)2;
Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from Rj2 and 0-3 substituents independently selected from F, Cl, Br, or I;
Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from Rι2 and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;
Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;
Lower alkyl is both straight- and branched-chain moieties having from 1-4 carbon atoms; Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having
1 to (2n+l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
Lower halogenated alkyl is an alkyl moiety having from 1-4 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, -ORio, -SRio, -NRι0Rιo, -C(O)R10, -C(O)NR,0Rιo, -CN, -NRιoC(O)Rιo, -S(O)2NR,0Rιo, -NRι0S(O)2R10, -NO2, phenyl, or phenyl having 1 substituent selected from Rι5 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
Lower substituted alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from -ORio, -SR,o, -N(Rιo)2, -C(O)Rιo, -C(O)N(R,0)2, -CN, -NR,0C(O)R,0, -S(O)2N(R,0)2, -NRi0S(O)2Rio, -NO2, or phenyl, wherein each Rio is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl, wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl, and is further optionally substituted with one other substituent independently selected from -ORπ, -SRii, -N(Rιι)2, -C(O)R„, -C(O)N(R„)2, -CN, -CF3, -NRnC(O)Ru, -S(O)2N(R„)2, -NR, iS(O)2Rn, or -NO2, and wherein each Ri i is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;
Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond; Lower alkenyl is straight- and branched-chain moieties having from 2-4 carbon atoms and having at least one carbon-carbon double bond;
Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety; Lower halogenated alkenyl is an unsaturated alkenyl moiety having from 2-4 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R , R9, -ORio, -SRio, -NR]0Rιo, -C(O)Rιo, -C(O)NR,0Rio, -NR10C(O)R,0, -S(O)2NR,0Rιo, -NR10S(O)2R,0, -CN, phenyl, or phenyl having 1 substituent selected from Rι , and further having 0-3 substituents independently selected from F, Cl, Br, or I; Lower substituted alkenyl is lower alkenyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -OR10, -SRio, -N(R,o)2, -C(O)Rι0> -C(O)N(R,0)2, -CN, -NR,0C(O)R10, -S(O)2N(R,0)2, -NR,oS(O)2R,o, -NO2, or phenyl, wherein each Rio is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl, wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl, and is further optionally substituted with one other substituent independently selected from -ORn, -SR, ,, -N(Rι,)2, -C(O)R„, -C(O)N(Rn)2, -CN, -CF3, -NR„C(O)Rn, -S(O)2N(Rι ι)2, -NRuS(O)2Rn, or -NO2, and wherein each Ri i is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl; Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
Lower alkynyl is straight- and branched-chained moieties having from 2-4 carbon atoms and having at least one carbon-carbon triple bond;
Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
Lower halogenated alkynyl is an unsaturated alkynyl moiety having from 3-4 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety; Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R7, R9, -ORio, -SRio, -NRι0Rιo, -C(O)Rι0, -C(O)NRιoRιo, -NRi0C(O)Rio, -S(O)2NR10R,o, -NRι0S(O)2R,0, -CN, phenyl, or phenyl having 1 substituent selected from Rι5, and further having 0-3 substituents independently selected from F, Cl, Br, or I;
Lower substituted alkynyl is lower alkynyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -OR10, -SRio, -N(R,o)2, -C(O)R,o, -C(O)N(Rιo)2, -CN, -NR10C(O)R10, -S(O)2N(R10)2, -NR,0S(O)2Rιo, -NO2, or phenyl, wherein each Rio is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl, wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl, and is further optionally substituted with one other substituent independently selected from -ORn, -SR„, -N(R„)2, -C(O)R„, -C(O)N(Rπ)2, -CN, -CF3, -NRnC(O)Rπ, -S(O)2N(Ru)2, -NRnS(O)2Rii, or -NO2, and wherein each Ri i is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;
Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;
Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl; Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -ORio, -SRio, -NRioRio, -C(O)Rι0, -CN, -C(O)NRι0Rιo, -NR10C(O)R,o, -S(O)2NRιoRιo, -NRι0S(O)2Rι0, -NO2, phenyl, or phenyl having 1 substituent selected from Rι5, and further having 0-3 substituents independently selected from F, Cl, Br, or I;
Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(Rι9)-, or -O-;
Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R]9)-, or -O-, and having 1-4 substituents independently selected from F, or Cl;
Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(Rι )-, or -O- and having 0-3 substituents independently selected from -F, or -Cl, and further having 1 substituent selected from R7, R9, -ORio, -SRio, -NR10R,0, -C(O)R10, -C(O)NR,0Rιo, -CN, -NRι0C(O)Rι0, -NO2, -S(O)2NRιoRιo, -NRi0S(O) Rio, phenyl, or phenyl having 1 substituent selected from Ris and further having 0-3 substituents independently selected from F, Cl, Br, or I;
Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a =O on a carbon adjacent to said nitrogen, and having up to 1 additional ring atom being oxygen, sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or Rι5 where valency allows;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from -O-, =N-, -N(Rt )-, and -S-, and having 0-1 substituent selected from Rι5 and 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
Figure imgf000032_0001
wherein each A is independently CRι8 or N, provided that only up to one A is N, E1 and E2 are independently selected from CRι8, O, S, or NRt , and G is CRι8, provided
1 7 that R[8 or Rι4 of E , E , and G can be a bond when — forms a double bond and further provided that only one Rι8 or R]4 can be a bond for bonding R7 to a moiety to which it is attached;
Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or Rι5; R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from Rι2 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or
R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from Rι and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond for bonding R9 to a moiety to which it is attached where valency allows;
Each Rio is independently -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rι3, cycloalkyl substituted with 1 substituent selected from R) , heterocycloalkyl substituted with 1 substituent selected from Rι3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
Each Ri i is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; Rι2 is -ORi i, -SRi i, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRπ, -C(O)Rn, -NO2, -C(0)NRnRn, -CN, -NRπCΪOjR,,, -S(O)2NR, ,Rn, or -NR,,S(O)2Rn;
R13 is -ORn, -SR, ,, -NRnRii, -C(O)Ru, -SOR„, -SO2Rn, -C(O)NRnRu, -CN, -CF3, -NR„C(O)Rn, -S(O)2NR,,R,,, -NRπS(O)2Rn, or -NO2;
Each Rι4 is independently bond, H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
Ris is alkyl, substituted alkyl, halogenated alky, -ORn, -CN, -NO2, -NRJORIO; Each Rι is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRi i, -NR] iRn, -C(O)Rπ, -NO2, -C(O)NRιιRπ, -CN, -NRπC(O)Rπ, -S(O)2NRπRπ, or -NRπS(O)2Rπ, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRπ, -NRnRπ, -C(O)Rπ, -NO2, -C(O)NRιιRπ, -CN, -NR,,C(O)R,,, -S(O)2NRπRπ, or -NRiiS(O)2R,„ and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;
Rι is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and Rj5; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
The compound of Formula I are used to treat, or are used to prepare medicament(s) to treat, a disease or condition, wherein the diseases, disorders, and or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g., "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" or "hr" for hour or hours, min for minute or minutes, and "rt" or "RT" for room temperature).
All temperatures are in degrees Centigrade.
Room temperature is within the range of 15-25 degrees Celsius. AChR refers to acetylcholine receptor. nAChR refers to nicotinic acetylcholine receptor.
Pre-senile dementia is also known as mild cognitive impairment.
5HT3R refers to the serotonin-type 3 receptor. α-btx refers to α-bungarotoxin. FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecular Screening, 1(2), p 75-80, 1996).
TLC refers to thin-layer chromatography.
HPLC refers to high pressure liquid chromatography. MeOH refers to methanol.
EtOH refers to ethanol.
IP A refers to isopropyl alcohol.
THF refers to tetrahydrofuran. DMSO refers to dimethylsulfoxide.
DMF refers to N,N-dimethylformamide.
EtOAc refers to ethyl acetate.
TMS refers to tetramethylsilane. TEA refers to triethylamine.
DIEA refers to N.N-diisopropylethylamine.
MLA refers to methyllycaconitine.
Ether refers to diethyl ether.
HATU refers to O-(7-azabenzotriazol-l-yl)-Ν,Ν,Ν', N'-tetramethyluronium hexafluorophosphate .
DBU refers to l,8-diazobicyclo[5.4.0]undec-7-one.
CDI refers to carbonyl diimidazole.
NMO refers to N-methylmorpholine-N-oxide.
TPAP refers to tetrapropylammonium perruthenate. Halogen is F, Cl, Br, or I.
Na SO4 refers to sodium sulfate.
K2CO3 refers to potassium carbonate.
MgSO4 refers to magnesium sulfate.
When Na2SO , K2CO3, or MgSO4 is used as a drying agent, it is anhydrous. The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Cj-j indicates a moiety of the integer 'i" to the integer "j" carbon atoms, inclusive. Thus, for example, Cι-6 alkyl refers to alkyl of one to six carbon atoms. Non-inclusive examples of heteroaryl compounds that fall within the definition of R7 and R9 include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pydridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl. Non- inclusive examples of heterocycloalkyl include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine, azetidino, azetidinono, oxindolo, dihydroimidazolo, and pyrrolidinono
Mammal denotes human and other mammals. Brine refers to an aqueous saturated sodium chloride solution.
Equ means molar equivalents.
IR refers to infrared spectroscopy.
Lv refers to leaving groups within a molecule, including Cl, OH, or mixed anhydride. NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from TMS.
MS refers to mass spectrometry expressed as m/e or mass/charge unit. HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit. [M+H]+ refers to an ion composed of the parent plus a proton. [M-H]" refers to an ion composed of the parent minus a proton. [M+Na]+ refers to an ion composed of the parent plus a sodium ion. [M+K]+ refers to an ion composed of the parent plus a potassium ion. El refers to electron impact. ESI refers to electrospray ionization. CI refers to chemical ionization. FAB refers to fast atom bombardment.
Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), tert butoxy carbonyl (BOC) and the like. Examples of other suitable amino protecting groups are known to person skilled in the art and can be found in "Protective Groups in Organic synthesis," 3rd Edition, authored by Theodora Greene and Peter Wuts.
Compounds of the present invention maybe in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino- ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of Cι-6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect. As pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.
The amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely. The compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I. The pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in one to four doses per day.
In addition to the compound(s) of Formula I, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients. The term "carrier" material or "excipient" herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration. Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl- methyl cellulose, or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition. In addition to the oral dosing, noted above, the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable carrier. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The serotonin type 3 receptor (5HT R) is a member of a superfamily of ligand- gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the γ-aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT3R exhibits a large degree of sequence homology with α7 nAChR but functionally the two ligand-gated ion channels are very different. For example, α7 nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT3R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin. These experiments suggest that the α7 nAChR and 5HT R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT3R antagonist, has little activity at the α7 nAChR. The converse is also true. For example, GTS-21 , a highly selective α7 nAChR agonist, has little activity at the 5HT R.
OJ nAChR is a ligand-gated Ca++ channel formed by a homopentamer of α7 subunits. Previous studies have established that α-bungarotoxin (α-btx) binds selectively to this homopetameric, α7 nAChR subtype, and that α7 nAChR has a high affinity binding site for both α-btx and methyllycaconitine (MLA). α7 nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas. α7 nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
Data from human and animal pharmacological studies establish that nicotinic cholinergic neuronal pathways control many important aspects of cognitive function including attention, learning and memory (Levin, E.D., Psychopharmacology, 108:417-31, 1992; Levin, E.D. and Simon B.B., Psychopharmacology, 138:217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that activates α4β2 and α7 nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et. al., Psychopharmacology (Berl)., 142(4):334-42, Mar. 1999; Wilens, T. E. et. al., Am. J. Psychiatry, 156(12):1931-7, Dec. 1999). It is also clear that nicotine and selective but weak α7 nAChR agonists increase cognition and attention in rodents and non-human primates. Schizophrenia is a complex multifactorial illness caused by genetic and non- genetic risk factors that produce a constellation of positive and negative symptoms. The positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing. No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors. Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and delusions. Clozapine, an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine' s utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., Am J Psychiatry, 153:321- 30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder. One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating. In this test, electroencepholographic (EEG) recordings of neuronal activity of the hippocampus are used to measure the subject's response to a series of auditory "clicks" (Adler, L.E. et. al., Biol. Psychiatry, 46:8-18, 1999). Normal individuals respond to the first click with greater degree than to the second click. In general, schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, CM. et. al., Schizophr. Res., 10:131-41, 1993). These data reflect a schizophrenic's inability to "filter" or ignore unimportant information. The sensory gating deficit appears to be one of the key pathological features of this disease (Cadenhead, K.S. et. al., Am. J. Psychiatry, 157:55-9, 2000). Multiple studies show that nicotine normalizes the sensory deficit of schizophrenia (Adler, L.E. et. al., Am. J. Psychiatry, 150:1856-61, 1993). Pharmacological studies indicate that nicotine's effect on sensory gating is via the α7 nAChR (Adler, L.E. et. al., Schizophr. Bull, 24:189-202, 1998). Indeed, the biochemical data indicate that schizophrenics have 50% fewer of α7 nAChR receptors in the hippocampus, thus giving a rationale to partial loss of α7 nAChR functionality (Freedman, R. et. al., Biol Psychiatry, 38:22-33, 1995). Interestingly, genetic data indicate that a polymorphism in the promoter region of the α7 nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., Proc. Nat'l Acad. Sci. USA, 94(2):587-92, 1997; Myles-Worsley, M. et. al., Am. J. Med. Genet, 88(5):544-50, 1999). To date, no mutation in the coding region of the α7 nAChR has been identified. Thus, schizophrenics express the same α7 nAChR as non-schizophrenics. Selective α7 nAChR agonists may be found using a functional assay on FLIPR
(see WO 00/73431 A2). FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes. This assay may be used to accurately measure the functional pharmacology of α7 nAChR and 5HT3R. To conduct such an assay, one uses cell lines that expressed functional forms of the OJ nAChR using the α7/5-HT3 channel as the drug target and cell lines that expressed functional 5HT3R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.
The compounds of the present invention are α7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.
Schizophrenia is a disease having multiple aspects. Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat the cognitive and attention deficits associated with schizoaffective disorders, or similar symptoms found in the relatives of schizophrenic patients. Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him. In the past, the term psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
There are a variety of antipsychotic drugs. The conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
These conventional antipsychotic drugs have several side effects, including sedation, weight gain, tremors, elevated prolactin levels, akathisia (motor restlessness), dystonia and muscle stiffness. These drugs may also cause tardive dyskinesia. Unfortunately, only about 70% of patients with schizophrenia respond to conventional antipsychotic drugs. For these patients, atypical antipsychotic drugs are available.
Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects. Although these drugs each produce different side effects, as a group the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.
In a combination therapy to treat multiple symptoms of diseases such as schizophrenia, the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously. Examples of anti-psychotic drugs, in addition to those listed above, include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX, Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.
A pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I and a therapeutically effective amount of anti-psychotic drugs. These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and maybe formulated as sustained relief dosage forms and the like.
When separately administered, therapeutically effective amounts of compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule. One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval. A therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b). The methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.
As discussed, the compounds of the present invention are al nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
Alzheimer's disease has many aspects, including cognitive and attention deficits. Currently, these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects. Thus, there is a need for a drug that stimulates a portion of the cholinergic pathways and thereby provides improvement in the cognitive and attention deficits associated with Alzheimer's disease without the side effects created by nonspecific stimulation of the cholinergic pathways. Neurodegeneration is a common problem associated with diseases such as
Alzheimer's disease. While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease. Pre-senile dementia (mild cognitive impairment) concerns memory impairment rather than attention deficit problems and otherwise unimpaired cognitive functioning. Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. There currently is no medication specifically identified for treatment of mild cognitive impairment, due somewhat to the newness of identifying the disease. Therefore, there is a need for a drug to treat the memory problems associated with mild cognitive impairment.
Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits. Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.
As discussed, the compounds of the present invention are α7 nAChR agonists. Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Attention deficit disorder is generally treated with methylphenidate, an amphetamine-like molecule that has some potential for abuse. Accordingly, it would be desirable to provide a drug that treats attention deficit disorder while having fewer side effects than the currently used drug.
Attention deficit hyperactivity disorder, otherwise known as ADHD, is a neurobehavioral disorder affecting 3-5% of all American children. ADHD concerns cognitive alone or both cognitive and behavioral actions by interfering with a person's ability to stay on a task and to exercise age-appropriate inhibition. Several types of ADHD exist: a predominantly inattentive subtype, a predominantly hyperactive- impulsive subtype, and a combined subtype. Treatment may include medications such as methylphenidate, dextroamphetamine, or pemoline, which act to decrease impulsivity and hyperactivity and to increase attention. No "cure" for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.
Depression is a mood disorder of varying lengths of normally several months to more than two years and of varying degrees of feelings involving sadness, despair, and discouragement. The heterocyclic antidepressants (HCA's) are currently the largest class of antidepressants, but monoamine oxidase inhibitors (MAOI's) are used in particular types of depression. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.
Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of umet medical needs in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IN (1994), pp 393-394, for various disease forms of anxiety.
General anxiety disorder (GAD) occurs when a person worries about things such as family, health, or work when there is no reason to worry and is unable not to worry. About 3 to 4% of the U.S. population has GAD during the course of a year. GAD most often strikes people in childhood or adolescence, but can begin in adulthood, too. It affects women more often than men. Currently, treatment involves cognitive-behavioral therapy, relaxation techniques, and biofeedback to control muscle tension and medications such as benzodiazepines, imipramine, and buspirone. These drugs are effective but all have side-effect liabilities. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.
Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed. The disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp. The affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly lost a loved one. Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression. Various forms of exposure therapy (such as systemic desensitization and imaginal flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.
Mood and affective disorders fall within a large group of diseases, including monopolar depression and bi-polar mood disorder. These diseases are treated with three major classes of compounds. The first group is the heterocyclic antidepressant (HCA's). This group includes the well-known tricyclic antidepressants. The second group of compounds used to treat mood disorders is the monoamine oxidase inhibitors (MAOI's) that are used in particular types of diseases. The third drug is lithium. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Benign side effects from the use of lithium include, but are not limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor. Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful. Borderline personality disorder, although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.
Acquired immune deficiency syndrome (AIDS) results from an infection with the human immunodeficiency virus (HIN). This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems. HIN infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS. Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement. Currently, there is no cure for amyotrophic lateral sclerosis although patients may receive treatment from some of their symptoms and although Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.
Traumatic brain injury occurs when the brain is damaged from a sudden physical assault on the head. Symptoms of the traumatic brain injury include confusion and other cognitive problems. Therefore, there is a need to address the symptoms of confusion and other cognitive problems.
Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms of behavioral and cognitive problems.
Persons with Down's syndrome have in all or at least some of their cells an extra, critical portion of the number 21 chromosome. Adults who have Down's syndrome are known to be at risk for Alzheimer-type dementia. Currently, there is no proven treatment for Down's syndrome. Therefore, there is a need to address the dementia associated with Down's syndrome.
Genetically programmed degeneration of neurons in certain areas of the brain cause Huntington's disease. Early symptoms of Huntington's disease include mood swings, or trouble learning new things or remembering a fact. Most drugs used to treat the symptoms of Huntington's disease have side effects such as fatigue, restlessness, or hyperexcitability. Currently, there is no treatment to stop or reverse the progression of Huntington's disease. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects. Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently, treatment concerns addressing the parkinsonian and psychiatric symptoms. However, medicine to control tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need of a pharmaceutical agent to treat dementia with Lewy bodies.
Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.
Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address the symptoms of tardive dyskinesia.
Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances. Currently, there is no specific treatment or cure for Pick's disease but some symptoms can be treated with cholinergic and serotonin-boosting antidepressants. In addition, antipsychotic medications may alleviate symptoms in FTD patients who are experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.
Dysregulation of food intake associated with eating disease, including bulemia nervosa and anorexia nervosa, involve neurophysiological pathways. Anorexia nervosa is hard to treat due to patients not entering or remaining in after entering programs. Currently, there is no effective treatment for persons suffering from severe anorexia nervosa. Cognitive behavioral therapy has helped patients suffering from bulemia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.
Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.
Smoke cessation programs may involve oral dosing of the drug of choice. The drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during the day. The preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed. Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help control nicotine craving or thoughts about cigarette use in people trying to quit. Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking. These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous injection, especially if sustained release formulations are used.
Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.
In addition drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug. Drugs that produce strong physical dependence, such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some pleasurable manner. Among the drugs that are commonly abused are ethyl alcohol, opioids, anxiolytics, hypnotics, cannabis (marijuana), cocaine, amphetamines, and hallucinogens. The current treatment for drug-addicted people often involves a combination of behavioral therapies and medications. Medications, such as methadone or LAAM (levo-alpha-acetyl-methadol), are effective in suppressing the withdrawal symptoms and drug craving associated with narcotic addiction, thus reducing illicit drug use and improving the chances of the individual remaining in treatment. The primary medically assisted withdrawal method for narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal symptoms, and then gradually taper off the substitute medication. The medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives. Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.
Gilles de la Tourette's Syndrome is an inherited neurological disorder. The disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements. The symptoms generally manifest in an individual before the person is 18 years of age. The movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones. Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances. Coprolalia (involuntary scatologic utterances) occurs in 50% of patients. Severe tics and coprolalia may be physically and socially disabling. Tics tend to be more complex than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.
Currently simple tics are often treated with benzodiazepines. For simple and complex tics, Clonidine may be used. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases, antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.
Age-related macular degeneration (AMD) is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision required for "straight ahead" activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD. Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision. Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease intraocular pressure. However, current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.
Ischemic periods in glaucoma cause release of excitotoxic amino acids and stimulate inducible form of nitric oxide synthase (iNOS) leading to neurodegeneration. Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitablity. Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma. Persons afflicted with pain often have what is referred to as the "terrible triad" of suffering from the pain, resulting in sleeplessness and sadness, all of which are hard on the afflicted individual and that individual's family. Pain can manifest itself in various forms, including, but not limited to, headaches of all severity, back pain, neurogenic, and pain from other ailments such as arthritis and cancer from its existence or from therapy to eradicate it. Pain can be either chronic (persistent pain for months or years) or acute (short-lived, immediate pain to inform the person of possible injury and need of treatment). Persons suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective methods for treating pain. Finally, the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs (also called an anti-psychotic agent). All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs. Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol. Some atypical antipsychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine. Compounds of Formula I can be prepared as shown in Scheme 1. The key step in the preparation of this class of compounds is the coupling of an amino-azabicyclic moiety with the requisite acid chloride (Lv = Cl), mixed anhydride (e.g., Lv = diphenyl phosphoryl, bis(2-oxo-3-oxazolidinyl)phosphinyl, or acyloxy of the general formula of O-C(O)-RLv, where R v includes phenyl or t-butyl), or carboxylic acid (Lv = OH) in the presence of an activating agent. Suitable activating reagents are well known in the art, for examples see Kiso, Y., Yajima, H. "Peptides" pp. 39-91, San Diego, CA, Academic Press, (1995), and include, but are not limited to, agents such as carbodiimides, phosphonium and uronium salts (such as HATU).
Scheme 1
Lv W + Azabicyclo-NH2 ► Azabicyclo — N W
0 O
Generally, the acid is activated using HATU or is converted to the acyl azide by using DPPA or is converted into a mixed anhydride by treatment with bis (2-oxo-3- oxazolidinyl) phosphinic chloride in the presence of TEA with CH C12 or CHC13 as the solvent. In the case where R6 is tert-butyloxycarbonyl (where Azabicyclo is VII), deprotection of the 7-aza group can be conveniently accomplished under acidic conditions in a suitable solvent such as methanol.
Preferably, for Azabicyclo III, Azabicyclo IV, and Azabicyclo VII, the acid is converted into a mixed anhydride by treatment with bis (2-oxo-3 -oxazolidinyl) phosphinic chloride in the presence of TEA with CH2C12 or CHC13 as the solvent. The resulting anhydride solution is directly reacted with the appropriate Azabicyclo moiety added neat or using DMF or aqueous DMF as solvent. In some cases, the ester (Lv being OMe or OEt) may be reacted directly with the amine in refluxing methanol or ethanol to give the compounds of Formula I.
The appropriate amine is reacted with TEA if the amine is in the form of an acid salt and added to a solution of the appropriate anhydride or azide to give the desired final compounds. In some cases, the ester (Lv being OMe or OEt) may be reacted directly with the amine in refluxing methanol or ethanol to give the compounds of Formula I.
Substituted ?-naphthoic acids are prepared by several known methods, making noncritical changes (Schemes 2-4). The acids required in Examples 2, 3 and 4 are synthesized from the requisite naphthols according to the method of Kehr et. al. (Kehr, C; Neidlein, R.; Engh, R.A.; Brandstetter, H.; Kucznierz, R.; Leinert, H.; Marzenal, K.; Strein, K.; von der Saal, W. Helv. Chim. Acta 1997, 80, 892. However, the conditions for the conversion of the triflate to the nitrile in Tschaen, D.M. et. al. Syn. Comm., 1994, 24, 887 are more effective in these examples). The naphthol is converted to the trilate with an aryl sulfonimide in the presence of a base. Cyanation of the triflate is accomplished by the action of a palladium catalyst in the presence of zinc cyanide. Hydrolysis of the resulting nitrile with potassium hydroxide yields the naphthoic acid.
Scheme 2
Figure imgf000054_0001
The acids required for Examples 5 and 6 are constructed from methoxynaphthonitrile as shown in Scheme 3. The methyl ether is removed with boron tribromide in dichloromethane. Conditions for demethylation of a methyl ether are well know in the art (for examples see Greene, T.W.; and Wuts, P.G.M. Protective Groups in Organic Synthesis, Wiley Interscience: New York, 1991; ppl46-149 and references therein). The resulting alcohol is reacted with a base such as sodium hydride followed by benzyl bromide to give the benzyl ether. Conditions for benzylation of a phenol are also well known in the art (for examples see Greene, T.W.; and Wuts, P.G.M. Protective Groups in Organic Synthesis, Wiley Interscience: New York, 1991; pp 156 and references therein). For Example 6, the required hydroxy acid is synthesized by removal of the corresponding benzyl ether by catalytic transfer hydrogenation using palladium on carbon as the catalyst and 1,4-cyclohexadiene.
Scheme 3
Figure imgf000055_0001
In Example 7, the triflate intermediate described above is converted directly to the desired carboxylic amide by a palladium catalyzed carbonylation in the presence of 3-aminoquinulcidine. (Hammarberg, et. al. J. Med. Chem, 2000, 43, 2827-2850, Scheme 4).
Scheme 4
Figure imgf000055_0002
Substituted isoquinoline carboxylic acids in Examples 13 and 14 are synthesized from the corresponding phthalic acids as shown in Scheme 5. The phthalic acid is converted to the diester under Fisher esterification conditions, reduced to the diol with LAH then oxidized to the dialdehyde under Swern conditions (Faroq, O. Synthesis, 1994, 1035-1036). The dialdehyde is treated with a phosphonoglycinate reagent to form the isoquinoline ring. (Hiebl, J.; et.al. Jet. Lett., 1999, 40, 7935- 7938. Zoller, U.; Ben-Ishai, D. Tetrahedron, 1975, 31, 863-866. Schmidt, U.; Lieberknecht, A.; Wild, j. Synthesis, 1984, 53-60.). Hydrolysis of the ester with potassium hydroxide is well known in the art and gives the isoquinoline carboxylic acid.
Scheme 5
Figure imgf000055_0003
One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-aminoquinuclidine (R2 is H) are equally applicable to substituted compounds (R2 is other than H). Certain 6-substituted-[2.2.2]-3-amines (Azabicyclo I) are known in the art. The preparation of compounds where R2 is at C-6 of the quinuclidine and is other than H is described in Acta Pol. Pharm. 1981, 179. Certain 2-substituted-[2.2.2]-3-amines (Azabicyclo I) are known in the art. The preparation of compounds where R2 is at C-2 of the quinuclidine and is other than H is described in J. Med. Chem. 1975, 18, 587.
Alternatively, there are several methods by which the amine precursor for Azabicyclo I where R2 is other than H can be obtained. Although the scheme depicted below is for compounds where R2 is at the C-6 position of the quinuclidine, one of ordinary skill in the art would be able to obtain the quinuclidine with substitution at C-2 also. The substituted-[2.2.2]-3-amine can be prepared by reduction of an oxime or an imine of the corresponding substituted-3-quinuclidinone by methods known to one of ordinary skill in the art (see J. Labelled Compds. Radiopharm. 1995, 53; J. Med. Chem. 1998, 988; Synth. Commun. 1992, 1895; Synth. Commun. 1996, 2009). Alternatively, the substituted-[2.2.2]-3-amine can be prepared from a substituted- 3- hydroxyquinuclidine by Mitsunobu reaction followed by deprotection as described in Synth. Commun. 1995, 1895. Alternatively, the substituted-[2.2.2]-3-amine can be prepared by conversion of a substituted-3-hydroxyquinuclidine into the corresponding mesylate or tosylate, followed by displacement with sodium azide and reduction as described inJ. Med. Chem. 1975, 587.
Figure imgf000056_0001
The 2-substituted-3-quinuclidinones, where R2 is substituted alkyl or cycloalkyl, can be prepared by known procedures (see Jett. Eett. 1972, 1015; J. Am. Chem. Soc. 1994, 1278; J. Am. Chem. Soc. 1989, 4548; Tetrahedron, 2000, 1139). The 2-substituted-3-quinuclidinones, where R2 is aryl, can be prepared by palladium catalyzed arylation as described inJ. Am. Chem. Soc. 1999, 1473 andJ. Am. Chem. Soc. 2000, 1360. The 6-substituted-3-quinuclidinones can be prepared by known procedures (see J. Gen. Chem. Russia 1963, 3791, J. Chem. Soc. Perkin Trans. 71991, 409, J. Org. Chem. 2000, 3982).
One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-amino-l-azabicyclo[2.2.1]heptane (R2=H) are equally applicable to substituted compounds (R2 ?? H). For where Azabicyclo II has substitution at C-2, compounds can be prepared from appropriately substituted nitro alcohols using procedures described in Tetrahedron (1997), 53, p. 11121 as shown below. Methods to synthesize nitro alcohols are well known in the art (see J. Am. Chem. Soc. (1947), 69, p 2608). The scheme below is a modification of the synthesis of exo-3-amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein, to show how to obtain these amine precursors. The desired salt can be made using standard procedures.
Figure imgf000057_0001
Figure imgf000058_0001
exo-2-sub-[2.2.1]-3 Amine
For Azabicyclo II where R2 is other than H at the C-6 position, compounds can also be prepared by modification of intermediates described in the synthesis of exø-3- amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein. For example, Int 6 can be oxidized to the aldehyde and treated with an organometallic reagent to provide Int 20 using procedures described in Tetrahedron (1999), 55, p 13899. Int 20 can be converted into the amine using methods described for the synthesis of exo-3-amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt. Once the amine is obtained, the desired salt can be made using standard procedures.
e
Figure imgf000058_0002
xo-6-sub-[2.2.1]-3-Amine
Int 21
The schemes used are for making exo-3-amino-l-azabicyclo[2.2.1]heptane. However, the modifications discussed are applicable to make the endo isomer also. One of ordinary skill in the art will also recognize that the methods described for the reaction of the unsubstituted 1 -azabicyclo[3.2.1 ]octan-3-amine or 1 - azabicyclo[3.2.2]nonan-3-amine (R2=H) are equally applicable to substituted compounds (R2 ? H). The R2 substituent may be introduced as known to one skilled in the art through standard alkylation chemistry. Exposure of 1- azabicyclo[3.2.1]octan-3-one or l-azabicyclo[3.2.2]nonan-3-one to a hindered base such as LDA (lithium diisopropylamide) in a solvent such as THF or ether between 0°C to -78°C followed by the addition of an alkylating agent (R2Lv, where Lv = Cl, Br, I, OTs, etc.) will, after being allowed to warm to about 0°C to rt followed by an aqueous workup, provide the desired compound as a mixture of isomers. Chromatographic resolution (flash, HPLC, or chiral HPLC) will provided the desired purified alkylated ketones. From there, formation of the oxime and subsequent reduction will provide the desired stereoisomers.
N-(2-azabicyclo[2.2.1]hept)-5-amine and 6-amine:
Figure imgf000059_0001
2-azabicyclo[2.2.1]heptan-5-amine
[2.2.1]-5-Amine
Figure imgf000059_0002
2-azabicyclo[2.2.1]heptan-6-amine [2.2.1]-6-Amine where Lv can be -CH2Ph, -CH(Me)Ph, -OH, -OMe, or -OCH2Ph.
The respective amine precursors for Azabicyclo V and Azabicyclo NI can be prepared by reduction of an oxime or an imine of the corresponding N-2- azabicyclo[2.2. l]-heptanone by methods known to one skilled in the art (see J. Labelled Compds. Radiopharm., 53-60 (1995), J. Med. Chem. 988-995, (1998), Synth. Commun. 1895-1911 (1992), Synth. Commun. 2009-2015 (1996)). The oximes can be prepared by treatment of the N-2-azabicyclo[2.2.1]heptanones with hydroxylamine hydrochloride in the presence of a base. The imines can be prepared by treatment of the N-2-azabicyclo[2.2.1]-heptanones with a primary amine under dehydrating conditions. The N-2-azabicyclo[2.2.1 ]heptanones can be prepared by known procedures (see Jet. Eett. 1419-1422 (1999), J. Med. Chem. 2184-2191 (1992), J. Med. Chem. 706-720 (2000), J. Org. Chem., 4602-4616 (1995)).
It will be apparent to those skilled in the art that the requisite carboxylic acids can be obtained through synthesis via literature procedures or through the slight modification thereof.
AMINES
Preparation of N-(2S,3R)-2-methyl-l-azabicyclo[2.2.2]octan-3-amine dihydrochloride (2S-methyl-2.2.2-Amine): Preparation of 2-methylquinuclidin-3-one.
A mixture of 2-methylene-3-quinuclidinone dihydrate hydrochloride (27.18g, 0.1296mol, leq) and K2CO3 (86.0g, 0.6213mol, 4.8eq) is dissolved in 130mL water and 250mL CH2C12 and stirred vigorously. After 3 days, the layers are separated and the aqueous layer is extracted with CH2C12. The combined organic layers are dried (MgSO4), filtered and concentrated to give 17.8g (100%) of 2-methylenequinuclidin- 3-one as a yellow oil. MS (ESI) for C8Hι,NO m/z 138.1 (M+).
Preparation of 2-methylquinuclidin-3-one. 2-Methylenequinuclidin-3-one (17.8g, 0.1296mol, leq) is dissolved in 40mL
MeOH in a Parr hydrogenation bottle. A THF slurry of 10% Pd/C (0.57g) is added. The mixture is hydrogenated for 45 min at 45 psi, recharging as needed. The mixture is filtered through a pad of Celite. The Celite is washed with excess MeOH. The solution is concentrated to give a solid and a yellow oil. The mixture is taken up in ether, filtered and concentrated to provide 16.2g (90%) of 2-methylquinuclidin-3-one. MS (ESI) for C8Hι3NO m/z 140.2 (M+).
Preparation of (3E/Z)-2-methyl- 1 -azabicyclo[2.2.2]octan-3-one oxime hydrochloride. 2-Methylquinuclidin-3-one (39.59g, 0.2844mol, leq) and hydroxylamine hydrochloride (20. Og, 0.2878mol, l.Oleq) are dissolved in 170mL absolute ΕtOH. The mixture is heated under reflux until a clear solution develops (about 20 min), after which is immediately followed by formation of a white precipitate. The reaction is cooled and allowed to stand overnight. The mixture is cooled in an ice bath, the solids are filtered and dried (house vacuum) to provide 46.4g of (3E/Z)-2-methyl-l- azabicyclo[2.2.2]octan-3-one oxime hydrochloride. A second crop of 2.4g is also obtained. Overall yield is 48.8g (90%). The 2-methyl-l-azabicyclo[2.2.2]octan-3-one oxime hydrochloride is a 4:1 mixture of oxime isomers. MS (ΕSI) for C8Hι4N2O m/z 154.8 (M+). Partial Η NMR (400 MHz, DMSO) ? 4.39 (0.2H), 4.29 (0.8H), 1.57 (0.6H), 1.47 (2.4H).
Preparation of trans 2-methyl-l-azabicyclo[2.2.2]octan-3-amine dihydrochloride. A solution of sodium n-propoxide (prepared from 5.5g sodium (0.24mol) and lOOmL n-propanol) is added dropwise to a suspension of (3E/Z)-2-methyl-l- azabicyclo[2.2.2]octan-3-one oxime hydrochloride (45.8g, 0.24mol, leq) in 150 mL n-propanol. After complete addition, 250mL of n-propanol is added, and the mixture is heated under reflux. Sodium (55.2g, 2.40mol, 10 eq) is added in portions to the refluxing mixture. The mixture is heated under reflux overnight. After about 14h, the mixture is cooled, water is added and the layers are separated. The n-propanol layer is washed with brine and dried (MgSO ). The combined aqueous layers are extracted with CHC13 and dried (MgSO ). The combined, dried organic layers are treated with about 70mL concentrated HCl. The solvent is removed in vacuo. Absolute ΕtOH is added, and the solvent is removed. The sequence is repeated 2-3 times with fresh ΕtOH until a white solid formed. Absolute ΕtOH is added, the solids are filtered and dried (vacuum oven, about 60°C) to provide 36.5g of trans 3-amino-2- methylquinuclidine dihydrochloride. MS (ΕSI) for C8Hι6N2 m/z 141.3 (M+). Additional material is obtained from the mother liquor: 7.8g (2nd crop) and 1.5g (3rd crop); this material is a mixture of both trans and cis isomers.
Preparation of 4-chloro-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yljbenzamide. 4-Chlorobenzoic acid (26.3g, 0.1681mol, l.leq) and TEA (106mL, 0J64mol,
5eq.) are dissolved in 300mL THF. Diphenylphosphoryl chloride (32.0mL, 0.1681mol, l.leq) is added dropwise. After lh, trans 2-methylquinuclidin-3-amine dihydrochloride (32.6g, 0.1528mol, leq) is added. The mixture is allowed to stir at RT overnight. IN NaOH (about lOOmL) is added, and the pH is adjusted to pH 11 with 50%) NaOH and about 50g K2CO . The layers are separated. The aqueous layer is extracted with CHC1 . The combined organic layers are dried (MgSO4), filtered and concentrated. The residue is taken up in heptane and concentrated to give 35. lg (82%>) of 4-chloro-N-(2-methyl-l-azabicyclo[2.2.2]oct-3-yl)phenyl-2-carboxamide as a light yellow solid. The enantiomers are separated on a 5 x 50 cm Chiralcel OD column at 30°C, eluting with 15% IP A heptane + 0.1% DEA at 90mL/min to provide 17.4g of the eutomer at about 97% ee. The p-TsOH salt is prepared and recrystallized from EtOH/EtOAc. [?]25 D = +3° (c 0.96, methanol). HRMS (FAB) calcd for Cι5H,9ClΝ2O +H 279.1264, found 279.1272.. Preparation of N-(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]octan-3-amine dihydrochloride.
A solution of 4-chloro-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]benzamide (17.2g, 61 Jmmol) in absolute EtOH (70mL) and concentrated HCl (70mL) is heated under reflux for about 64h. The reaction is monitored for disappearance of starting amide by reverse phase HPLC (ZORBAX Eclipse XDB-C8, 4.6mm x 15cm, 80:12:8 H2O/CH3CΝ/IPA). The solvent is removed in vacuo. The residue is dissolved/suspended in EtOH and the solvent is removed (twice). The solid is suspended in boiling EtOH, filtered and dried (vacuum oven, about 60°C) to provide 8.8g (67%) of N-(2S,3R)-2-methyl-l-azabicyclo[2.2.2]octan-3-amine dihydrochloride as a white solid. MS (El) m/z 141.2 (M+).
Preparation of the l-azabicyclo-2.2.1 Amines: Synthesis of (3R,4S)-3-amino-l-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt (ex -[2.2.1]-Amine):
HO-\^Ν02 Br^^C02Et I Step A I Step B
,NO,
BzO HN^,ph
Int 1 S Stteepp CC - O Int 2
Int 3
Figure imgf000062_0001
Step A. Preparation of 2-(benzoyloxy)- 1 -nitroethane (Int 1 ).
Benzoyl chloride (14.9 mL, 128 mmol) is added to a stirred solution of nitroethanol (9.2 mL, 128 mmol) in dry benzene (120 mL). The solution is refluxed for 24 hr and then concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 1 as a white solid (68% yield): 1H NMR (300 MHz, CDC13) δ 8.0, 7.6, 7.4, 4.9, 4.8.
Step B. Preparation of ethyl E-4-(benzylarnino)-2-butenoate (Int 2).
Ethyl E-4-bromo-2-butenoate (10 mL, 56 mmol, tech grade) is added to a stirred solution of benzylamine (16 mL, 146 mmol) in CH C12 (200 mL) at rt. The reaction mixture stirs for 15 min, and is diluted with ether (1 L). The mixture is washed with saturated aqueous NaHCO3 solution (3x) and water, dried over Na2SO4, filtered and concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (70:30) affords Int 2 as a clear oil (62% yield): JH NMR (300 MHz, CDC13) 5 7.4-7.2, JO, 6.0, 4.2, 3.8, 3.4, 2.1-1.8, 1.3.
Step C. Preparation of tr-.n-?-4-nitro-l-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 3).
A solution of Int 1 (6.81 g, 34.9 mmol) and h t 2 (7.65 g, 34.9 mmol) in EtOH (70 mL) stirs at rt for 15 h and is then concentrated in vacuo. The residue is diluted with ether (100 mL) and saturated aqueous NaHCO3 solution (100 mL). The organic layer is separated and dried over Na SO4, filtered and concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes- EtOAc (85:15) affords Int 3 as a clear oil (76% yield): Η NMR (300 MHz, CDC13) δ 7.4-7.3, 4.8-4J, 4.1, 3.8-3.6, 3.3-3.0, 2J-2.6, 2.4-2.3, 1.2.
Step D. Preparation of trαns-4-amino- 1 -(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 4).
A mixture of Int 3 (3.28 g, 11.2 mmol) and RaNi (1.5 g) in EtOH (100 mL) is placed in a Parr bottle and hydrogenated for 4 h under an atmosphere of hydrogen (46 psi) at rt. The mixture is filtered through a pad of Celite, and the solvent is removed in vacuo to afford Int 4 as a clear oil (100% yield): Η NMR (300 MHz, CDC13) δ 7.3- 7.2, 4.1, 3.6, 3.2, 3.0-2.9, 2.8, 2.8-2.6, 2.6-2.4, 2.30-2.2, 1.2.
Step E. Preparation of tr-.n->-4-(l,l-dimethylethoxycarbonylamido)-l-
(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 5). Di-tert-butyldicarbonate (3.67 g, 16.8 mmol) is added to a stirred solution of Int 4 (2.94 g, 11.2 mmol) in CH2C12 (30 mL) cooled in an ice bath. The reaction is allowed to warm to rt and stirred overnight. The mixture is concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 5 as a white solid (77% yield): Η NMR (300 MHz, CDC13) δ 7.4-7.2, 5.1-4.9, 4.1, 4.0-3.8, 3.6, 3.2-3.0, 2.8-2.6, 2.5-2.4, 2.3-2.1, 1.4, 1.3.
Step F. Preparation of trans (tert-butoxycarbonylamino)-4-(2-hydroxyethyl)- 1 - (N-phenylmethyl) pyrrolidine (Int 6).
LiAlH4 powder (627 mg, 16.5 mmol) is added in small portions to a stirred solution of Int 5 (3.0 g, 8.3 mmol) in anhydrous THF (125 mL) in a -5°C bath. The mixture is stirred for 20 min in a -5°C bath, then quenched by the sequential addition of water (0.6 mL), 15% (w/v) aqueous NaOH (0.6 mL) and water (1.8 mL). Excess anhydrous K2CO is added, and the mixture is stirred for 1 h, then filtered. The filtrate is concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with EtOAc affords Int 6 as a white solid (94% yield): 1H NMR (300 MHz, CDC13) δ 7.4-7.3, 5.3-5.2, 4.1-4.0, 3.9-3.7, 3.3-3.2, 2.8-2.7, 2.3-2.1, 1.7, 1.5.
Int 6 is a racemic mixture that can be resolved via chromatography using a Diacel chiral pack AD column. From the two enantiomers thus obtained, the (+)-enantiomer, [ ]25o +35 (c 1.0, MeOH), gives rise to the corresponding enantiomerically pure exø-4-S final compounds, whereas the (-)-enantiomer, [o]25 D - 34 (c 0.98, MeOH), gives rise to enantiomerically pure exo-4-R final compounds. The methods described herein use the (+)-enantiomer of Int 6 to obtain the enantiomerically pure exo-4-S final compounds. However, the methods used are equally applicable to the (-)-enantiomer of Int 6, making non-critical changes to the methods provided herein to obtain the enantiomerically pure exo-4-R final compounds.
Step G. Preparation of exo 3-(tert-butoxycarbonylamino)-l- azabicyclo[2.2.1]heptane (Int 7). TEA (8.0 g, 78.9 mml) is added to a stirred solution of Int 6 (2.5 g, 7.8 mmol) in CH2C1 (50 mL), and the reaction is cooled in an ice-water bath. CH3SO2Cl (5.5 g, 47.8 mmol) is then added dropwise, and the mixture is stirred for 10 min in an ice- water bath. The resulting yellow mixture is diluted with saturated aqueous NaHCO3 solution, extracted with CH2C1 several times until no product remains in the aqueous layer by TLC. The organic layers are combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue is dissolved in EtOH (85 mL) and is heated to reflux for 16 h. The reaction mixture is allowed to cool to rt, transferred to a Parr bottle and treated with 10% Pd/C catalyst (1.25 g). The bottle is placed under an atmosphere of hydrogen (53 psi) for 16 h. The mixture is filtered through Celite, and fresh catalyst (10% Pd/C, 1.25 g) is added. Hydrogenolysis continues overnight. The process is repeated three more times until the hydrogenolysis is complete. The final mixture is filtered through Celite and concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with CHCl3-MeOH-NH OH (90:9.5:0.5) affords Int 7 as a white solid (46% yield): Η NMR (300 MHz, CDC13) δ 5.6-5.5, 3.8-3.7, 3.3-3.2, 2.8-2.7, 2.0-1.8, 1.7-1.5, 1.5.
Step H. Preparation of exo-3-amino-l-azabicyclo[2.2.1]heptane bis(hydro- > r -toluenesulfonate). Pαr -toluenesulfonic acid monohydrate (1.46 g, 7.68 mmol) is added to a stirred solution of Int 7 (770 mg, 3.63 mmol) in EtOH (50 mL). The reaction mixture is heated to reflux for 10 h, followed by cooling to rt. The precipitate is collected by vacuum filtration and washed with cold EtOH to give exø-[2.2.1]-Amine as a white solid (84% yield): 1H NMR (400 MHz, CD3OD) δ 7.7, 7.3, 3.9-3.7, 3.7-3.3, 3.2, 2.4, 2.3-2.2, 1.9-1.8.
Synthesis of en--ø-3-amino- 1 -azabicyclo[2.2.1 ]heptane as the bis(hydro para-toluenesulfonate) salt (e« o-[2.2.1]-Amine):
Figure imgf000066_0001
Step I. Preparation of ethyl 5-hydroxy-6-oxo- 1 ,2,3,6-tetrahydropyridine-4- carboxylate (Int 10).
Absolute EtOH (92.0 mL, 1.58 mol) is added to a mechanically stirred suspension of potassium ethoxide (33.2 g, 395 mmol) in dry toluene (0.470 L). When the mixture is homogeneous, 2-pyrrolidinone (33.6 g, 395 mmol) is added, and then a solution of diethyl oxalate (53.1 mL, 390 mmol) in toluene (98 mL) is added via an addition funnel. After complete addition, toluene (118 mL) and EtOH (78 mL) are added sequentially. The mixture is heated to reflux for 18 h. The mixture is cooled to rt and aqueous HCl (150 mL of a 6.0 M solution) is added. The mixture is mechanically stirred for 15 min. The aqueous layer is extracted with CH2C12, and the combined organic layers are dried (MgSO4), filtered and concentrated in vacuo to a yellow residue. The residue is recrystallized from EtOAc to afford Int 10 as a yellow solid (38% yield): Η NMR (300 MHz, CDC13) δ 11.4, 7.4, 4.3, 3.4, 2.6, 1.3.
Step J. Preparation of ethyl c/-»-3-hydroxy-2-oxopiperidine-4-carboxylate (Int
11).
A mixture of Int 10 (15 g, 81 mmol) and 5% rhodium on carbon (2.0 g) in glacial acetic acid is placed under an atmosphere of hydrogen (52 psi). The mixture is shaken for 72 h. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo to afford Int 11 as a white solid (98% yield): 1H NMR (300 MHz, CDC13) δ 6.3, 4.2, 4.0-3.8, 3.4, 3.3-3.2, 2.2, 1.3. Step K. Preparation of cis- 4-(hydroxymethyl)piperidin-3-ol (Int 12).
Int 11 (3J g, 19.9 mmol) as a solid is added in small portions to a stirred solution of LiAlH4 in THF (80 mL of a 1.0 M solution) in an ice-water bath. The mixture is warmed to rt, and then the reaction is heated to reflux for 48 h. The mixture is cooled in an ice-water bath before water (3.0 mL, 170 mmol) is added dropwise, followed by the sequential addition of NaOH (3.0 mL of a 15% (w/v) solution) and water (9.0 mL, 500 mmol). Excess K2CO3 is added, and the mixture is stirred vigorously for 15 min. The mixture is filtered, and the filtrate is concentrated in vacuo to afford Int 12 as a yellow powder (70% yield): 1H NMR (300 MHz, DMSO-- ) δ 4.3, 4.1, 3.7, 3.5-3.2, 2.9-2.7, 2.5-2.3, 1.5, 1.3.
Step L. Preparation of benzyl c/-.-3-hydroxy-4-(hydroxymethyl)piperidine- 1 - carboxylate (Int 13).
N-(benzyloxy carbonyloxy)succinimide (3.04 g, 12.2 mmol) is added to a stirred solution of Int 12 (1.6 g, 12.2 mmol) in saturated aqueous ΝaHCO (15 mL) at rt. The mixture is stirred at rt for 18 h. The organic and aqueous layers are separated. The aqueous layer is extracted with ether (3X). The combined organic layers are dried over anhydrous K2CO3, filtered and concentrated in vacuo to afford Int 13 as a yellow oil (99% yield): 1H NMR (300 MHz, CDC13) δ 7.4-7.3, 5.2, 4.3, 4.1, 3.8-3.7, 3.0-2.8, 2.1, 1.9-1.7, 1.4.
Step M. Preparation of benzyl c«-3-hydroxy-4-[(4-methylphenyl)sulfonyl oxymethyl]piperidine-l -carboxylate (Int 14).
Eαra-toluenesulfonyl chloride (1.0 g, 5.3 mmol) is added to a stirred solution of Int 13 (3.6 g, 5.3 mmol) in pyridine (10 mL) in a -15°C bath. The mixture is stirred for 4 h, followed by addition of HCl (4.5 mL of a 6.0 M solution). CH2C12 (5 mL) is added. The organic and aqueous layers are separated. The aqueous layer is extracted with CH C1 . The combined organic layers are washed with brine, dried (MgSO4), filtered and concentrated in vacuo to afford Int 14 as a colorless oil (78% yield): 1H NMR (300 MHz, CDC13) δ 7.8, 7.4-7.2, 5.1, 4.3-4.2, 4.1, 3.9-3.8, 2.9-2.7, 2.4, 1.9, 1.6-1.3.
Step N. Preparation of exo- 1 -azabicyclo[2.2.1 ]heptan-3-ol (Int 15). A mixture of Int 14 (3.6 g, 8.6 mmol) and 10% Pd/C catalyst (500 mg) in EtOH (50 mL) is placed under an atmosphere of hydrogen. The mixture is shaken for 16 h. The mixture is filtered through Celite. Solid NaHCO3 (1.1 g, 13 mmol) is added to the filtrate, and the mixture is heated in an oil bath at 50°C for 5 h. The solvent is removed in vacuo. The residue is dissolved in saturated aqueous K CO3 solution. Continuous extraction of the aqueous layer using a liquid-liquid extraction apparatus (18 h), followed by drying the organic layer over anhydrous K CO3 and removal of the solvent in vacuo affords Int 15 as a white solid (91% yield): Η NMR (300 MHz, CDC13) δ 3.8, 3.0-2.8, 2.6-2.5, 2.4-2.3, 1.7, 1.1.
Step O. Preparation of en- o-3-azido- 1 -azabicyclo[2.2.1 ]heptane (Int 16).
To a mixture of Int 15 (1.0 g, 8.9 mmol) and triphenyl phosphine (3.0 g, 11.5 mmol) in toluene-THF (50 mL, 3:2) in an ice-water bath are added sequentially a solution of hydrazoic acid in toluene (15 mL of ca. 2 M solution) and a solution of diethyl azadicarboxylate (1.8 mL, 11.5 mmol) in toluene (20 mL). The mixture is allowed to warm to rt and stir for 18 h. The mixture is extracted with aqueous 1.0M HCl solution. The aqueous layer is extracted with EtOAc, and the combined organic layers are discarded. The pH of the aqueous layer is adjusted to 9 with 50% aqueous NaOH solution. The aqueous layer is extracted with CH2C12 (3X), and the combined organic layers are washed with brine, dried over Na SO , filtered and concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with CHCl3-MeOH-NH4OH (92:7:1) affords Int 16 as a colorless oil (41% yield): 1H NMR (300 MHz, CDC13) δ 4.1 , 3.2, 2.8, 2.7-2.5, 2.2, 1.9, 1.5.
Step P. Preparation of en-io-3-amino-l-azabicyclo[2.2.1]heptane bis(hydro- ? ra-toluenesulfonate).
A mixture of Int 16 (250 mg, 1.8 mmol) and 10% Pd C catalyst (12 mg) in EtOH (10 mL) is placed under an atmosphere of hydrogen (15 psi). The mixture is stirred for 1 h at rt. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo. The residue is dissolved in EtOH (10 mL) and ?αrα- toluenesulfonic acid monohydrate (690 mg, 3J mmol) is added. The mixture is stirred for 30 min, and the precipitate is filtered. The precipitate is washed sequentially with cold EtOH and ether. The precipitate is dried in vacuo to afford endo-[2.2.1]-Amine as a white solid (85% yield): 1H NMR (300 MHz, CD3OD) δ 7.7, 7.3, 4.2, 3.9, 3.6-3.4, 3.3-3.2, 2.4, 2.3, 2.1.
Preparation of exo-tert-butyl (IS, 2R, 4R)-(+)-2-amino-7- azabicyclo[2.2.1]heptane-7-carboxylate (7-aza-[2.2.1]-Amine):
Figure imgf000069_0001
7-aza-[2.2.1]-Amine
Preparation of rnethyl-3-bromo-propiolate:
Methyl propiolate (52 ml, 0.583 mole) is combined with recrystallized N- bromo-succinimide (120 g, 0.674 mole) in 1,700 ml acetone under nitrogen. The solution is treated with silver nitrate (9.9 g, 0.0583 mole) neat in a single lot and the reaction is stirred 6 h at RT. The acetone is removed under reduced pressure (25°C, bath temperature) to provide a gray slurry. The slurry is washed with 2 x 200 ml hexane, the gray solid is removed by filtration, and the filtrate is concentrated in vacuo to provide 95 g of a pale yellow oily residue. The crude material was distilled via short path under reduced pressure (65°C, about 25 mm Hg) into a dry ice/acetone cooled receiver to give 83J g (88%) of methyl-3-bromo-propiolate as a pale yellow oil. Anal, calc'd for C4H3BrO2: C, 29.48; H, 1.86. Found: C, 29.09; H, 1.97.
Preparation of 7-tert-butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5- diene-2,7-dicarboxylate.
Methyl-3-bromo-propiolate (83J g, 0.513 mole) is added to N-t-butyloxy- pyrrole (430 ml, 2.57 mole) under nitrogen. The dark mixture is warmed in a 90 °C bath for 30 h, is cooled, and the bulk of the excess N-t-butyloxy-pyrrole is removed in vacuo using a dry ice/acetone condenser. The dark oily residue is chromatographed over 1 kg silica gel (230-400 mesh) eluting with 0-15% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 97 g (57%) of 7-tert- butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2J-dicarboxylate as a dark yellow oil. HRMS (FAB) calc'd for Cι3H,6BrΝO4+H: 330.0341, found 330.0335 (M+H)+. Preparation of (+/-) E/.-iø-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane- 2,7-dicarboxylate.
7-tert-Butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7- dicarboxylate (97 g, 0.294 mole) is added tol 0% Pd/C (6.8g) in 900 ml absolute
ΕtOH in a PARR bottle. The suspension is diluted with a solution of NaHCO3 (25 g, 0.301 mole) in 250 ml water and the mixture is hydrogenated at 50 PSI for 2.5 h. The catalyst is removed by filtration, is washed with fresh ΕtOH, and the filtrate is concentrated in vacuo to give a residue. The residue is partitioned between 1 x 200 ml saturated NaHCO3 and CH C12 (4 x 100 ml). The combined organic layer is dried over 1 :1 anhydrous K Cθ3/anhydrous MgSO4 and concentrated in vacuo to afford 72.8 g (98%) of (+/-) e«-/ø-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2J- dicarboxylate. MS (ΕI) for Cι4H22O4, m/z: 255 (M)+.
Preparation of (+/-) exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1 ]heptane-
2-carboxylic acid.
(+/-)E«-fo-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1 ]heptane-2,7-dicarboxylate (72.8 g, 0.285 mole) is dissolved in 1000 ml dry MeOH in a dried flask under nitrogen. The solution is treated with solid NaOMe (38.5 g, 0.713 mole) neat, in a single lot and the reaction is warmed to reflux for 4h. The mixture is cooled to 0°C, is treated with 400 ml water, and the reaction is stirred lh as it warms to RT. The mixture is concentrated in vacuo to about 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12N HCl. The precipitate is collected and dried. The tan, slightly tacky solid is washed with 2 x 100 ml 60% ether in hexane and is dried to provide 47 g (68%) of exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1 ]heptane-2-carboxylic acid as an off-white powder. HRMS (FAB) calc'd for Cι2H]9NO4+H: 242.1392, found 242.1390 (M+H)+.
Preparation of (+/-) exo-tert-butyl 2-{[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1]heptane-7-carboxylate.
(+/-)Exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (32.5 g, 0.135 mole) is combined with TEA (24.4 ml, 0.175 mole) in 560 ml dry toluene in a dry flask under nitrogen. The solution is treated drop-wise with diphenylphosphoryl azide (37.7 ml, 0.175 mole), and is allowed to stir for 20 min at RT. The mixture is treated with benzyl alcohol (18.1 ml, 0.175 mole), and the reaction is stirred overnight at 50°C. The mixture is cooled, is extracted successively with 2 x 250 ml 5% citric acid, 2 x 200 ml water, 2 x 200 ml saturated sodium bicarbonate, and 2 x 100 ml saturated NaCl. The organic layer is dried over anhydrous MgSO and concentrated in vacuo to an amber oil. The crude material was chromatographed over 800 g silica gel (230-400 mesh), eluting with 15-50% EtOAc/hexane. The appropriate fractions are combined and concentrated to give 44 g (94%o) of (+/-) exo-tert-butyl 2-{[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. 1H NMR (CDC13) δ 1.29-1.60, 1.44, 1.62-2.01, 3.76-3.88, 4.10, 4.24, 5.10, 7.36 ppm.
Preparation of exo-tert-butyl (IS, 2R, 4R)-(+)-2{[(benzyloxy)carbonyl]amino}-
7-azabicyclo[2.2.1]heptane-7-carboxylate and exo-tert-butyl (IR, 2S, 4S)-(-)- 2 { [(benzyloxy)carbonyl]amino} -7-azabicyclo[2.2.1 ]heptane-7-carboxylate. The isolated (+/-) exo-tert-butyl 2-{[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1]heptane-7-carboxylate is resolved via preparative chiral HPLC
(50x500 mm Chiralcel OJ column, 30 deg. C, 70 mL/min. 10/90 (v/v) isopropanol/heptane). The resolution affords 10.5 g of exo-tert-butyl (IS, 2R, 4R)-(+)- 2{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate and 15.5 g ofexo-tert-butyl-(lR, 2S, 4S)(-)-2{[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1 ]heptane-7-carboxylate.
The 2R enantiomer is triturated with 12 ml ether followed by 12 ml hexane (to remove lingering diastereo and enantiomeric impurities) and is dried to afford 9.5 g (43%) of purified exo-tert-butyl (IS, 2R, 4R)-(+)-2 {[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess. MS (El) for
C19H26N2O4, m/z 346 (M)+. [α]25 D = 22, (c 0.42, chloroform).
The 2S enantiomer is triturated with 20 ml ether followed by 20 ml hexane to give 14 g (64%) of purified exo-tert-butyl (IR, 2S, 4S)-(-)- 2 { [(benzyloxy)carbonyl] amino} -7-azabicyclo[2.2.1 ]heptane-7-carboxylate with 99% enantiomeric excess. MS (El) for d9H26N2O4ι m/z 346 (M)+. [α]25 D = -23, (c 0.39, chloroform). Preparation of exo-tert-butyl-(lS, 2R, 4R)-(+)-2-amino-7- azabicyclo[2.2.1]heptane-7-carboxylate (7-aza-[2.2.1]-Amine).
Exo-tert-butyl (IS, 2R, 4R)-(+)-2{[(benzyloxy)carbonyl]amino}-7- azabicyclo[2.2.1]heptane-7-carboxylate (9.5 g, 27.4 mmol) is combined with 950 mg 10%) Pd/C in 75 ml absolute ΕtOH in a 500 ml Parr bottle. The reaction mixture is hydrogenated at 50 PSI for 3h, the catalyst is removed by filtration, and the filter cake was washed with MeOH. The filtrate is concentrated in vacuo to give 6.4 g of a residue. The crude material is chromatographed over 200 g silica gel (230-400 mesh) eluting with 7% CH3OH/CHCl3 containing 1% cone. NH4OH. The appropriate fractions are combined and concentrated to give 5.61 g (96%) of exo-tert-butyl-(lS, 2R, 4R)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. MS (ΕI) for C, ,H20N2O2, m/z: 212 (M)+. [??25D = 9, (c 0.67, chloroform).
Preparation of l-azabicyclo[3.2.1]octan-3-amine:
Preparation of the 3R,5R-[3.2.1]-Amine:
Figure imgf000072_0001
(3S)-l-[(S)-l-Phenethyl]-5-oxo-3-pyrroIidine-carboxylic acid:
Figure imgf000072_0002
According to the literature procedure (Nielsen et al. J. Med. Chem 1990, 70- 77), a mixture of itaconic acid (123.17 g, 946.7 mmol) and (S)-(-)-α-methyl benzylamine (122.0 mL, 946.4 mmol) were heated (neat) in a 160°C oil bath for 4 h. Upon cooling, MeOH (-200 mL) was added and the resulting solid collected by filtration. The solid was treated with EtOH (-700 mL) and warmed using a steam bath until -450 mL solvent remained. After cooling to rt, the solid was collected and dried to afford 83.2 g as a white crystalline solid: [?]25 D - -80 (c 0.97, DMSO). MS (El) m/z 233 (M+), 233, 218, 160, 105, 104, 103, 91, 79, 78, 77.
The lack of a resonance 3.59 indicates a single diastereomer. The other diastereomer can be retrieved from the initial MeOH triturant. Attempts to crystallize this material generally led to small quantities of (3RS)-l-[(S)-l-phenethyι]-5-oxo-3- pyrrolidine-carboxylic acid.
(3S)-1- [(S)-l -Phenethyl] -3-(hydroxymethyl)pyrrolidine :
Figure imgf000073_0001
A suspension (3S)-l-[(S)-l-phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid (82.30 g,
352.8 mmol) in Et2O (200 mL) was added in small portions to a slurry of LiAlH4
(17.41 g, 458.6 mmol) in Et2O (700 mL). The mixture began to reflux during the addition. The addition funnel containing the suspension was rinsed with Et O (2 x 50 mL), and the mixture was heated in a 50 °C oil bath for an additional 2 h and first allowed to cool to rt and then further cooled using an ice bath. The mixture was carefully treated with H O (62 mL). The resulting precipitate was filtered, rinsed with Et2O, and discarded. The filtrate was concentrated to a yellow oil. When EtOAc was added to the oil, a solid began to form. Hexane was then added and removed by filtration and dried to afford 43.3 g as a white solid. [?]25 D = -71 (c 0.94, CHC13). MS (El) m/z 205 (M+), 191, 190, 128, 105, 91, 86, 84, 79, 77, 51.
(3R)-l-[(5)-l-Phenethyl]-3-(cyanomethyl)pyrrolidine:
Figure imgf000074_0001
A solution of (3S)-l-[(S)-l-phenethyl]-3-(hydroxymethyl)pyrrolidine (42.75 g, 208.23 mmol) in chloroform (350 mL) was heated to reflux under N2. The solution was treated with a solution of thionyl chloride (41.8 mL, 573 mmol) in chloroform (40 mL) dropwise over 45 min. The mixture stirred for an additional 30 min, was cooled and concentrated. The residue was diluted with H2O (-200 mL), 1 N NaOH was added until a pH - 8 (pH paper). A small portion (-50 mL) of sat. NaHCO3 was added and the basic mixture was extracted with EtOAc (3 x 400 mL), washed with brine, dried (MgSO ), filtered and concentrated to give 46.51 g of a red-orange oil for (3S)-l-[(S)-l-phenethyl]-3-(chloromethyl)pyrrolidine: Rf. 0.50 (EtOAc-hexane 1:1); MS (ESI+) m/z 224.2 (MH+). The chloride (46.35 g, 208.0 mmol) was transferred to a flask, dimethyl sulfoxide (200 mL) was added, and the solution was treated with NaCN (17.84 g, 363.9 mmol). The mixture was heated under N2 in a 100°C oil bath overnight and was cooled. The brown mixture was poured into H2O (300 mL) and extracted with EtOAc (1000 mL in portions). The combined organic layer was washed with H2O (6 x -50 mL), brine (-100 mL), dried (MgSO4), filtered and concentrated to give 40.61 g as an orange-red oil: Rf. 0.40 (EtOAc-PhCH3 1 :1). MS (ESI+) for m/z 215.2 (M+H+).
(3R)-Methyl l-[(S)-l-phenylethyl]pyrrolidine-3-acetate:
Figure imgf000074_0002
Acetyl chloride (270 mL, 3.8 mol) was carefully added to a flask containing chilled (0°C) methanol (1100 mL). After the addition was complete, the acidic solution stirred for 45 min (0 °C) and then (3R)-l-[(S)-l-phenethyl]-3- (cyanomethyl)pyrrolidine (40.50 g, 189.0 mmol) in methanol (200 mL) was added. The ice bath was removed and the mixture stirred for 100 h at rt. The resulting suspension was concentrated. Water (-600 mL) was added, the mixture stirred for 45 min and then the pH was adjusted (made basic) through the addition of -700 mL sat. aq. NaHCO3. The mixture was extracted with EtOAc (3 x 300 mL). The combined organics were washed with brine, dried (MgSO4), filtered through celite and concentrated to give 36.86 g as an orange-red oil. MS (ESI+) m/z 248.2 (M+H+).
(5R)-l-Azabicyclo[3.2.1]octan-3-one hydrochloride:
Figure imgf000075_0001
A solution of (3R)-methyl l-[(S)-l-phenylethyl]pyrrolidine-3-acetate (25J2g, 104.0 mmol) in THF (265 mL) was cooled under N2 in a CO2/acetone bath. Next, ICH2C1 (22J mL, 312.0 mmol) was added, and the mixture stirred for 30 min. A solution of 2.0M lithium diisopropylamide (heptane/THF/ethylbenzene, 156 mL, 312 mmol) was added slowly over 30 min. The internal temperature reached a maximum of-40°C during this addition. After 1 h, sat. NH4C1 (100 mL) was added and the mixture was allowed to warm to rt. The organic layer was separated, dried (MgSO4), filtered and concentrated. The resulting red-brown foam was chromatographed (300 g SiO2, CHCl3-MeOH-NH4OH (89:10:1) followed by CHCl3-MeOH (3:1). The product fractions were pooled and concentrated to afford (5R)-3-oxo-l-[(lS)-l-phenylethyl]-l- azoniabicyclo[3.2.1]octane chloride (10.12g) as a tan foam (MS (ESI+) m/z 230.1 (M+H+). This foam (10.1 g, 38 mmol) was taken up in MeOH (500 mL), 10% Pd(C) (3.0 g) added and the mixture was hydrogenated (45 psi) overnight. The mixture was filtered and re-subjected to the reduction conditions (9.1 g, 10%> Pd C, 50 psi). After 5 h, TLC indicated the consumption of the (5R)-3-oxo-l-[(lS)-l-phenylethyl]-l- azoniabicyclo[3.2.1]octane chloride. The mixture was filtered, concentrated and triturated (minimal /PrOH) to give 3J3 g of (5R)-l-azabicyclo[3.2.1]octan-3-one hydrochloride, in two crops, as an off-white solid: [?]25 D = 33 (c 0.97, DMSO). MS (El) m/z 125 (M+).
(3R,5R)-l-azabicyclo[3.2.1]octan-3-amine dihydrochloride:
Figure imgf000076_0001
• HCl
{3R, 5R)-[3.2.1]-Amιne
To a flask containing (5R)-l-azabicyclo[3.2.1]octan-3-one hydrochloride (3.64 g, 22.6 mmol), hydroxylamine hydrochloride (2.04 g, 29.4 mmol), and ethanol (130 mL) was added sodium acetate trihydrate (9.23 g, 67.8 mmol). The mixture stirred for 3 h and was filtered and concentrated. The resulting white solid was taken up in n- propanol (100 mL) and sodium (-13.6 g, 618 mmol) was added over 20-25 portions. The reaction spontaneously began to reflux, and the reaction was heated in an oil bath (100°C). The addition was complete in -20 min and the mixture had solidified after -40 min. The oil bath was removed and n-propanol (2 x 25 mL) was added dissolving the remaining sodium metal. The mixture was carefully quenched through the dropwise addition of H2O (100 mL). Saturated aq. NaCl (20 mL) was added, and the layers were separated. The organic layer was dried (MgSO ), filtered, treated with freshly prepared MeOH/HCl, and concentrated. The resulting solid was triturated with 30 mL EtOH, filtered and dried in vaccuo to afford 3.51 g as a white solid: [?]25 D = -3 (c 0.94, DMSO). MS (FAB) m/z 127 (MH+).
Preparation of en<-ø-l-azabicyclo[3.2.1]octan-3-amine dihydrochloride (e«-fo-[3.2.1]-Amine):
< H° N 2N HCl A mixture of l-azabicyclo[3.2.1]octan-3-one hydrochloride (2.80 g, 17.3 mmol), ethanol (25 mL), and hydroxylamine hydrochloride (1.56 g, 22.4 mmol) is treated with sodium acetate trihydrate (7.07 g, 51.2 mmol). The mixture is stirred for 3 h and evaporated in vacuo. The residue is diluted with CH2C12, treated with charcoal, filtered and evaporated. The resulting oxime (3.1 mmol) is treated with acetic acid (30 mL) and hydrogenated at 50 psi over PtO2 (50 mg) for 12 h. The mixture is then filtered and evaporated. The residue is taken up in a minimal amount of water (6 mL) and the pH is adjusted to >12 using solid NaOH. The mixture is then extracted with ethyl acetate (4 X 25 mL), dried (MgSO ), filtered, treated with ethereal HCl, and evaporated to give the give en-7o-[3.2.1]-Amine. Preparation of the 3.2.2 Amines:
Figure imgf000077_0001
Int 104 Preparation of tert-butyl 4-(2-oxopropylidene)piperidine- 1 -carboxylate (Int
101):
Sodium hydride (60% oil dispersion, 2.01 g, 50.2 mmol) is washed with pentane (3X) and suspended in dry THF (40 mL). The solution is cooled to 0°C before diethyl (2-oxopropyl)phosphonate (9.75 g, 50.2 mmol) is added dropwise. After complete addition, the solution is warmed to rt and stirred for 30 min. tert- Butyl 4-oxo-l-piperidinecarboxylate (5.0g, 25.1 mmol) is added in portions over 10 min, followed by stirring at rt for 2 h. A saturated aqueous solution of ammonium chloride is added, followed by dilution with ether. The organic layer is extracted with water. The organic layer is dried over anhydrous MgSO4, filtered and concentrated to a yellow oil. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-ether (60:40) gave 4.5 g (75%>)of Int 101 as a white solid: 1H NMR (400 MHz, CDC13) δ 6.2, 3.5, 3.4, 2.9, 2.3, 2.2, 1.5.
Preparation of tert-butyl 4-(2-oxopropyl)piperidine-l -carboxylate (Int 102): A mixture of Int 101 (4.5 g, 19 mmol) and 10% palladium on activated carbon
(450mg) in EtOH (150 mL) is placed in a Parr bottle and hydrogenated for 5 h at 50 psi. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo to afford 4.3 g (94%) of Int 102 as a clear oil: Η NMR (400 MHz, CDC13) δ 4.1, 2.8, 2.4, 2.2, 2.0, 1.7, 1.5, 1.1.
Preparation of tert-butyl 4-(3-bromo-2-oxopropyl)piperidine-l -carboxylate (Int 103):
To a stirred solution lithium hexamethyldisilylamide in THF (20. 0 mL, 1.0 M) in a -78 °C bath is added chlorotrimethylsilane (11.0 mL, 86.4 mmol) dropwise. The mixture is stirred at -78 °C for 20 min, followed by addition of Int 102 (3.21 g, 13.3 mmol) in a solution of THF (50 mL) dropwise. After complete addition, the mixture is stirred at -78 °C for 30 min. The mixture is warmed to 0°C in an ice-water bath and phenyltrimethylammonium tribromide (5.25 g, 14.0 mmol) is added. The mixture is stirred in an ice-bath for 30 min, followed by the addition of water and ether. The aqueous layer is washed with ether, and the combined organic layers are washed with saturated aqueous sodium thiosulfate solution. The organic layer is dried over anhydrous MgSO , filtered and concentrated in vacuo to afford a yellow oil. The crude product is purified by flash chromatography on silica gel. Elution with hexanes- ether (60:40) gave 2.2 g (52%) of Int 103 as a It. yellow oil: 1H NMR (400 MHz, CDC13) δ 4.2-4.1, 3.9, 2.8, 2.7, 2.6, 2.1-2.0, 1.7, 1.5, 1.2-1.1.2.
Preparation of 1 -bromo-3-piperidin-4-ylacetone trifluoroacetate (Int 104):
To a stirred solution of Int 103 (2.2 g, 6.9 mmol) in CH2C12 (30 mL) in an ice- water bath is added trifluoroacetic acid (10 mL, 130 mmol). The mixture is stirred at 0°C for 30 min. The volatiles are removed in vacuo to afford 2.0 g (87%) of Int 104 as a yellow residue: MS (ESI) for C8Hι5BrNO [M+H] m/e 220.
Preparation of l-azabicyclo[3.2.2]nonan-3-one (Int 105): To a stirred solution of DIEA (13 mL) in acetoniltrile (680 mL) at reflux temperature is added a solution of Int 104 (2.0 g, 6.0 mmol) in acetonitrile (125 mL) over a 4 h period via syringe pump. The mixture is kept at reflux temperature overnight. The mixture is concentrated in vacuo and the remaining residue is partitioned between a saturated aqueous K2CO solution and CHCl -MeOH (90:10). The aqueous layer is extracted with CHCl3-MeOH (90:10), and the combined organic layers are dried (MgSO ), filtered and concentrated in vacuo to a brown oil. The crude product is purified by flash chromatography on silica gel. Elution with CHC1 - MeOH-NH4OH (95:4.5:0.5) gives 600 mg (72%) of Int 105 as a clear solid: Η NMR (400 MHz, CDC13) δ 3.7, 3.3-3.2, 3.1-3.0, 2.7, 2.3, 2.0-1.8.
Preparation of l-azabicyclo[3.2.2]nonan-3-amine bis(4- methylbenzenesulfonate) ([3.2.2]-Amine):
To a stirred mixture of Int 105 (330 mg, 2.4 mmol) and sodium acetate 'trihydrate (670 mg, 4.8 mmol) in EtOH (6.0 mL) is added hydroxylamine'hydrochloride (200 mg, 2.8 mmol). The mixture is stirred at rt for 10 h. The mixture is filtered and the filtrate is concentrated in vacuo to a yellow solid. To a solution of the solid (350 mg, 2.3 mmol) in n-propanol (30 mL) at reflux temperature is added sodium metal (2.0 g, 87 mmol) in small portions over 30 min. Heating at reflux is continued for 2 h. The solution is cooled to rt and brine is added. The mixture is extracted with n-propanol, and the combined organic layers are concentrated in vacuo. The residue is taken up in CHC13 and the remaining solids are filtered. The filtrate is dried over anhydrous MgSO4, filtered and concentrated in vacuo to a clear solid. To a stirred solution of the solid (320 mg, 2.3 mmol) in EtOH (4 mL) is added j7-toluenesulfonic acid monohydrate (875 mg, 4.6 mmol). The solution is warmed in a water bath to 45°C for 30 min, followed by concentration of the solvent to afford 710 mg (62%) of [3.2.2]-Amine as a white solid: Η NMR (400 MHz, CD3OD) δ 7.7, 7.3, 4.1-3.9, 3.6-3.4, 2.6-2.5, 2.4, 2.2-2.1, 2.1-2.0, 1.9.
Resolution of stereoisomers:
The amine can be coupled to form the appropriate amides as a racemic mixture. The racemic mixture can then be resolved by chromatography using chiral columns or chiral HPLC, techniques widely known in the art, to provide the requisite resolved enantiomers 3(R) and 3(5) of said amides.
COUPLINGS The following examples are provided as examples and are not intended to limit the scope of this invention to only those provided examples and named compounds. Also, the salts made in the examples are only exemplary and are not intended to limit the invention. Any pharmaceutically acceptable salt can be made by one of ordinary skill in the art. Further, the naming of specific stereoisomers is for exemplification, and is not intended to limit in anyway the scope of the invention. The invention includes the following examples in pure stereoisomeric form or as racemic mixtures.
Example 1; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-naphthamide hydrochloride:
Figure imgf000080_0001
2-Νaphthoic acid (0.19g, 1.1 mmol) and TEA (LOmL, 7.2mmol) are dissolved in lOmL THF. Diphenylphosphinic chloride (0.26g, 1.lmmol) is added dropwise. After 0.5h, (2S,3R)-2-methyl-l-azabicyclo[2.2.2]octan-3-amine dihydrochloride (0.21g, l.Ommol) is added, and the reaction is allowed to stir at RT. After 1 day, IN NaOH is added, and the mixture is extracted with CHC13. The combined organic layers are dried (MgSO4), filtered and concentrated. The residue is purified by chromatography (Biotage 40S, 90:9: 1 CHCl3/MeOH/NH4OH). The hydrochloride salt is prepared and recrystallized from MeOH/EtOAc to provide 0.246g (74%>) of the product. HRMS (FAB) calcd for Cι9H22N2O+H 295.1810, found 295.1815.
Example 2: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide:
Figure imgf000080_0002
N-Phenyl-bis(trifluoromethanesulfonamide) (6.14g, 17.2mmol) is added to a solution of 2-hydroxy-7-methoxy naphthalene (3.0g, 17.2mmol) and TEA (2.4mL,
17.2mmol) in CH2C1 (75mL). The reaction is allowed to stir for 4 hours then poured into water. The resulting solution is extracted three times with CH2C12. The combined organic extracts are dried (Na SO ), filtered and concentrated. The resulting material is purified by column chromatography (step gradient, 25-50%>
CH2C1 in hexanes) to give 7-methoxy-2-naphthyl trifluoromethanesulfonate as a clear oil (4.95g, 94%). HRMS (El) calculated for Cι2H9F3O4S: 306.0174, found 306.0169. A solution of 7-methoxy-2-naphthyl trifluoromethanesulfonate (4.95g, 16.1 mmol) in DMF (20mL) is degassed by repeatedly evacuating the flask then flushing with N2. Zinc cyanide (1.13g, 9Jmmol) is added followed by Pd(PPh3) (930mg, 0.81mmol). The resulting mixture is again degassed and heated to 80°C for 3 hours. The reaction is allowed to cool, poured into water and washed twice with toluene and once with CH2C12. The combined organic extracts are dried (Na2SO4), filtered and concentrated. The resulting material is purified by column chromatography (step gradient, 25-50%> CH2C12 in hexanes) to give 7-methoxy-2- naphthonitrile as a white solid (2.36g, 80%). HRMS (El) calculated for C12H9NO: 183.0684, found 183.0684.
A solution of 7-methoxy-2-naphthonitrile (501mg, 2J4mmol) and KOH (503mg, 9.0mmol) in 95%> ethanol (5mL) is heated to reflux for 24 hours. The reaction mixture is allowed to cool, diluted with water and then acidified to pH<2 with concentrated HCl. The resulting precipitate is collected by filtration, washed with water and dried by heating at 70°C under vacuum to give 7-methoxy-2-naphthoic acid as a white solid (540mg, 98%>). HRMS (FAB) calculated for Cι2Hι0O3 + H+: 203.0708, found 203.0701.
HATU (532mg, 1.4mmol) is added to a solution of DIEA (730μL, 4.2mmol), (R)-3-aminoquinuclidine dihydrochloride (28 lmg, 1.4mmol) and 7-methoxy-2- naphthoic acid (285 mg, 4mmol) in DMF (8mL). The resulting solution is stirred at rt for 24 hours. Methanol (lOmL) is added and the resulting mixture is loaded onto a column of AG50Wx2 resin(H+ form). The column is washed with methanol then the product is eluted with 5% TEA in methanol. The solvents are removed by evaporation to give Example 2 as a white solid (423mg, 97%). HRMS (FAB) calculated for Cι9H22N2O2+H+: 311.1759, found 311.1755.
Example 3: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-2-naphthamide hydrochloride:
Figure imgf000081_0001
Bromocatecholborane (4.1 lg, 20Jmmol) is added to a solution of 1,6- dimethoxynaphthalene (3.89g, 20Jmmol) in dichloroethane (60mL). The resulting solution is heated to reflux for 72 hours, allowed to cool, and then poured into IN HCl. The resulting mixture is extracted three times with CH2C12. The combined organic layers are dried (Na2SO4), filtered and concentrated to dryness. The product is purified by three columns (step gradient of 50-60-65%CH2Cl in hexanes) to give 5- methoxy-2-hydroxy naphthalene as an oil that solidifies on sitting (955mg, 27%>). 1H NMR (300 MHz, CDC13) δ 8.17, 7.2-7.4, 7.0-7.1, 6.66, 5.08, 3.97.
2-[N, N-Bis(trifluoromethanesulfonyl)amino]-5-chloropyridine ( 1.81 g, 4.6mmol) is added to a solution of 2-hydroxy-5-methoxy naphthalene (802mg,
4.6mmol) and TEA (640μL, 4.6mmol) in CH2C12 (15mL). The reaction is allowed to stir for 2 hours then poured into water. The resulting solution is extracted three times with CH2C1 . The combined organic extracts are dried (Νa SO4), filtered and concentrated. The resulting material is purified by column chromatography (25%) CH C12 in hexanes) to give 5-methoxy-2-naphthyl trifluoromethanesulfonate as a white solid (1.14g, 80%). HRMS (El) calculated for Cι2H9F3O4S 306.0174, found 306.0172.
A solution of 5-methoxy-2-naphthyl trifluoromethanesulfonate (1.04g, 3.4mmol) in DMF (5mL) is degassed by repeatedly evacuating the flask then flushing with N2. Zinc cyanide (234mg, 2.0mmol) is added followed by Pd(PPh3)4 (196mg, 0.17mmol). The resulting mixture is again degassed and heated to 80°C for 3 hours. The reaction is allowed to cool, poured into water and washed twice with toluene and once with CH2C1 . The combined organic extracts are dried (Na SO4), filtered and concentrated. The resulting material is purified by column chromatography (step gradient, 25-50%> CH2C1 in hexanes) to give 5-methoxy-2-naphthonitrile as a white solid (560mg, 90%). HRMS (El) calculated for Cι2H9NO 183.0684, found 183.0684.
A solution of 5-methoxy-2-naphthonitrile (455mg, 2.5mmol) and KOH (460mg, 8.2mmol) in 95% ethanol (5mL) is heated to reflux for 24 hours. The reaction mixture is allowed to cool, diluted with water then acidified to pH<2 with concentrated HCl. The resulting precipitate is collected by filtration, washed with water and dried by heating at 70°C under vacuum to give 5 -methoxy-2 -naphthoic acid as a white solid (47 lmg, 94%). HRMS (El) calculated for Cι2Hι0O3: 202.0630, found 202.0627. HATU (380mg, l.Ommol) is added to a solution of DIEA (521μL, 3.0mmol), (R)-3-aminoquinuclidine dihydrochloride (199mg, l .Ommol) and 5-methoxy-2- naphthoic acid (204, l.Ommol) in DMF (5mL) containing a few drops of water. The resulting solution is stirred at rt for 24 hours. Methanol (lOmL) is added and the resulting mixture is loaded onto a column of AG50Wx2 resin (H+ form). The column is washed with methanol then the product is eluted with 5%> TEA in methanol. The solvents are removed by evaporation. The resulting product is dissolved in IM HCl in methanol then evaporated to dryness to give Example 3 as a white solid (248mg, 71%). HRMS (El) calculated for Cι9H22N2O2 310.1681, found 310.1683.
Example 4: N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide hydrochloride:
Figure imgf000083_0001
Bromocatecholborane (4.18g, 21 mmol) is added to a solution of 1,7- dimethoxynaphthalene (1.97g, 10.5mmol) in dichloroethane (20mL). The resulting solution is heated to reflux for 72 hours, allowed to cool and then poured into IN HCl. The resulting mixture is extracted three times with CH2C1 . The combined organic layers are dried (Na2SO ), filtered and concentrated to dryness. The product is purified by three columns (step gradient of 50-60-70% CH C1 in hexanes) to give 8- methoxy-2 -hydroxy naphthalene as a gummy solid (92% pure, 633mg, 35%). Η NMR (300 MHz, CDC13) δ 7.72, 7.55, 7.36, 7.20, 7.11, 6.79, 5.02, 3.97.
N-Phenyl-bis(trifluoromethanesulfonimide) (1.3g, 3.6mmol) is added to a solution of 2-hydroxy-8-methoxy naphthalene (630mg, 3.6mmol) and TEA (504μL, 3.6mmol) in CH2C12 (8mL). The reaction is allowed to stir for 18 hours then poured into water. The resulting solution is extracted three times with CH2C12. The combined organic extracts are dried (Νa SO4), filtered and concentrated. The resulting material is purified by column chromatography (5% CH C12 in hexanes) to give 8-methoxy-2-naphthyl trifluoromethanesulfonate as a colorless oil (97 lmg, 87%). HRMS (FAB) calculated for C,2H9F3O4S+H+: 307.0252, found 307.0258. A solution of 8-methoxy-2-naphthyl trifluoromethanesulfonate (871 mg,
2.8mmol) in DMF (4mL) is degassed by repeatedly evacuating the flask then flushing with N2. Zinc cyanide (200mg, lJmmol) is added followed by Pd(PPh3)4 (165mg, 0.14mmol). The resulting mixture is again degassed and heated to 80°C for 3 hours. The reaction is allowed to cool, poured into water and washed four times with ether. The combined organic extracts are dried (Na2SO4), filtered, and concentrated. The resulting material is purified by column chromatography (step gradient, 10-30% CH2C12 in hexanes) to give 8-methoxy-2-naphthonitrile as a white solid (493, 84%>). HRMS (El) calculated for C,2H9NO: 183.0684, found 183.0681.
A solution of 8-methoxy-2-naphthonitrile (263mg, 1.44mmol) and KOH (242mg, 4.3mmol) in 95%> ethanol (5mL) is heated to reflux for 72 hours. The solvent boiled off during heating leaving a solid. The reaction mixture is allowed to cool, dissolved in 1 :1 ethanol-water then acidified to pH<2 with concentrated HCl. The resulting precipitate is collected by filtration, washed with water and dried by heating at 70°C under vacuum to give 8-methoxy-2-naphthoic acid as a white solid (288mg, 99%). HRMS (El) calculated for Cι2Hι0O3: 202.0630, found 202.0629. HATU (365mg, 0.94mmol) is added to a solution of TEA (392μL, 2.8mmol),
(R)-3-aminoquinuclidine dihydrochloride (187mg, 0.94mmol) and 8-methoxy-2- naphthoic acid (190mg, 0.94mmol) in DMF (5mL). The resulting solution is stirred at rt for 24 hours. Methanol (lOmL) is added and the resulting mixture is loaded onto a column of AG50Wx2 resin(H+ form). The column is washed with methanol then the product is eluted with 5% TEA in methanol. The solvents are removed by evaporation. The resulting product is converted to the hydrochloride salt with IM HCl in methanol then crystallized from methanol/iPA to give Example 4 as a white solid (271mg, 83%). HRMS (FAB) calculated for Cι9H22N2O2+H+: 311.1759, found 311.1761.
Example 5: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-benzyloxy-2-naphthamide hydrochloride:
Figure imgf000084_0001
A solution of BBr3 (840μL, 8.8mmol) in CH2C12 (4mL) is added to a solution of 7-methoxy-2-naphthonitrile (646mg, 3.53mmol) in CH C1 (6mL). The reaction is allowed to stir for 30 hours. Water (about 5mL) is slowly added. The pH is adjusted to 7 with saturated Na CO3 then the mixture is extracted with CH2C12. The combined organic layers are dried (Na SO4), filtered and concentrated to dryness. The crude material is purified by column chromatography (step gradient of 1% MeOH in CH2C12 to 5 % MeOH in CH C12) to give 7-hydroxy-2-naphthonitrile as a white solid (477mg, 80%). HRMS (El) calculated for C, ,H7NO: 169.0528, found 169.0527.
Sodium hydride (15 lmg, 60% in mineral oil, 3J7mmoι) is added to a stirring solution of 7-hydroxy-2-naphthonitrile (530mg, 3.14mmol) in DMSO (lOmL). After the bubbling subsides, benzyl bromide (448μL, 3J7mmol) is added and the resulting mixture is allowed to stir for 4 hours. The reaction mixture is poured into water and extracted with ether. The ether layer is dried (Na2SO4), filtered, and concentrated to dryness. The product is purified by column chromatography (step gradient, 25 to 50% CH C12 in hexanes) to give 7-benzyloxy-2-naphthonitrile (735mg, 90%) as a white solid. HRMS (El) calculated for C18H13NO: 259.0997, found 259.0993.
KOH (406mg, 7.3mmol) is added to a suspension of 7-benzyloxy-2- naphthonitrile (626mg, 2.42mmol) in water, ethanol, and toluene (15mL, 1 :3:2). The reaction is heated to 80°C for 72 hours. The reaction is allowed to cool, poured into IM HCl and extracted three times with CH2C12. The combined organic layers are dried (Na2SO ), filtered and concentrated to dryness. The product is purified by column chromatography (step gradient, 5 to 10% methanol in CH2C12). The resulting material is crystallized from ethanol-water to give 7-benzyloxy-2-naphthoic acid
(484mg, 72%) as a white solid. HRMS (El) calculated for Cι8Hι4O3: 278.0943, found 278.0947.
Coupling: (R)-3-aminoquinuclidine (80mg, 0.4mmol) is dissolved in water (200μL). Triethylamine (165μL, 1.2mmol), DMF (2mL), 7-benzyloxy-2-naphthoic acid (11 lmg, 0.4mmol), and HATU (152mg, 0.4mmol) are added in order. The resulting mixture is allowed to stir for 24 hours, diluted with methanol, and poured onto a column of AG50Wx2 resin (H+ form). The column is washed with methanol then the product is eluted with 5% TEA in methanol. The resulting material is evaporated to dryness. The material is dissolved in IM HCl in methanol, evaporated to dryness then crystallized from MeOH/IPA to give Example 5 as an off-white solid (116mg, 69%). HRMS (FAB) calculated for C25H26N2O2+H+ 387.2072, found 387.2073. Example 6: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide fumarate:
Figure imgf000086_0001
A suspension of 7-benzyloxy-2-naphthoic acid (208mg, 0J5mmol) and 10%> palladium on carbon (208mg) in 1 ,4-cyclohaxadiene (ImL) and ethanol (2mL) is heated at 60°C for 24 hours. The reaction is allowed to cool and filtered through a plug of AG50Wx2 resin (H+ form). The plug is washed with methanol and the washes are evaporated to dryness to give 7-hydroxy-2-naphthoic acid as a tan solid (87mg, 62%). 1H ΝMR (400 MHz, CD3OD) δ 8.4, 7.8, 7.2. Example 6 is obtained following the coupling procedures of Example 5 making non-critical changes and recrystallizing from MeOH/CH3CΝ to give Example 6 as an off-white solid (127mg, 67%). HRMS (El) calculated for Cι8H20N2O2: 296.1525, found 296.1516.
Example 7: 5-Amino-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide 4- methylbenzenesulfonate :
Figure imgf000086_0002
2-Hydroxy-5-aminonaphthalene (10.0 g, 159 mmol) is dissolved in THF (400 mL). Di-tert-butyl dicarbonate (13J g, 63 mmol) is added in small portions and the reaction is heated to 70°C under N2 for 48 hours. The reaction is then cooled to rt and the volatiles are evaporated. The crude product is purified by silica gel chromatography using a step gradient of 30%> EtOAc to 60% EtOAc in hexanes in 5% increments. The product is dried in vacuo to yield tert-butyl 2-hydroxy-5- naphthylcarbamate as a pink solid (8.90 g, 55%>). HRMS (El) calculated for Cι5H,7NO3: 259.1208, found 259.1209. tert-Butyl 2-hydroxy-5-naphthylcarbamate (8.73 g, 34 mmol) is dissolved in CH2C12 (150 mL). TEA (4.69 mL, 34 mmol) is added, followed by N-phenyl- bis(trifluromethanesulfonimide) (12.04 g, 34 mmol). The reaction is stirred under N2 for 48 hours at rt. The reaction is poured into 500 mL of EtOAc, and then washed with 2 x 250 mL of brine solution and once with 250 mL of water. The organic layer is dried (MgSO4), filtered, and the volatiles are evaporated. The crude material is purified by column chromatography using a step gradient of 55%> CH2C12 in hexanes containing 1%> TEA to 60%> CH C12 in hexanes containing 1% TEA. The resulting solid is dissolved in CHCl3/MeCN and evaporated to dryness. The product is then concentrated from CHC13 and dried in vacuo to yield 5-[(tert-butoxycarbonyl)amino]- 2-naphthyl trifluoromethanesulfonate as a white solid (11.91 g, 90%). HRMS (ESI) calculated for Cι6Hι6F3NO5S + H+: 392.0779, found 392.0785.
(R)-3-aminoquinuclidine dihydrochloride is free-based by dissolving the salt in minimal water and MeOH and passing it through a plug of Amberjet resin (OH" form). This material is repeatedly concentrated from MeCN until a white solid is obtained. This white solid (1.00 g, 7.94 mmol) is combined with 5-[(tert- butoxycarbonyl)amino]-2-naphthyl trifluoromethanesulfonate (0.932 g, 2.38 mmol), palladium (II) acetate (0.178 g, 0J9 mmol), and l,3-bis(diphenylphosphino)ferrocene (0.484 g, 0.87 mmol). DMSO (10 mL) is added and the reaction is stirred vigorously. The flask is evacuated and flushed six times with CO, and the reaction is stirred under a CO balloon at 70°C for 18 hours. The reaction is cooled to rt and 50 mL of water is added. The water layer is washed with 5 x 50 mL of methyl-tert-butyl ether, and then 5 x 200 mL of EtOAc. The methyl-tert-butyl ether layers are discarded, and the EtOAc layers are dried (MgSO4), filtered, and concentrated. The crude product is dissolved in MeOH and loaded onto a column of AGW-X2 resin (H+ form). The resin is washed with MeOH, and the product is eluted with a solution of 5%TEA in MeOH. This solution is then evaporated to dryness. This material is converted to the tosylate salt and the resulting solid is dried in vacuo at 80°C for 1 hour, then at 60°C overnight to yield Example 7 as a brown solid (0.373 g, 22% in two steps). HRMS (ESI) calculated for Cι8H21N3O + H+: 296.1763, found 296.1767
Example 8: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-hydroxyquinoline-2-carboxamide hydrochloride:
Figure imgf000088_0001
HCl DIEA (1J4 mL, 10 mmol), DMF (50 mL), 8-hydroxyquinoline-2-carboxylic acid (0.95 g, 5 mmol) and HATU (1.90 g, 5 mmol) are added to a solution of (R)-3- aminoquinuclidine dihydrochloride (1.00 g, 5 mmol) in water (5 mL). The resulting solution is stirred for 18 hours under N2. The solution is diluted with 1 volume of MeOH and loaded onto a column of AG50W-X2 resin (H+ form). The resin is washed with MeOH and the product is eluted with a solution of 5% TEA in MeOH. The resulting solution is concentrated, and then concentrated again from MeCN. The free base is dissolved in 15 mL IN HCl/MeOH and evaporated to dryness. This material is crystallized from MeOH/ -PrOH. The resulting yellow solid is filtered, concentrated three times from methanol then dried at 100°C for 2 days to yield Example 8 as a yellow solid (0.55 g, 33%). HRMS (FAB) calculated for Cι7Hι9N3O2 + H+: 298.1555, found 298.1556.
Example 9: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-3-carboxamide dihydrochloride:
Figure imgf000088_0002
Example 9 is obtained using the procedure of Example 8, making non-critical changes. Example 9 is obtained as a white solid (0.34 g, 19.4%) by triturating the crude product in hot MeOH, cooling to rt, and rinsing with MeOH. HRMS (FAB) calculated for Cι7Hι9Ν3O + H+: 282.1606, found 282.1604.
Example 10: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide:
Figure imgf000088_0003
Example 10 is obtained using the procedure of Example 8, making non-critical changes. The crude salt is dissolved in MeOH and passed through a plug of Amberjet resin (OH" form). The solution is loaded onto a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH and the product is eluted with a solution of 5% TEA in MeOH. The solution is evaporated to dryness then concentrated from MeCN. The resulting material is concentrated from MeOH/water then dried in vacuo to yield Example 10 as a brown solid (0.58 g, 42%). HRMS (FAB) calculated for Cι7H!9N3O + H+: 282.1606, found 282.1606.
Example 11: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 1 ,8-naphthyridine-2-carboxamide:
Figure imgf000089_0001
Example 11 is obtained in 82%> yield as a brown solid using the procedure of Example 8, making non-critical changes. HRMS (FAB) calculated for Cι6Hι8N O + H+: 283.1559, found 283.1555.
Example 12: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitroquinoline-2-carboxamide:
Figure imgf000089_0002
DIEA (156 μL, 0.9 mmol), DMF (25 mL), 5-nitroquinoline-2-carboxylic acid (0.098 g, 0.45 mmol), and HATU (0.171 g, 0.45 mmol) are added to a solution of (R)- 3-aminoquinuclidine (0.090 g, 0.45 mmol) in water (2.5 mL). The resulting solution is stirred for 48 hours under N . The solution is diluted with 1 volume of MeOH and loaded onto a column of AG50W-X2 resin (H+ form). The resin is washed with MeOH and the product is eluted with a solution of 5% TEA in MeOH. This solution is evaporated to dryness, concentrated from MeCN, and dried in vacuo. The resulting material is dissolved in /-PrOH and heated to 60°C. 1 equivalent of fumaric acid (0.0516 g, 0.44 mmol) is added and a brown solid precipitates immediately. The solution is cooled to rt and the solid is filtered. The resulting salt is dissolved in MeOH and passed through a plug of Amberjet 4400 resin (OH- form). The resulting material is concentrated from MeOH three times and then dried in vacuo to yield Example 12 as a brown solid (0.094 g, 64%). HRMS (FAB) calculated for C17Hι8N4O3 + H+: 327.1457, found 327.1439.
Example 13: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloroisoquinoline-3- carboxamide:
Figure imgf000090_0001
The monosodium salt of 4-chlorophthalic acid (10.00 g, 45 mmol) is added to MeOH (100 mL). Concentrated H2SO4 (5 mL) is added, and the solution is heated at reflux for 48 hours under Ν . The reaction is cooled to rt and concentrated to a yellow solid. 100 mL of H O is added and the aqueous layer is extracted with 3 x 100 mL of EtOAc. The organic layers are combined and washed with 2 x 100 mL of brine solution followed by 2 x 100 mL of water, and then dried (MgSO4), filtered, and concentrated. The crude product is purified by column chromatography using a step gradient of 80%> to 90% CHC13 in hexanes in 5% increments. Product-containing fractions are concentrated and dried overnight at 60°C in vacuo to yield dimethyl-4- chlorophthalate as a colorless oil (8.76 g, 85%). HRMS (El) calculated for Cι0H9ClO4: 228.0189, found 228.0194.
LAH (1.81 g, 47.8 mmol) is added to an oven-dried flask under N2 followed by dry THF (75 mL). The solution is cooled to -78°C. Dimethyl-4-chlorophthalate (5.45 g, 23.9 mmol) is added as a solution in THF (25 mL) via an addition funnel over one hour. The reaction is warmed slowly to rt, and then heated at reflux for 18 hours. The reaction is cooled to 0°C and quenched with 200 mL of ice-cold 15% NaOH solution followed by 200 mL of water. The aqueous layer is extracted with 150 mL of THF, which is washed with 3 x 150 mL of brine solution. The original aqueous layer is then extracted with 2 x 150 mL of CH2C12. The organic layers are combined, dried (MgSO ), filtered, and concentrated. The crude product is purified via column chromatography using a step gradient of 3% MeOH to 4% MeOH in CHC13. The resulting material is dried in vacuo at 60°C to yield ((4-chloro-2- hydroxymethyl)phenyl)methanol as a white solid (3.44 g, 84%>). HRMS (El) calculated for C8H9ClO2: 172.0291, found 172.0293. Oxalyl chloride (3.3 mL, 38.0 mmol) is added to 70 mL of CH2C12 under N2 and the resulting solution is cooled to -78°C. DMSO (5.9 mL, 83.6 mmol) is added drop-wise as a solution in CH C12 (5.9 mL) followed by ((4-chloro-2- hydroxymethyl)phenyl)methanol (3.29 g, 19.1 mmol) as a solution in CH2C12 (20 mL) and DMSO (3 mL). TEA (47.9 mL, 342 mmol) is added via addition funnel over 1 hour, and then the reaction is slowly warmed to rt. 150 mL of cold water is added, and the CH2C1 layer is separated. The aqueous layer is extracted with 4 x 150 mL of CH2C12 and the organic layers are combined, dried (MgSO4), filtered, and concentrated. The crude product is purified via column chromatography using a step gradient of 45%> CHC13 to 75% CHCI3 in hexanes in 5% increments. This material is dried in vacuo at 60°C to yield 4-chlorophthaldehyde as a yellow solid (2.32 g, 73%>). HRMS (El) calculated for C8H5ClO2: 167.9978, found 167.9978.
DBU (2.36 mL, 15.2 mmol) and methyl {[(benzyloxy)carbonyl]amino} (dimethoxyphosphoryl)acetate (5.02 g, 15.2 mmol) are dissolved in CH C12 (75 mL). The resulting solution is added drop-wise to a solution of 4-chlorophthalaldehyde (2.31 g, 13.8 mmol) in CH2C12 (100 mL) at 0°C. The reaction is stirred for 1 hour at 0°C and then for 18 hours at rt. The volatiles are evaporated to yield a yellow oil, which is dissolved in CHC13 (10 mL). DBU (2.36 mL, 15.2 mmol) and TFAA (2.15 mL, 15.2 mmol) are added. The reaction is stirred under N for 3 hours and is quenched with 150 mL of saturated NaHCO3 solution. The organic layer is separated, and the aqueous layer is extracted with 2 x 150 mL of CHC13. The combined organic layers are dried (MgSO ), filtered, and concentrated to a yellow oil. This mixture is purified by column chromatography using a step gradient of 25%> to 45% EtOAc in hexanes in 5%> increments. Product containing fractions are concentrated, dissolved in MeOH and loaded onto a column of AGW-X2 resin (H+ form). The column is rinsed with MeOH, and the product is eluted with a solution of 5% TEA in MeOH. The product is concentrated from MeOH/ MeCN several times to yield methyl 6- chloroisoquinoline-3-carboxylate as a white solid in 67% purity by HPLC (0.810 g). An analytically pure sample of methyl 6-chloroisoquinoline-3-carboxylate is obtained via a Fischer esterification on a pure sample of 6-chloroisoquinoline-3- carboxylic acid. The acid (0.058 g, 0.28 mmol) is dissolved in MeOH (5 mL), and concentrated H2SO4 (250 μL) is added. The reaction is heated at reflux for 48h, cooled to rt, and concentrated. 15 mL of water is added, and the aqueous layer is extracted with 5 x 10 mL of EtOAc. The EtOAc extracts are combined and washed with 2 x 25 mL of brine solution followed by 2 x 25 mL of water, then dried (MgSO4), filtered, and concentrated. The crude product is purified via column chromatography using a step gradient of 0% MeOH in CHC13 to 2% MeOH in CHC13 in 1% MeOH increments. The resulting yellow solid is concentrated from CHCI3 three times and dried in vacuo at 60°C to yield methyl 6-chloroisoquinoline-3- carboxylate (0.033 g, 54%). HRMS (FAB) calculated for d ιH8ClNO2 + H+: 222.0322, found 222.0318.
Methyl 6-chloro-isoquinoline3-carboxylate (0.80 g, 3.6 mmol) is suspended in 95% EtOH (35 mL). KOH (0.61 g, 10.9 mmol) is added, and the reaction is heated to 80°C. When a white precipitate begins to form, 10 mL of H2O is added and all solid is redissolved. After heating for 1 hour, the reaction is cooled to rt and a white precipitate forms. The precipitate (identified as the K+ salt) is collected by vacuum filtration. The filtrate is acidified with concentrated HCl until the pH is between 4 and 5. The filtrate is loaded directly onto a column of AGW-X2 resin (H+form) and the column is rinsed with MeOH. The product is eluted with a solution of 5% TEA in MeOH. This solution is concentrated, evaporated from MeCN three times, and the resulting solid is recrystallized from EtOH/H2O. This material is purified by preparative achiral HPLC to yield 0.10 g (13%>) of 6-chloroisoquinoline-3-carboxylic acid. HRMS (FAB) calculated for Cι0H6ClNO2 + H+: 208.0165, found 208.0164.
DIEA (187 μL, 1.45 mmol), DMF (6 mL), 6-chloroisoquinoline-3-carboxylic acid (0.150 g, 0J3 mmol), and HATU (0.252 g, 0.66 mmol) are added to a solution of R-(3)-aminoquinuclidine dihydrochloride (0.120 g, 0.60 mmol) in H2O (1 mL). The resultant yellow solution is stirred for 18 hours at rt under N2. The solution is diluted with 1 volume of MeOH and loaded onto a column of AGW-X2 resin (H+ form). The resin is washed with MeOH and the product is eluted with a solution of 5%> TEA in MeOH. The resultant brown solid is concentrated twice from MeCN and dried in vacuo at 60°C. The free base is dissolved in MeOH, 10 mL of 1 N HCl/MeOH is added, and the solution is concentrated to dryness. The HCl salt is crystallized from MeOH//-PrOH, and the solid is filtered. The HCl salt is too hygroscopic to isolate, so the salt is dissolved in MeOH and passed through a plug of Amberjet resin (OH" form). The resulting solution is evaporated from MeCN three times, and then dried at 60°C in vacuo for 24 hours to yield Example 13 as a brown solid (0.062 g, 32%). HRMS (FAB) calculated for C17H,8 C1 N3 O + H+: 316.1216, found 316.1206.
Example 14: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3- carboxamide dihydrochloride:
Figure imgf000093_0001
2 HCl 4-Methylphthalic acid (10.00 g, 55.5 mmol) is dissolved in MeOH (120 mL) and concentrated H2SO4 (6 mL) is added slowly. The reaction is heated at reflux for 24 hours under N2. The reaction is cooled to rt and concentrated. 100 mL of water is added and the aqueous layer is extracted with 3 x 100 mL of EtOAc. The combined organic layers are washed with 2 x 100 mL of brine solution and 2 x 100 mL of water, and then dried (MgSO4), filtered, and concentrated. The crude material is purified by column chromatography with using a step gradient of 75% CHC13 in hexanes to 100% CHC13 in 5% increments. The resulting colorless oil is dried overnight at 60°C in vacuo to yield dimethyl 4-methylρhthalate (10.62 g, 92%). HRMS (FAB) calculated for Cι,Hι2O4 + H+: 209.0814, found 209.0809.
LAH (2.88 g, 76.0 mmol) is added to an oven-dried flask under N2. Dry THF (120 mL) is added, and the reaction is cooled to -78°C. Dimethyl 4-methylphthalate (7.91 g, 38.0 mmol) in dry THF (38 mL) is added via addition funnel over 1 hour. The reaction is warmed slowly to rt and then heated at reflux for 18 hours. The reaction is cooled to 0°C and quenched with 300 mL of ice-cold 15% NaOH solution, followed by 300 mL of water. 200 mL of THF is added and the two layers are separated. The THF layer is washed with 2 x 250 mL of brine solution. The original aqueous layer is extracted with 2 x 250 mL of CH2C12. The organic layers are combined, dried (MgSO4), filtered, and concentrated. The crude product is purified by column chromatography using a step gradient of 3% MeOH in CHCI3 to 4%> MeOH in CHCI3. The resulting material is dried in vacuo at 60°C to yield ((4-methyl- 2-hydroxymethyl)phenyl)methanol as a white solid (4.153 g, 86%). HRMS (El) calculated for C9H,2O2: 152.0837, found 152.0832. Oxalyl chloride (5.6 mL, 64 mmol) is added to CH C12 (115 mL) under N2 and the reaction is cooled to -78°C. DMSO ( 10.0 mL, 141 mmol) in CH2C12 (10.0 mL) is added drop-wise and the resulting solution is stirred for 5 minutes. ((4-Methyl-2- hydroxymethyl)phenyl)methanol (4.82 g, 32 mmol) dissolved in a minimal volume of CH2C12 is added drop-wise to the reaction, which is stirred for 30 minutes. Finally, TEA (81.0 mL, 576 mmol) is added via addition funnel over 1 hour, and the reaction is slowly warmed to rt and stirred for 18 hours. 150 mL of cold water is added and the organic layer is separated. The aqueous layer is extracted with 4 x 150 mL of CH2C1 and the organic layers are combined, dried (MgSO4), filtered, and concentrated. The crude product is purified by column chromatography using a step gradient of 75% CHCI3 to 85% CHCI3 in hexanes in 5% increments. The resulting material is dried at 60°C in vacuo to yield 4-methylphthalaldehyde as a yellow solid (4.06 g, 86%). HRMS (FAB) calculated for C9H8O2 + H+: 149.0603, found 149.0607.
DBU (4J1 mL, 31.5 mmol) and methyl {[(benzyloxy)carbonyl]amino} (dimethoxyphosphoryl)acetate (10.43 g, 31.5 mmol) are dissolved in CH2C12 (175 mL). The resulting solution is added drop- wise a solution of 4-methylphthalaldehyde (4.24 g, 28.6 mmol) in CH2C12 (200 mL) at 0°C. The reaction is stirred cold for 1 hour at 0°C and then for an additional 18 hours at rt. The volatiles are evaporated to an orange oil, which is dissolved in CHCI3 (200 mL). DBU (4.79 mL, 32.0 mmol) and TFAA (4.52 mL, 32.0 mmol) are added. The reaction is stirred under N2 for 3 hours. Upon completion, the reaction is quenched with 250 mL of saturated NaHCO3 solution. The organic layer is separated and the aqueous layer is extracted with 2 x 250 mL of CHCI3. The organic layers are combined, dried (MgSO ), filtered, and concentrated. The crude reaction mixture is purified by column chromatography using a step gradient of 20% EtOAc to 26% EtOAc in hexanes in 2% intervals. The resulting product-containing fractions are concentrated and purified via preparative achiral HPLC to yield 0.84 g of methyl 6-methyl-isoquinoline-3-carboxylate as a yellow solid. HRMS (FAB) calculated for Cι2HπN O2 + H+: 202.0868, found 202.0863. Methyl 6-methyl-isoquinoline-3-carboxylic acid (0.618 g, 3.07 mmol) is dissolved in 95% EtOH (30 mL). KOH pellets (0.517 g, 9.21 mmol) are added and the reaction is heated at reflux for 1 hour. While heating, a precipitate began to form. Upon cooling, this precipitate (the K+ salt) is filtered and dried at 60°C in vacuo. The precipitate is dissolved in water and the pH is adjusted to 4-5. The water solution is then loaded onto a column of AGW-X2 resin (H+ form). The resin is rinsed with MeOH, and the desired product is eluted with a solution of 5% TEA in MeOH. The product is concentrated three times from MeOH/ MeCN and dried in vacuo. The solid is then dried overnight at 60°C to yield 6-methyl-isoquinoline-3-carboxylic acid (0.41 g, 71%). HRMS (FAB) calculated for Cn H8 N O2K: 188.0711, found 188.0714.
DIEA (320 μL, 1.84 mmol), DMF (10 mL), 6-methyl-isoquinoline-3- carboxylic acid (0.200 g, 1.10 mmol), and HATU (0.380 g, 1.00 mmol) are added to a solution of (R)-3-aminoquinuclidine dihydrochloride (0.183 g, 0.92 mmol) in water (1 mL). The reaction is stirred for 18 hours under N2, then diluted with 1 volume of MeOH and loaded onto a column of AGW-X2 resin (H+ form). The resin is rinsed with MeOH, and the product is eluted with a solution of 5%> TEA in MeOH. The solvent is evaporated and the residue in concentrated three times from MeCN. The resulting yellow oil is dried at 60°C in vacuo. The resulting material is dissolved in 10 mL of 1 N HCl in MeOH and the solvent is evaporated. The dihydrochloride salt is crystallized from MeOH/t-PrOH and the resulting solid is filtered. The solid is concentrated from MeOH three times, and then dried in vacuo at 100°C for one hour, then 60°C overnight to yield Example 14 as a yellow solid (0.210 g, 62%). HRMS (FAB) calculated for Cι8H2,N3O + H+: 296.1763, found 296.1754.
Example 15: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloropyridine-2-carboxamide hydrochloride:
Figure imgf000095_0001
A mixture of 5-chloro-2-pyridinol (7.00 g, 54.0 mmol) and phosphorus oxybromide (24.8 g) is stirred for 16 h at reflux. After cooling to rt, 100 mL of water is added and the mixture extracted with CH2C1 , the organic layers dried (MgSO4), filtered and concentrated. The residue is purified by chromatography (biotage; 10% EtOAc/10% CH2C12/1%> ΝH4OH in hexane) to give 2-bromo-5-chloropyridine. 1H NMR (400 MHz, CDC13) δ 8.40, 7.57, 7.48. A mixture of 2-bromo-5-chloropyridine (4.35 g, 22.6 mmol), ethanol (15 mL), diisopropylethylamine (5.0 mL, 28.7 mmol), and Pd(PPh3)4 (0.523 g) is heated at reflux under carbon monoxide for 4 h. After cooling, the mixture is concentrated and the residue purified by flash chromatography (7% EtOAc/ 1% NH OH in hexane) to give ethyl 5-chloropyridine-2-carboxylate as a solid. 1H NMR (400 MHz, CDC13) δ 8.79, 7.97, 7.70, 4.35, 1.32. A mixture of ethyl 5-chloropyridine-2-carboxylate (0.800 g, 4.31 mmol) and
150 mL of 3 N HCl is heated at reflux for 10 h. After cooling to rt, the mixture is concentrated and recrystallized from ethyl acetate to give 605 mg of 5-chloropyridine- 2-carboxylate as the hydrochloride salt. ]H NMR (400 MHz, MeOO-d4) δ 8.96, 8.53, 8.41. Example 15 is obtained using the coupling procedures of Example 3, making non-critical changes to give Example 15 as a solid. Η NMR (400 MHz, MeOD-cλ/) δ 8.75, 8.13-8.30, 4.50-4.62, 3.80-3.93, 3.30-3.60, 2.33-2.45, 2.20-2.32, 2.08-2.20, 1.90-2.07.
The present invention also includes, by representation but not limitation, any one compound as a racemic mixture or pure enantiomer as discussed herein or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes: N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-pyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(methylthio)pyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2 4-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2 5-chloro-6-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2 5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2 5-fluoro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)- l-azabicyclo[2 5-chloro-6-hydroxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2 6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2 6-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2 6-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2 6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2 6-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2, pyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2, 5-chloropyrimidine-2-carboxamide;
N-[(3R 1 -azabicyclo[2 5-chloro-4-fluoropyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[2 5-chloro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2, ■5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2, 5-chloro-4-hydroxypyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[2, 4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[(3R)- 1 -azabicyclo[2, 4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[(3R)-1 -azabicyclo[2, 4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2. 4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2. 4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[(3R)- 1 -azabicyclo[2 , 2-naphthamide;
N-[(3R)-l-azabicyclo[2,
Figure imgf000097_0001
7-cyano-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-2-naphthamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-8-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-ethynyl-2-naphthamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R 1 -azabicyclo[2.2.2]oct-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-cyanoisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloroisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyanoisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ethynyl isoquinoline-3-carboxamide; any of which is optionally substituted at the C-2 position of quinuclidine in the S configuration with methyl for example to give N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.
The present invention also includes, by representation but not limitation, any one compound as a racemic mixture or pure enantiomer as discussed herein or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes:
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-pyridine-2-carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-(methylthio)pyridine-2-carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-methoxypyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2J.l]hept-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S -azabicyclo[2.2. 5-fluoro-4-trifluoromethylpyridine-2- carboxamide N-[(exo-4S -azabicyclo[2.2. 5-chloro-4-hydroxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2. 4-chloro-5-fluoropyridine-2-carboxamide; N-[(exo-4S)- -azabicyclo[2.2. 4-chloro-5-hydroxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 4-chloro-5-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 4-fluoro-5-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 4-chloro-5-methoxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 5-chloro-6-fluoropyridine-2-carboxamide; N-[(exo-4S)- -azabicyclo[2.2. 5-chloropyridine-2-carboxamide; N-[(exo-4S)- -azabicyclo[2.2.1 5-chloro-6-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 5-fluoro-6-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 5 -chloro-6-hydroxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 6-chloro-5-fluoropyridine-2-carboxamide; N-[(exo-4S)- -azabicyclo[2.2.1 6-chloro-5-hydroxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 6-chloro-5-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo [2.2.1 6-fluoro-5-trifluoromethylpyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 6-chloro-5-methoxypyridine-2- carboxamide N-[(exo-4S)- -azabicyclo[2.2.1 pyrimidine-2-carboxamide; N-[(exo-4S)- -azabicyclo[2.2.
Figure imgf000099_0001
5-chloropyrimidine-2-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-chloro-4-fluoropyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo [2.2.1 ]hept-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo [2.2.1 ]hept-3-yl]-4-chloro-5-fluoropyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2. l]hept-3-yl]-4-chloro-5-hydroxypyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide;
N-[(exo-4S)-l -azabicyclo [2.2. l]hept-3-yl]-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-methoxy-2-naphthamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-methoxy-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-methoxy-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-benzyloxy-2-naphthamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-7-hydroxy-2-naphthamide; 5-amino-N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-chloro-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-chloro-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-ethynyl-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-ethynyl-2-naphthamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl ]-8-ethynyl-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]quinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]quinoline-6-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-6-chloroisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl ]-6-methylisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-6-cyanoisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-6-methoxyisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-6-ethynylisoquinoline-3-carboxamide; N-[exo-4S)-l-azabicyclo[2.2.1]hept-3-yl] 5-chloroisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-5-methylisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-5-cyanoisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl ]-5-methoxyisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl ]-5-ethynyl isoquinoline-3-carboxamide;
N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-pyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1]oct-3-yl]-4-methoxypyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[(3R,5R)-1 •azabicyclo[3.2.1]oct-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 ]oct-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1 ]oct-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo [ 3.2.1 ] oct-3 -yl] -4-chloro-5 -hydroxypyridine-2-carboxamide ; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo [ 3.2.1 ] oct-3 -yl] -4-fluoro-5 -trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo [ 3.2.1 ] oct-3 -yl] -4-chloro- 5 -methoxypyridine-2-carboxamide ; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1]oct-3-yl]-5-chloropyridine-2-carboxamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo [3.2.1 oct-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-5-chloro-6-hydroxypyridine-2-carboxamide; N-[(3R,5R)-1 -azabicyclo [3.2.1 oct-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide; N-[(3R,5R)-1 •azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-hydroxypyridine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo [3.2.1 oct-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1 oct-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-methoxypyridine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo [3.2.1 oct-3-yl]-pyrimidine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-5-chloropyrimidine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo [3.2.1 oct-3-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-hydroxypyrimidine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo [3.2.1 oct-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(3R,5R)-1 ■azabicyclo[3.2.1 oct-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide; N-[(3R,5R)-1 azabicyclo [3.2.1 oct-3-yl]-2-naphthamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-7-methoxy-2-naphthamide; N-[(3R,5R)-1 azabicyclo[3.2.1 oct-3-yl]-5-methoxy-2-naphthamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-8-methoxy-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-7-benzyloxy-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-2-naphthamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-7-cyano-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-cyano-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-8-cyano-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-7-chloro-2-naphthamide;
N-[(3R,5R)- 1 -azabicyclo[3.2.1 ]oct-3-yl]-5-chloro-2-naphthamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-8-chloro-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-7-ethynyl-2-naphthamide;
N-[(3R,5R)- 1 -azabicyclo[3.2.1 ]oct-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]quinoline-3-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]quinoline-6-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-6-chloroisoquinoline-3-carboxamide;
N-[(3R,5R)- 1 -azabicyclo[3.2.1 ]oct-3-yl]-6-methylisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-6-methoxyisoquinoline-3-carboxamide; N-[(3R,5R)-1 -azabicyclo[3.2.1 ]oct-3-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-chloroisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-methylisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-ethynyl isoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-pyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-methoxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[3 2.2]non-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3 2.2]non-3 -5-chloro-4-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3 2.2]non-3 -4-chloro-5-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3 2.2]non-3 -4-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3 2.2]non-3 -4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3 2.2]non-3-yl -4-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[3. 2.2]non-3- -4-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3 2.2]non-3- -5-chloro-6-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3, 2.2]non-3- -5-chloropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3, 2.2]non-3- -5-chloro-6-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[3. 2.2]non-3-yl -5-fluoro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3, 2.2]non-3- -5-chloro-6-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3- -6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3- -6-chloro-5-hydroxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3- -6-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3. 2.2]non-3-yl -6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3. 2.2]non-3- -6-chloro-5-methoxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3- -pyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3- -5-chloropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3- -5-chloro-4-fluoropyrimidine-2-carboxamide;
N- [(3R)- 1 -azabicyclo[3.2.2]non-3- -5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(3R)-l-azabicyclo[3. 2.2]non-3-yl -5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[3. 2.2]non-3- -5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3- -4-chloro-5-fluoropyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methoxy-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-benzyloxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(3R)- 1 -azabicyclo[3.2.2]non-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-cyano-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-chloro-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]quinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]quinoline-6-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloroisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-ethynylisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloroisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-ethynyl isoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1 hept-5-yl]-ρyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-(methylthio)pyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-4-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-fluoro-4-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-chloro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-fluoro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-4-chloro-5-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-6-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-6-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-fluoro-6-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-6-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-6-chloro-5-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5 -yl] -6-chloro-5 -hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-6-chloro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-6-fluoro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-6-chloro-5-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-pyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloropyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1 hept-5-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1 hept-5 -yl] - 5 -chloro-4-hydroxypyrimidine-2-carboxamide ; N-[2-azabicyclo[2.2.1]hept-5 ■yi -4-chloro-5-fluoropyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 -yi -4-chloro-5-hydroxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 -yi -4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[2-azabicyclo[2.2.1]hept-5 -yl -4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-5 •yl]-4-chloro-5-methoxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl]-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 •yl] -7-methoxy-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 •yl]-5-methoxy-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-5 •yl]-8-methoxy-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl] -7-benzyloxy-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-5 •yl] -7-hydroxy-2-naphthamide; 5 -amino-N- [2 -azabicyclo [2.2 1 ]hept-5-yl]-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 •yl]-7-cyano-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl]-5-cyano-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 •yl]-8-cyano-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-7-chloro-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl]-5-chloro-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-8-chloro-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-7-ethynyl-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl]-5-ethynyl-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl] - 8 -ethynyl-2-naphthamide ; N-[2-azabicyclo[2.2.1]hept-5 yl]quinoline-3 -carboxamide; N-[2-azabicyclo[2.2.1]hept-5 yl] quinoline-6-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-5 yl]-6-chloroisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 ■yl]-6-methylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-5 yl]-6-cyanoisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-6-methoxyisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-6-ethynylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-5-chloroisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-5 yl]-5-methylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-5 ■yl]-5-cyanoisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-methoxyisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 hept-5-yl]-5-ethynyl isoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-pyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-(methylthio)pyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-fluoro-4-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-chloro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl] -4-fluoro-5 -trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-4-chloro-5-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-6-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-6-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-fluoro-6-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl] -5 -chloro-6-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-6-chloro-5-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-6-chloro-5-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-6-chloro-5-trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl] -6-fluoro-5 -trifluoromethylpyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-6-chloro-5-methoxypyridine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-pyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloropyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1 hept-6-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide; N-[2-azabicyclo[2.2.1 hept-6-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-methoxy-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-benzyloxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[2-azabicyclo[2.2.1]hept-6-yl]-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-8-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-chloro-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]quinoline-3-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]quinoline-6-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-6-chloroisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-6-methylisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-6-methoxyisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloroisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-methylisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-cyanoisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-methoxyisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-ethynyl isoquinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-pyridine-2-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-methoxypyridine-2-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-3-fluoropyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-fluoropyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-chloro-4-hydroxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-fluoropyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-chloro-5-hydroxypyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-methoxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-6-fluoropyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloropyridine-2-carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide; N-[(1S,2R,4R)7 -azabicyclo 2.2.1 hept-2-yl]-5-chloro-6-hydroxypyridine-2- carboxamide; N-[(1S,2R,4R)7 -azabicyclo 2.2.1 hept-2-yl]-6-chloro-5-fluoropyridine-2- carboxamide; N-[(1S,2R,4R)7 -azabicyclo 2.2.1 hept-2-yl]-6-chloro-5-hydroxypyridine-2- carboxamide; N-[(1S,2R,4R)7 •azabicyclo 2.2.1 hept-2-yl] -6-chloro-5 -trifiuoromethylpyridine-2- carboxamide; N-[(1S,2R,4R)7 ■azabicyclo 2.2.1 hept-2-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(1S,2R,4R)J ■azabicyclo 2.2.1 hept-2-yl]-6-chloro-5-methoxypyridine-2- carboxamide; N-[(1S,2R,4R)7 ■azabicyclo 2.2.1 hept-2-yl]-pyrimidine-2-carboxamide; N-[(1S,2R,4R)7 ■azabicyclo 2.2.1 hept-2-yl] -5 -chloropyrimidine-2-carboxamide; N-[(1S,2R,4R)J ■azabicyclo 2.2.1 hept-2-yl]-5-chloro-4-fluoropyrimidine-2- carboxamide; N-[(1S,2R,4R)7- •azabicyclo 2.2.1 hept-2-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(1S,2R,4R)7 ■azabicyclo 2.2.1 hept-2-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(1S,2R,4R)7- ■azabicyclo 2.2.1 hept-2-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide; N-[(1S,2R,4R)7- ■azabicyclo 2.2.1 hept-2-yl]-4-chloro-5-fluoropyrimidine-2- carboxamide; N-[(1S,2R,4R)J ■azabicyclo 2.2.1 hept-2-yl]-4-chloro-5-hydroxypyrimidine-2- carboxamide; N-[(1S,2R,4R)7- ■azabicyclo 2.2.1 hept-2-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(1S,2R,4R)7- •azabicyclo 2.2.1 hept-2-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(1S,2R,4R)7- •azabicyclo 2.2.1 hept-2-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide; N-[(1S,2R,4R)7- ■azabicyclo 2.2.1 hept-2-yl]-2-naphthamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-methoxy-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-methoxy-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-8-methoxy-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-7-benzyloxy-2-naphthamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[( 1 S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-cyano-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-cyano-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-cyano-2-naphthamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-7-chloro-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-chloro-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-7-ethynyl-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-ethynyl-2-naphthamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-ethynyl-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]quinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]quinoline-6-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-6-methylisoquinoline-3-carboxamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloroisoquinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-methylisoquinoline-3-carboxamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-methoxyisoquinoline-3-carboxamide; or N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-ethynyl isoquinoline-3-carboxamide.
Materials and Methods for Determining α7 nAChR Agonist Activity
Cell-based Assay for Measuring the EC n of α7 nAChR Agonists
Construction and expression of the 7-5HT receptor: The cDNA encoding the N-terminal 201 amino acids from the human α7 nAChR that contain the ligand binding domain of the ion channel was fused to the cDNA encoding the pore forming region of the mouse 5HT3 receptor as described by Eisele JL, et al., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), Dec. 2;366(6454):479-83, and modified by Groppi, et al., WO 00/73431. The chimeric α7-5HT3 ion channel was inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and hygromycin B, respectively. Both plasmids were simultaneously transfected into SH- EP1 cells and cell lines were selected that were resistant to both G-418 and hyrgromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent α-bungarotoxin on their cell surface. The cells with the highest amount of fluorescent α-bungarotoxin binding were isolated using a Fluorescent Activated Cell Sorter (FACS). Cell lines that stably expressed the chimeric α7-5HT3 were identified by measuring fluorescent α-bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 μg/ml hygromycin B, and 400 μg/ml G-418 at 37° C with 6% CO2 in a standard mammalian cell incubator for at least 4 weeks in continuous culture.
Assay of the activity of the chimeric α7-5HT3 receptor
To assay the activity of the α7-5HT3 ion channel, cells expressing the channel were plated into each well of either a 96 or 384 well dish (Corning #3614) and grown to confluence prior to assay. On the day of the assay, the cells were loaded with a 1 : 1 mixture of 2 mM Calcium Green 1 , AM (Molecular Probes) dissolved in anhydrous DMSO and 20% pluronic F-127 (Molecular Probes). This solution was added directly to the growth media of each well to achieve a final concentration 2 μM. The cells were incubated with the dye for 60 min at 37° C and then washed with a modified version of Earle's balanced salt solution (MMEBSS) as described in WO 00/73431. The ion conditions of the MMEBSS was adjusted to maximize the flux of calcium ion through the chimeric α7-5HT3 ion channel as described in WO 00/73431. The activity of compounds on the chimeric α7-5HT3 ion channel was analyzed on FLIPR. The instrument was set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio. Agonist activity of each compound was measured by directly adding the compound to cells expressing the chimeric α7-5HT3 ion channel and measuring the resulting increase in intracellular calcium that is caused by the agonist-induced activation of the chimeric ion channel. The assay is quantitative such that concentration-dependent increase in intracelluar calcium is measured as concentration-dependent change in Calcium Green fluorescence. The effective concentration needed for a compound to cause a 50% maximal increase in intracellular calcium is termed the EC50. Example 8 is inactive; the rest of the examples have EC50 values from about 30 nM to about 49,500 nM.
Binding Constants:
Another way for measuring α7 nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay. For α7 nAChR agonists, there is good correlation between functional EC50 values using the chimeric α7-5HT3 ion channel as a drug target and binding affinity of compounds to the endogenous α7 nAChR.
Membrane Preparation. Male Sprague-Dawley rats (300-350g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1 ,000 x g for 10 minutes at 4 ?C. The supernatant is collected and centrifuged at 20,000 x g for 20 minutes at 4 ?C. The resulting pellet is resuspended to a protein concentration of 1 - 8 mg/mL. Aliquots of 5 mL homogenate are frozen at -80 ?C until needed for the assay. On the day of the assay, aliquots are thawed at rt and diluted with Kreb's - 20 mM Hepes buffer pH 7.0 (at rt) containing 4.16 mM NaHCOβ, 0.44 mM KH2PO4, 127 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl2, and 0.98 mM MgCl2, so that 25 - 150 ?g protein are added per test tube. Proteins are determined by the Bradford method (Bradford, M.M., Anal. Biochem., 72, 248-254, 1976) using bovine serum albumin as the standard. Binding Assay.
For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 ?C. Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 mis MLA for a final concentration of 1 ?M, added before the radioligand. In competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 mis [3H]-MLA for a final concentration 3.0 to 4.0 nM. The incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCl pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry. Data Analysis.
In competition binding studies, the inhibition constant (Ki) was calculated from the concentration dependent inhibition of [ H]-MLA binding obtained from nonlinear regression fitting program according to the Cheng-Prusoff equation (Cheng, Y.C. and Prussoff, W.H., Biochem. Pharmacol, 22,' . 3099-3108, 1973). Hill coefficients were obtained using non-linear regression (GraphPad Prism sigmoidal dose-response with variable slope).

Claims

What is claimed:
1. A compound of the Formula I:
Azabicyclo
Figure imgf000116_0001
Formula I wherein Azabicyclo is
Figure imgf000116_0002
W is a six-membered heterocyclic ring system having 1 -2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six- six-fused-ring system, and further having 1-2 substitutents independently selected from R3, provided that when Azabicyclo is Nil the 10-membered system has 1-2 nitrogen atoms, and further provided that when there are two R3, each R3 is other than H;
X is O or S; Ro is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl;
Ri is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
R2 is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; k is 1 or 2, provided that when k is 2, each R2 is other than H;
Each R3 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, -ORio, -SRio, -SORio, -SO2Rιo, -NR,0C(O)R7, -NR,0C(O)R8, -NR10C(O)R9, -NR10Rιo, -NO2, -C(O)R10, -CN, -C(O)2R10, -C(O)NR10Rio, -SCN, -NR,oC(O)R10, -S(O)NR10R10, -S(O)2NR10Rιo, -NRιoS(O)2R,o, R7, or R9;
Each R5 is independently H, alkyl, or substituted alkyl;
R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH(alkyl), or -N(alkyl)2;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from -O-, =N-, -N(Rι4)-, and -S-, and having 0-1 substituent selected from Ri5 and 0-3 substituents independently selected
Figure imgf000117_0001
or R is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
Figure imgf000117_0002
wherein each A is independently CRι8 or N, provided that only up to one A is N, E1 and E2 are independently selected from CRι8, O, S, or NRι4, and G is CRι8, provided that Ris or R]4 of E1, E2, and G can be a bond when — forms a double bond and further provided that only one Rι8 or RH can be a bond for bonding R7 to a moiety to which it is attached;
Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or Rι5; R is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from Rι2 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or
R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from Rι and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond for bonding R9 to a moiety to which it is attached where valency allows;
Each Rio is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rn, cycloalkyl substituted with 1 substituent selected from Rn, heterocycloalkyl substituted with 1 substituent selected from Rι3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
Each Rn is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; Rι2 is -ORi i, -SRi i, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)R,ι, -NO2, -C(O)NRnRn, -CN, -NR, ,C(O)R, ,, -S(O)2NR, ,R, ,, or -NRιιS(O)2R, ,;
R13 is -ORn, -SRπ, -NR, ,R,i, -C(O)R,,, -SORπ, -SO2Rn, -C(O)NRnR,,, -CN, -CF3, -NRnC(O)Rn, -S(O)2NRnR,ι, -NRι,S(O)2R, „ or -NO2;
Each R]4 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
Ris is alkyl, substituted alkyl, halogenated alky, -ORn, -CN, -NO2, -NRioRio; Each R]8 is independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRnRn, -C(O)Rn, -NO2, -C(O)NR„R„, -CN, -NR„C(O)R„, -S(O)2NR„R„, or -NRi i S(O)2Rι i, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRnRn, -C(O)Rn, -NO2, -C(O)NR, ιR, ,, -CN, -NR, ,C(O)Rn, -S(O)2NR,ιR, „ or -NR, ,S(O)2Rιι. and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
2. The compound according to claim 1 , wherein X is O.
3. The compound according to claim 2, wherein Ri is H, lower alkyl, or lower halogenated alkyl.
4. The compound according to claim 3, wherein R2 is H, lower alkyl, or lower halogenated alkyl, or lower substituted alkyl.
5. The compound according to claim 4, wherein W is any positional isomer of pyridinyl, pyrimidinyl, naphthyl, quinolinyl, or isoquinolinyl, any of which is optionally substituted with 1-2 substituents independently selected from F, Cl, lower alkyl, lower halogenated alkyl, lower substituted alkyl, lower alkynyl, -CN, -NO2, -ORio, -SRio, -N(Rιo)2, -C(O)N(R10)2, or -C(O)R10, wherein each Rio is independently H, lower alkyl, or lower halogenated alkyl.
6. The compound according to claim 5, wherein R2 is H or methyl.
7. The compound according to claim 6, wherein Azabicyclo is I or II.
8. The compound according to claim 7, wherein the compound is N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-pyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(methylthio)pyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloropyridine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-6-hyαjOxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-pyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloropyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-benzyloxy-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide; 5-amino-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-chloro-2-naphthamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-7-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-chloroisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-6-ethynylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloroisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ethynyl isoquinoline-3-carboxamide; any of which is optionally substituted at the C-2 position of quinuclidine in the S configuration with methyl, or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 7, wherein the compound is
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-pyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-4-(methylthio)pyridine-2-carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-methoxypyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloro-4-hydroxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-4-chloro-5-hydroxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-4-chloro-5-methoxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloropyridine-2-carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloro-6-hydroxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo [2.2.1 hept-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-6-chloro-5-hydroxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo [2.2.1 hept-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-6-chloro-5-methoxypyridine-2- carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-pyrimidine-2-carboxamide; N-[(exo-4S)-l -azabicyclo[2.2.1 hept-3-yl]-5-chloropyrimidine-2-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-chloro-4-fluoropyrimidine-2- carboxamide;
N-[(exo-4S)-l-azabicyclo[2J.l]hept-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo [2.2.1 ]hept-3-yl]-4-chloro-5-fluoropyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-chloro-5-hydroxypyrimidine-2- carboxamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-methoxy-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-methoxy-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-methoxy-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-benzyloxy-2-naphthamide;
N-[(exo-4S)- 1 -azabicyclo [2.2.1 ]hept-3-yl]-7-hydroxy-2-naphthamide; 5-amino-N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-2-naphthamide;
N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hept-3-yl]-7-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-cyano-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-chloro-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-chloro-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-8-chloro-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-7-ethynyl-2-naphthamide;
N-[(exo-4S)-l-azabicyclo[2.2.1]hept-3-yl]-5-ethynyl-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep 3-yl]-8-ethynyl-2-naphthamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep -3-yl] quinoline-3 -carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep :-3-yl]quinoline-6-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep 3-yl]-6-chloroisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep -3-yl]-6-methylisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep -3-yl]-6-cyanoisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep -3-yl]-6-methoxyisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep 3-yl]-6-ethynylisoquinoline-3-carboxamide; N-[exo-4S)- 1 -azabicyclo[2.2.1 ]hept 3-yl]-5-chloroisoquinoline-3-carboxamide; N-[(exo-4S)-l-azabicyclo[2.2.1]hep 3-yl]-5-methylisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep 3-yl]-5-cyanoisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep 3-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(exo-4S)- 1 -azabicyclo[2.2.1 ]hep 3-yl]-5-ethynyl isoquinoline-3 -carboxamide; or a pharmaceutically acceptable sal thereof.
10. The compound according to claim 6, wherein Azabicyclo is III or IN, and wherein k is 1.
11. The compound according to claim 10, wherein the compound is Ν-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-pyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-4-methoxypyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; N-[(3R,5R)- 1 -azabicyclo[3.2.1 ]oct-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide; N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-5-chloropyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide
N-[(3R,5R) -azabicyclo[3.2.1 oct-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide
N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-5-chloro-6-hydroxypyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide
N-[(3R,5R) -azabicyclo[3.2.1 oct-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-pyrimidine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-5-chloropyrimidine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide
N-[(3R,5R) -azabicyclo[3.2.1 oct-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide
N-[(3R,5R) -azabicyclo[3.2.1 oct-3-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide
N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3 -yl] -4-chloro-5 -hydroxypyrimidine-2- carboxamide
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide
N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-2-naphthamide; N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-7-methoxy-2-naphthamide; N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-5-methoxy-2-naphthamide; N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-8-methoxy-2-naphthamide; N-[(3R,5R)- -azabicyclo [3.2.1 oct-3-yl]-7-benzyloxy-2-naphthamide; N-[(3R,5R)- -azabicyclo[3.2.1 oct-3-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(3R,5R)-l-azabicyclo[3.2.1]oct-3-yl]-2-naphthamide;
N-[(3R,5R)- -azabicyclo 3.2.1 oct-3-yl]-7-cyano-2-naphthamide; N-[(3R,5R)- -azabicyclo 3.2.1 Oct-3-yl]-5-cyano-2-naphthamide; N-[(3R,5R)- -azabicyclo ;3.2.1 oct-3-yl]-8-cyano-2-naphthamide; N-[(3R,5R)- -azabicyclo ;3.2.1 oct-3-yl]-7-chloro-2-naphthamide; N-[(3R,5R)- -azabicyclo 3.2.1 oct-3-yl]-5-chloro-2-naphthamide; N-[(3R,5R)- -azabicyclo 3.2.1 oct-3-yl]-8-chloro-2-naphthamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-7-ethynyl-2-naphthamide; N-[(3R,5R)- -azabicyclo ;3.2.1 oct-3-yl]-5-ethynyl-2-naphthamide; N-[(3R,5R)- -azabicyclo 3.2.1 oct-3-yl]-8-ethynyl-2-naphthamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]quinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]quinoline-6-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-6-chloroisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-6-methylisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3 -yl]-6-cyanoisoquinoline-3 -carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-6-methoxyisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-6-ethynylisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-5-chloroisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-5-methylisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo| 3.2.1 oct-3-yl]-5-cyanoisoquinoline-3-carboxamide; N-[(3R,5R)- azabicyclo 3.2.1 oct-3-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(3R,5R) azabicyclo 3.2.1 oct-3-yl]-5-ethynyl isoquinoline-3 -carboxamide; or a pharmaceutically acceptable sai It thereof.
12. The compound according to claim 10, wherein the compound is N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-pyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-methoxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-methoxypyridine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-6-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-6-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloro-5-fluoropyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloro-5-hydroxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-pyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methoxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-methoxy-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-benzyloxy-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-cyano-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-cyano-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-chloro-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-7-ethynyl-2-naphthamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-8-ethynyl-2-naphthamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]quinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]quinoline-6-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-chloroisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-methylisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-methoxyisoquinoline-3-carboxamide;
N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-6-ethynylisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-chloroisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methylisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-cyanoisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(3R)-l-azabicyclo[3.2.2]non-3-yl]-5-ethynyl isoquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 6, wherein Azabicyclo is V or NI, and R0 is H.
14. The compound according to claim 13, wherein the compound is ept-5-yl]-pyridine-2-carboxamide; ept-5-yl]-4-(methylthio)pyridine-2-carboxamide; ept-5-yl]-4-methoxypyridine-2-carboxamide; ept-5-yl]-5-chloro-3-fluoropyridine-2-carboxamide; ept-5-yl]-5-chloro-4-fluoropyridine-2-carboxamide; ept-5-yl]-5-chloro-4-trifluoromethylpyridine-2-carboxamide; ept-5 -yl] -5 -fluoro-4-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-5-chloro-4-hydroxypyridine-2-carboxamide; ept-5-yl]-4-chloro-5-fluoropyridine-2-carboxamide; ept-5-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; ept-5-yl]-4-chloro-5-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-4-fluoro-5-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-4-chloro-5-methoxypyridine-2-carboxamide; ept-5-yl]-5-chloro-6-fluoropyridine-2-carboxamide; ept-5-yl]-5-chloropyridine-2-carboxamide; ept-5-yl]-5-chloro-6-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-5-fluoro-6-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-5-chloro-6-hydroxypyridine-2-carboxamide; ept-5-yl]-6-chloro-5-fluoropyridine-2-carboxamide; ept-5-yl]-6-chloro-5-hydroxypyridine-2-carboxamide; ept-5-yl]-6-chloro-5-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-6-fluoro-5-trifluoromethylpyridine-2-carboxamide; ept-5-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
Figure imgf000129_0001
ept-5-yl]-pyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-5-yl]-5-chloropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[2-azabicyclo[2.2.1 ]hept-5-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-5-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2. l]hept-5-yl]-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-7-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-5-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-8-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-7-benzyloxy-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-5-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[2-azabicyclo[2.2.1]hept-5-yl]-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-7-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-5-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-8-cyano-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5-yl]-7-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-5-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-8-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-7-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-5-yl]-5-ethynyl-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-5-yl]-8-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]quinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]quinoline-6-carboxamide;
N-[2-azabicyclo[2.2.1]hept-5-yl]-6-chloroisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2. l]hept-5-yl]-6-methylisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. l]hept-5-yl]-6-cyanoisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. 1 ] hept- 5 -yl] -6-methoxyisoquinoline-3 -carboxamide ;
N-[2-azabicyclo[2.2. l]hept-5-yl]-6-ethynylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2. l]hept-5-yl]-5-chloroisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. l]hept-5-yl]-5-methylisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. l]hept-5-yl]-5-cyanoisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. l]hept-5-yl]-5-methoxyisoquinoline-3-carboxamide;
N-[2-azabicyclo[2.2. 1 ]hept-5-yl]-5-ethynyl isoquinoline-3 -carboxamide; N-[2-azabicyclo[2.2. l]hept-6-yl]-pyridine-2-carboxamide;
N-[2-azabicyclo[2.2. 1 ]hept-6-yl] -4-(methylthio)pyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-4-methoxypyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-3-fluoropyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-4-fluoropyridine-2-carboxamide; N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-4-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-fluoro-4-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-4-hydroxypyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-4-chloro-5-fluoropyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-4-chloro-5-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2. l]hept-6-yl]-4-chloro-5-trifluoromethylpyridine-2-carboxamide;
N- [2-azabicyclo[2.2. l]hept-6-yl]-4-fluoro-5-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-4-chloro-5-methoxypyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-6-fluoropyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloropyridine-2-carboxamide; N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-6-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-fluoro-6-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-5-chloro-6-hydroxypyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-6-chloro-5-fluoropyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-6-chloro-5-hydroxypyridine-2-carboxamide; N-[2-azabicyclo[2.2. l]hept-6-yl]-6-chloro-5-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-6-fluoro-5-trifluoromethylpyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-6-chloro-5-methoxypyridine-2-carboxamide;
N-[2-azabicyclo[2.2. l]hept-6-yl]-pyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloro-4-fluoropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloro-4-hydroxypyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-fluoropyrimidine-2-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-hydroxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-4-chloro-5-methoxypyrimidine-2-carboxamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-methoxy-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-benzyloxy-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[2-azabicyclo[2.2.1 ]hept-6-yl]-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-7-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-cyano-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-cyano-2-naphthamide; N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-8-chloro-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-7-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]-5-ethynyl-2-naphthamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-8-ethynyl-2-naphthamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]quinoline-3-carboxamide;
N-[2-azabicyclo[2.2.1 ]hept-6-yl]quinoline-6-carboxamide;
N-[2-azabicyclo[2.2.1]hept-6-yl]-6-chloroisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-6-methylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-6-cyanoisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-6-methoxyisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-6-ethynylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-chloroisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-methylisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-cyanoisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-methoxyisoquinoline-3-carboxamide; N-[2-azabicyclo[2.2.1]hept-6-yl]-5-ethynyl isoquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof.
15. The compound according to claim 6, wherein Azabicyclo is NIL
16. The compound according to claim 15, wherein R6 is H or lower alkyl optionally substituted with F, Cl, -OH, -CΝ, -ΝH2, or -NH(lower alkyl).
17. The compound according to claim 15, wherein each R5 is independently H or lower alkyl or lower substituted alkyl.
18. The compound according to claim 15, wherein R6 and each R5 are H.
19. The compound according to claim 18, wherein the compound is N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-pyridine-2-carboxamide;
N-[( 1 S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-(methylthio)pyridine-2-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-methoxypyridine-2-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-3-fluoropyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-fluoropyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-trifluoromethylpyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-fluoro-4-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-hydroxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-fluoropyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-hydroxypyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-chloro-5-trifluoromethylpyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-chloro-5-methoxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-6-fluoropyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloropyridine-2-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-6-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-fluoro-6-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-6-hydroxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-chloro-5-fluoropyridine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-chloro-5-hydroxypyridine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-6-chloro-5-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-fluoro-5-trifluoromethylpyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-chloro-5-methoxypyridine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-pyrimidine-2-carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-chloropyrimidine-2-carboxamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-chloro-4-fluoropyrimidine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-chloro-4-trifluoromethylpyrimidine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-fluoro-4-trifluoromethylpyrimidine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-4-hydroxypyrimidine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-fluoropyrimidine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-hydroxypyrimidine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-4-fluoro-5-trifluoromethylpyrimidine-2- carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-4-chloro-5-methoxypyrimidine-2- carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]heρt-2-yl]-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-methoxy-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-methoxy-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-methoxy-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-benzyloxy-2-naphthamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-hydroxy-2-naphthamide;
5-amino-N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-cyano-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-cyano-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-cyano-2-naphthamide; N-[(l S,2R,4R)7-azabicyclo[2.2. l]hept-2-yl]-7-chloro-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloro-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]heρt-2-yl]-8-chloro-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-7-ethynyl-2-naphthamide;
N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-ethynyl-2-naphthamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-8-ethynyl-2-naphthamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]quinoline-3-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]quinoline-6-carboxamide;
N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-cyanoisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-methoxyisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-6-ethynylisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-chloroisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-methylisoquinoline-3-carboxamide; N-[(lS,2R,4R)7-azabicyclo[2.2.1]hept-2-yl]-5-cyanoisoquinoline-3-carboxamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-methoxyisoquinoline-3-carboxamide; N-[(l S,2R,4R)7-azabicyclo[2.2.1 ]hept-2-yl]-5-ethynyl isoquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a compound according to any one of claims 1-19, anti-psychotic agent(s), and a pharmaceutically acceptable excipient.
21. The pharmaceutical composition according to claim 20, wherein said compound and said agent are to be independently administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.
22. The pharmaceutical composition according to claim 21, wherein said compound is administered in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
23. The pharmaceutical composition according to claim 21 , wherein said compound is administered in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
24. The pharmaceutical composition according to claim 20, comprising a compound according to any one of claims 1-19 and a pharmaceutically acceptable excipient.
25. The pharmaceutical composition according to claim 24, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.
26. The pharmaceutical composition according to claim 25, wherein said compound is administered in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
27. The pharmaceutical composition according to claim 25, wherein said compound is administered in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
28. Use of a compound according to any one of claims 1-19 for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist.
29. The use according to claim 28, wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.
30. The use according to claim 28, wherein the disease or condition is schizophrenia or psychosis.
31. The use of claim 30, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist and anti-psychotic agent(s) for a therapeutically effective interval.
32. The use according to claim 28, wherein the disease or condition is depression, anxiety, general anxiety disorders, or post traumatic stress disorder.
33. The use according to claim 28, wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.
34. The use according to claim 28, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
35. A method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an α7 nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1-19.
36. The method according to claim 35, wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.
37. The method according to claim 35, wherein the disease or condition is schizophrenia or psychosis.
38. The method of claim 37, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist and anti-psychotic agent(s) for a therapeutically effective interval.
39. The method according to claim 35, wherein the disease or condition is depression, or anxiety and general anxiety disorders and post traumatic stress disorder.
40. The method according to claim 35, wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.
41. The method according to claim 35, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
PCT/US2003/002688 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity WO2003072578A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP20030710784 EP1478646A1 (en) 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
MXPA04007083A MXPA04007083A (en) 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity.
BR0307874-4A BR0307874A (en) 2002-02-20 2003-02-14 Activity of nicotinically alpha7 acetylcholine receptor azabicyclic compounds
AU2003214936A AU2003214936A1 (en) 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
JP2003571284A JP2005525357A (en) 2002-02-20 2003-02-14 Azabicyclic compounds with α7 nicotinic acetylcholine receptor activity
CA002475773A CA2475773A1 (en) 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35814602P 2002-02-20 2002-02-20
US60/358,146 2002-02-20

Publications (1)

Publication Number Publication Date
WO2003072578A1 true WO2003072578A1 (en) 2003-09-04

Family

ID=27765951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002688 WO2003072578A1 (en) 2002-02-20 2003-02-14 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity

Country Status (8)

Country Link
US (1) US7001900B2 (en)
EP (1) EP1478646A1 (en)
JP (1) JP2005525357A (en)
AU (1) AU2003214936A1 (en)
BR (1) BR0307874A (en)
CA (1) CA2475773A1 (en)
MX (1) MXPA04007083A (en)
WO (1) WO2003072578A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004099206A1 (en) * 2003-05-12 2004-11-18 Novartis Ag Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
WO2005092890A3 (en) * 2004-03-25 2006-02-02 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
JP2008506646A (en) * 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト 3- (Heteroaryl-oxy) -2-alkyl-1-aza-bicycloalkyl derivatives as α7nAChR ligands for treating CNS diseases
JP2008517913A (en) * 2004-10-25 2008-05-29 イーライ リリー アンド カンパニー Thienopyridines as allosteric potentiators of M4 muscarinic receptors
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7429664B2 (en) 2002-09-25 2008-09-30 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7488737B2 (en) 2004-04-22 2009-02-10 Memory Pharmaceutical Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7625924B2 (en) 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US7750022B2 (en) 2003-08-13 2010-07-06 Neurosearch A/S Quinuclidine derivatives and their pharmaceutical use
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US8048885B2 (en) 2005-12-16 2011-11-01 Novartis Ag Organic compounds
EP2409703A1 (en) 2007-08-02 2012-01-25 Targacept, Inc. Treatment with alpha7-selective ligands
US8119809B2 (en) 2007-11-16 2012-02-21 Rigel Pharmaceuticals, Inc. AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
WO2012056372A1 (en) 2010-10-29 2012-05-03 Pfizer Inc. N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
US8173667B2 (en) 2005-10-21 2012-05-08 Novartis Ag 1-aza-bicycloalkyl derivatives
US8227598B2 (en) * 2001-11-19 2012-07-24 Bayer Schering Pharma Aktiengesellschaft Heteroaryl carboxamides
US8236803B2 (en) 2002-09-04 2012-08-07 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8759346B2 (en) 2005-12-16 2014-06-24 Novartis Ag Organic compounds
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8901151B2 (en) 2009-01-26 2014-12-02 Targacept, Inc. Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US8933090B2 (en) 2004-06-18 2015-01-13 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000779A (en) * 2001-08-24 2004-04-20 Pharmacia & Up John Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease.
GB2403474B (en) * 2002-04-18 2006-10-11 Inst Med Molecular Design Inc Amide derivatives
US7280117B2 (en) * 2004-09-10 2007-10-09 Avid Technology, Inc. Graphical user interface for a keyer
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
MY159826A (en) 2008-11-19 2017-02-15 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CA2743700C (en) * 2008-12-15 2016-07-12 Taigen Biotechnology Co., Ltd. Stereoselective synthesis of piperidine derivatives
WO2011085188A1 (en) * 2010-01-07 2011-07-14 Eurand, Inc. Pharmaceutical compositions comprising anti-psychotic drugs
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
KR101928505B1 (en) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 Pharmaceutical composition comprising pyridone derivatives
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
MY186570A (en) 2014-05-13 2021-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
WO2019241329A2 (en) 2018-06-13 2019-12-19 Dandrea Michael R Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild cognitive impairment
BR112020025604A2 (en) 2018-06-15 2021-03-23 R.J. Reynolds Tobacco Company nicotine purification

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089960A (en) * 1975-09-25 1978-05-16 Ciba-Geigy Corporation Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4657911A (en) * 1982-07-02 1987-04-14 Delalande S.A. 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
US4933445A (en) * 1988-11-29 1990-06-12 Rorer Pharmaceutical Corporation Heteroazabenzobicyclic carboxamide 5-HT3 antagonists
EP0430190A2 (en) * 1989-11-28 1991-06-05 Syntex (U.S.A.) Inc. New tricyclic compounds
WO1991017161A1 (en) * 1990-04-27 1991-11-14 Beecham Group Plc Isoquinoline amides and esters as 5 ht3 receptor antagonists
WO2000073431A2 (en) * 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
WO2003022856A1 (en) * 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
US4093734A (en) 1975-11-03 1978-06-06 Boehringer Ingelheim Gmbh Amino-benzoic acid amides
ZA832549B (en) 1982-04-14 1988-09-28 Beecham Group Plc Pharmaceutically active compounds
FR2531083B1 (en) 1982-06-29 1986-11-28 Sandoz Sa NOVEL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
DE3689974T2 (en) 1985-03-14 1994-11-03 Beecham Group Plc Medicines to treat emesis.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
EP0272052B1 (en) 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides
EP0279990B1 (en) 1986-12-17 1995-07-12 Glaxo Group Limited Use of heterocyclic derivatives in the treatment of cognitive disorders
US5246941A (en) 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
US5237066A (en) 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
GB8720805D0 (en) 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
EP0353372B1 (en) 1988-08-04 1993-02-03 Synthelabo Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US6060473A (en) 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US6117889A (en) 1994-04-01 2000-09-12 University Of Virginia 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
SE9600683D0 (en) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089960A (en) * 1975-09-25 1978-05-16 Ciba-Geigy Corporation Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides
US4657911A (en) * 1982-07-02 1987-04-14 Delalande S.A. 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
US4920219A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US4933445A (en) * 1988-11-29 1990-06-12 Rorer Pharmaceutical Corporation Heteroazabenzobicyclic carboxamide 5-HT3 antagonists
EP0430190A2 (en) * 1989-11-28 1991-06-05 Syntex (U.S.A.) Inc. New tricyclic compounds
WO1991017161A1 (en) * 1990-04-27 1991-11-14 Beecham Group Plc Isoquinoline amides and esters as 5 ht3 receptor antagonists
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
WO2000073431A2 (en) * 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
WO2003022856A1 (en) * 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLUM E ET AL: "DESIGN AND SYNTHESIS OF NOVEL LIGANDS FOR THE 5-HT3 AND THE 5-HT4 RECEPTOR", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 2, no. 5, 1992, pages 461 - 466, XP000607037, ISSN: 0960-894X *
GONG, LEYI ET AL: "Synthesis of the 3H-labeled 4-HT3 antagonist (RS-25259-197) at high specific activity", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS ( 1996 ), 38(5), 425-433, XP009012605 *
KOWALCZYK, BRUCE A.: "A short total synthesis of palonosetron using catalytic hydrogenation", HETEROCYCLES ( 1996 ), 43(7), 1439-1446, XP009012612 *
LANGLOIS M ET AL: "DERIVATIVES F QUINUCLIDINE AS 5-HT3 RECEPTOR ANTOGONISTS: INFLUENCE OF AN ADDITIONAL CARBONYL GROUP ON THE RECOGNITION OF CHIRALITY BY THE RECEPTOR", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 3, no. 8, 1993, pages 1555 - 1558, XP001057029, ISSN: 0960-894X *
MACOR J E ET AL: "THE 5-HT3 ANTAGONIST TROPISETRON NICS 205-930) IS A POTENT AND SELECTIVE ALPHA7 NICOTINIC RECEPTOR PARTIAL AGONIST", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, 2001, pages 319 - 321, XP001120243, ISSN: 0960-894X *
ORJALES, AURELIO ET AL: "Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives", DRUG DESIGN AND DISCOVERY ( 2000 ), 16(4), 271-279, XP009012640 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227598B2 (en) * 2001-11-19 2012-07-24 Bayer Schering Pharma Aktiengesellschaft Heteroaryl carboxamides
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US9012451B2 (en) 2002-09-04 2015-04-21 Novartis Ag Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
US9849117B2 (en) 2002-09-04 2017-12-26 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
US9567343B2 (en) 2002-09-04 2017-02-14 Novartis Ag Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists
US8236803B2 (en) 2002-09-04 2012-08-07 Novartis Ag Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
US7429664B2 (en) 2002-09-25 2008-09-30 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7943773B2 (en) 2002-09-25 2011-05-17 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
AU2004235971B2 (en) * 2003-05-12 2008-04-03 Novartis Ag Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
AU2004235971C1 (en) * 2003-05-12 2008-12-04 Novartis Ag Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
WO2004099206A1 (en) * 2003-05-12 2004-11-18 Novartis Ag Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
US7683075B2 (en) 2003-05-12 2010-03-23 Novartis Ag Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
US7750022B2 (en) 2003-08-13 2010-07-06 Neurosearch A/S Quinuclidine derivatives and their pharmaceutical use
US7964600B2 (en) 2003-12-22 2011-06-21 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7790722B2 (en) 2003-12-22 2010-09-07 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US8158629B2 (en) 2003-12-22 2012-04-17 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
EP2336128A1 (en) * 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
US8691841B2 (en) 2004-03-25 2014-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof
US8486937B2 (en) 2004-03-25 2013-07-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof
US8263619B2 (en) 2004-03-25 2012-09-11 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
WO2005092890A3 (en) * 2004-03-25 2006-02-02 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US7902217B2 (en) 2004-04-22 2011-03-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7488737B2 (en) 2004-04-22 2009-02-10 Memory Pharmaceutical Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US8933090B2 (en) 2004-06-18 2015-01-13 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes
US9475811B2 (en) 2004-06-18 2016-10-25 Novartis Ag 1-aza-bicyclo[3.3.1]nonanes
US8609662B2 (en) 2004-07-14 2013-12-17 Novartis Ag 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases
US9657010B2 (en) 2004-07-14 2017-05-23 Novartis Ag Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators
JP2008506646A (en) * 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト 3- (Heteroaryl-oxy) -2-alkyl-1-aza-bicycloalkyl derivatives as α7nAChR ligands for treating CNS diseases
JP2008517913A (en) * 2004-10-25 2008-05-29 イーライ リリー アンド カンパニー Thienopyridines as allosteric potentiators of M4 muscarinic receptors
US7625924B2 (en) 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8173667B2 (en) 2005-10-21 2012-05-08 Novartis Ag 1-aza-bicycloalkyl derivatives
US8048885B2 (en) 2005-12-16 2011-11-01 Novartis Ag Organic compounds
US9206181B2 (en) 2005-12-16 2015-12-08 Novartis Ag 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
US8637517B2 (en) 2005-12-16 2014-01-28 Novartis Ag Organic compounds
US8759346B2 (en) 2005-12-16 2014-06-24 Novartis Ag Organic compounds
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
US8163760B2 (en) 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas
US8697727B2 (en) 2006-12-28 2014-04-15 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US9181220B2 (en) 2006-12-28 2015-11-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2409703A1 (en) 2007-08-02 2012-01-25 Targacept, Inc. Treatment with alpha7-selective ligands
EP2484363A1 (en) 2007-08-02 2012-08-08 Targacept, Inc. (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide
US8569340B2 (en) 2007-11-16 2013-10-29 Rigel Pharmaceuticals, Inc. AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same
US8119809B2 (en) 2007-11-16 2012-02-21 Rigel Pharmaceuticals, Inc. AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same
US9174964B2 (en) 2007-11-16 2015-11-03 Rigel Pharmaceuticals, Inc. AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same
US8895578B2 (en) 2007-12-12 2014-11-25 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
US8557822B2 (en) 2007-12-12 2013-10-15 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
US9353111B2 (en) 2008-04-23 2016-05-31 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8871770B2 (en) 2008-04-23 2014-10-28 Rigel Pharmaceuticals Inc. Carboxamide compounds and methods for using the same
US9062052B2 (en) 2008-04-23 2015-06-23 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8785449B2 (en) 2008-04-23 2014-07-22 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9255085B2 (en) 2008-04-23 2016-02-09 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9173876B2 (en) 2009-01-26 2015-11-03 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8901151B2 (en) 2009-01-26 2014-12-02 Targacept, Inc. Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
RU2577334C2 (en) * 2010-05-17 2016-03-20 Энвиво Фармасьютикалз, Инк. CRYSTALLINE FORM OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[b]THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
EP2952514A1 (en) 2010-10-29 2015-12-09 Pfizer Inc N1/n2-lactam acetyl-coa carboxylase inhibitors
WO2012056372A1 (en) 2010-10-29 2012-05-03 Pfizer Inc. N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
CA2475773A1 (en) 2003-09-04
US7001900B2 (en) 2006-02-21
US20030236270A1 (en) 2003-12-25
JP2005525357A (en) 2005-08-25
AU2003214936A1 (en) 2003-09-09
MXPA04007083A (en) 2004-10-29
EP1478646A1 (en) 2004-11-24
BR0307874A (en) 2004-12-28

Similar Documents

Publication Publication Date Title
US7001900B2 (en) Azabicyclic compounds for the treatment of disease
US6858613B2 (en) Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
US6951868B2 (en) Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
US20060116395A1 (en) 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease
US6894042B2 (en) Azabicyclic compounds for the treatment of disease
US20030207913A1 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
US6849620B2 (en) N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2002016356A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US20040147522A1 (en) Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
WO2003037896A1 (en) N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
US6852716B2 (en) Substituted-aryl compounds for treatment of disease
US20030069296A1 (en) Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007083

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2475773

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003710784

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003571284

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003710784

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003710784

Country of ref document: EP